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Stellingen 
behorende bij het proefschrift: 
The role of CETP and HDL metabolism In cardiac risk 
S11sa1111a E. Borggrel'e 
I. Een verhoogd circulerend CETP beschermt tegen hartvaatziekten (dir proefschrifr). 
2. CETP genotypen die leiden tot een verhoogd circulerend CETP beschermen tegen 
hartziekten (dir proefschrift). 
3. Het beschermende effect van het CETP -629CC genotype tegen hartziekten verloopt 
gedeeltelijk indirect, via een mechanisme dat los staat van het effect op circulerend 
CETP (dit proefschrift). 
4. Een verhoogd triglyceridengehalte vermindert het beschermend effect van circulerend 
CETP en van CETP genotypen op hartziekten (dit proefsc/1rift). 
5. Het CETP -629A allel heeft een duaal effect op hartz.iekten, hetgeen zich weerspiegelt 
in een positief effect op de hoogte van het HDL-cholesterol, maar een negatief direct 
effect op cardiovasculair risico (dit proefschrift). 
6. Automatische ECG analyse en door patienten gerapporteerd myocardinfarct 
overlappen niet voldoende om samen een betrouwbare samengestelde variabele te 
vormen voor doorgemaakt myocardinfarct (dit proefschrift). 
7. Bij patienten met metabool syndroom hebben zowel het circulerend CETP als het 
CETP genotype een ander effect op hartz.iekte dan bij mensen met een ongestoord 
vetmetabolisme (dit proefsc/1rif1). 
8. Gebruik van geneesmiddelen heeft een minder gunstig effect op gezondheid dan 
succesvolle aanpassing van leefstijl. 
9. De invloed van grate farmaceutische bedrijven op de medische wetenschap is duaal: 
bevorderend door het mecenaat, maar belemmerend door mogelijke 
belangenverstrengeling. 
10. Als hel waar is dat de wetenschap voortschrijdt en de waarheid eender blijft, betekent 
dit dat op enig moment in de wetenschapsgeschiedenis de kans slechts klein is dat wij 
het geheel bij het rechte eind hebben. 
11. Kennis is geen garantie voor wijsheid. 
12. Promoveren is behagen. (Hans Hillege) 
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aims and outline of the thesis 
JO Chapter 1 
Introduction 
Cardiovascular diseases belong to the most important causes of death in western 
societies. In the Netherlands, cardiovascular diseases accounted for one third of all­
cause mortality in 2004. 1 Fortunately, during the last years the cardiovascular 
mortality has decreased from 37% of total mortality in 1996 to 33% in 2004. 1 
Likewise, cardiovascular morbidity appears to diminish, as indicated by a decline in 
hospitalisations for acute myocardial infarction, heart failure and peripheral vascular 
disease from 1995 to 2003. 1 Notwithstanding these encouraging trends in the Dutch 
population, which may be partly accounted for by lipid-improving drugs and lifestyle 
changes,2 still 11 % of all cardiovascular patients die within one year after the first 
hospitalisation. 
Lipid-improving strategies were implemented after a large body of evidence 
indicated that cardiovascular disease is positively related to many lipids such as total 
cholesterol or triglycerides, but inversely to high density lipoprotein (HDL) 
cholesterol.3-9 Also cardiovascular-related lifestyle factors such as obesity and 
smoking negatively influence HDL cholesterol,5;s;IO while exercise and moderate 
alcohol consumption are known to raise HDL. s;i i Interest in HDL management is 
increasing because cardiovascular disease is still insufficiently reduced by present-day 
therapeutic strategies, which aim to lower atherogenic lipoproteins like low density 
lipoprotein (LDL) cholesterol and triglycerides. 12:13 There are several HDL 
subfractions, with various sizes and compositions, which differ in their association 
with atherosclerosis.3;4;6;7;9 Therefore, simply raising HDL cholesterol, irrespective of 
the way by which this is achieved, may not suffice to optimally protect against 
cardiovascular disease. Rather, further insight in HDL metabolism is required to 
develop strategies which target at specific pathways in the HDL metabolism in order 
to optimally mitigate atherosclerosis development and progression. 
During the last decades, intensive research towards the pathophysiology of 
cardiovascular diseases has yielded valuable information about the protection against 
atherosclerosis, as provided by HDL. In a process called reverse cholesterol transport, 
HDL acts as acceptor of excess cholesterol from peripheral cells.14;15 While an excess 
of cholesterol accumulating in the arterial wall eventually leads to atherosclerosis, 
pre�-HDL particles remove this cholesterol, thereby retarding or even reversing 
atherosclerosis.16-18 During the uptake of cholesterol, the first small, lipid poor HDL 
particle grows and, while conveying cholesterol, continuously shifts its shape under 
influence of various enzymes and proteins.14 Ultimately, this reverse cholesterol 
transport leads to uptake of cholesterol in the liver, subsequent metabolism and 
excretion in the bile. 14;IS;l9 
Several other mechanisms have been proposed by which HDL may protect 
against atherosclerosis.20;21 It may augment plaque stability through modulating 
effects on cell proliferation and inhibition of endothelial cell apoptosis. HDL may also 
protect against endothelial dysfunction, e.g. by enhancing nitric oxide secretion and 
antagonizing actions of oxidized LDL. Another atheroprotective effect may be 
mediated via secretion of prostaglandin Ii and of endothelin-1 by endothelium, which 
is stimulated by HDL. Additionally, development of the atherosclerotic plaque 
induced by leukocytes could be counteracted by HDL, when HDL inhibits the 
interaction as well as the adhesion of monocytes with or to endothelial cells. By 
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affecting both the activation of blood coagulation as well as production of coagulation 
factors, HDL may restore the balance between coagulation and fibrinolysis. Lastly, 
HDL may inhibit thrombocytic activation and oxidation ofLDL, the latter of which is 
considered to be a key event in atherosclerotic plaque formation. 
Cholesteryl ester transfer protein (CETP) is an important factor in reverse 
cholesterol transport, functioning as a facilitator of the reciprocal transfer of 
cholesteryl ester and triglycerides between HDL and triglyceride-rich 
lipoproteins. 14;22•24 This transfer reduces the cholesteryl ester content of large, 
spherical HDL in exchange for a gain of triglycerides. Triglyceride-rich lipoproteins, 
on the other hand, acquire cholesteryl ester and will become more depleted of 
triglycerides. Thereafter, size of HDL particles is further decreased when triglycerides 
are hydrolysed by hepatic lipase. Consequently, CETP plays an important role in 
HDL remodelling and metabolism, together with hepatic lipase, phospholipid transfer 
protein and lecithin:cholesterol acyltransferase. 14;22-24 
It is still unsettled whether and under which circumstances CETP has an 
atherogenic or a cardioprotective intluence.25-27 On one hand, CETP may be 
cardioprotective because it mediates in an additional route by which cholesteryl esters 
in HDL can be transferred towards the liver via VLDL and LDL. On the other hand, 
and atherogenic role is advocated by those who stipulate that CETP contributes to a 
lipid profile which is considered to be atherogenic. 
As CETP is an important factor in the reverse cholesterol transport, population 
variability in this process may occur because of CETP gene polymorphisms. These 
are common in the general population and may even have an effect on the incidence 
of cardiovascular disease. Several CETP polymorphisms, such as the -629C-A 
polymorphism in the CETP promoter, are clearly associated with altered levels of 
HDL cholesterol.28 The CETP -629A allele is associated with decreased transcription 
of CETP and thus with lower CETP mass in plasma.29;30 This will raise HDL 
cholesterol levels. Nonetheless, much is still unknown about the interaction of CETP 
genotypes with patient characteristics and lifestyle habits on HDL cholesterol. The 
CETP TaqIB polymorphism has been extensively studied; it is a single nucleotide 
polymorphism of the CETP gene, located in a non-functional regulatory site of the 
gene, is closely linked to the CETP -629 promoter polymorphism, which is located in 
a site of the gene which regulates CETP levels.3 1 For instance, the CETP TaqlB 
polymorphism has been suggested to interact with gender and environmental factors, 
such as use of alcohol, smoking, obesity and diabetes. 32·35 So far, these possible 
interactions on HDL cholesterol have not been unequivocally shown in large study 
populations. 
A considerable amount of research has focussed on associations of CETP 
polymorphisms with cardiovascular disease, but results are contradictory. The CETP 
Taql82 allele, which is associated with lower CETP levels,36 has been observed to be 
related to reduced coronary risk,37-4° but not all studies concur with these 
findings_33;4 t-45 It is noteworthy that these studies only included subjects with 
increased risk of heart disease, such as patients with a history of cardiac 
disease41 ;42;44;45 or only men33;39;40;4l;43, or were designed cross-sectionally33;37;39;4t_ 
Notably, the CETP -629C-A promoter, which is very closely linked to the TaqIB 
polymorphism,29 does not appear to be associated with cardiovascular disease,39;45-47 
except for some investigations into only cardiac patients48 or men40• Moreover, the V 
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allele of the CETP 1405V polymorphism, which is associated with lower CETP and 
higher HDL cholesterol, is reported to be related with increased risk of cardiovascular 
disease.49•5° Correspondingly, increased risk of coronary heart disease has been found 
in men with genetic CETP deficiency.51;52 In conclusion, the exact relationships of 
common CETP polymorphisms, such as -629C-A, TaqIB and 1405V, with 
cardiovascular disease still have to be established, as well as the modification of the 
CETP genotypes-HDL cholesterol associations by clinical and environmental factors. 
Aims and purpose of the thesis 
This thesis describes the effects of plasma CETP levels and common CETP 
polymorphisms, in their relation to HDL metabolism and triglycerides, on cardiac risk 
in a general western population. The studies of this thesis consist of epidemiological 
research based on data from PREVEND (Prevention of REnal and Vascular 
ENDstage Disease) Study, an ongoing population-based project carried out among 
inhabitants of the city of Groningen, the Netherlands. We have specifically focussed 
on possible effects of (genetic) variants of CETP on HDL-related compounds such as 
HDL cholesterol, triglycerides, the cholesteryl ester transfer and cholesterol efflux 
from vessel walls. The specific aims of this thesis are: 
I. Circulating CETP, HDL and cardiac disease 
1. To investigate how circulating CETP and HDL lipids and apolipoproteins 
relate to cardiac disease. We initially reviewed the current knowledge of actions of 
CETP and to which extent these relate to other factors in the HDL metabolism, in 
healthy subjects and in patients with abnormal triglyceride metabolism such as insulin 
resistance and type 2 diabetes mellitus (chapter 2). Then, the associations of HDL 
cholesterol and HDL-associated apolipoproteins with cardiovascular disease were 
studied in a large cohort of the general population (chapter 3). 
2. To verify whether the prognostic significance of plasma CETP levels for 
cardiac disease and whether this is influenced by different circulating triglyceride 
levels. The tentative modification by triglycerides is of importance because in 
subjects with hypertriglyceridaemia cardiac risk is increased. In addition, the transfer 
of cholesteryl esters and triglycerides which is facilitated by CETP has been observed 
to be altered in this state. This knowledge is clinically relevant, since drugs that 
inhibit CETP activity, newly developed to combat atherosclerosis were primarily 
tested in subjects with generally high triglyceride levels. This second aim is 
prospectively studied in the nested case-control study in chapter 4. 
II. CETP genotype, HDL and cardiac disease 
3. To investigate whether the associations of CETP polymorphisms with HDL 
cholesterol are modifyed by different circulating triglyceride levels. While the 
common CETP polymorphisms under study are known to be associated with variation 
in HDL cholesterol levels, multiple aspects of HDL metabolism are shown to be 
altered in hypertriglyceridaemic states. Therefore, we determined whether 
associations between CETP polymorphisms and HDL cholesterol were modified by 
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variations in triglycerides. This investigation is described using the large population­
based cohort PREVEND Study in chapter 5. 
4. To investigate the associations of CETP polymorphisms with incident cardiac 
disease, HDL cholesterol and cholesterol efflux, and to assess whether the putative 
associations with cardiac disease and HDL cholesterol are effected by respectively 
HDL cholesterol and the effect of CETP on lipid transfer. This was assessed in a large 
prospectively followed population cohort. We investigated whether these associations 
could be explained by the specific effects on HDL cholesterol levels associated with 
these polymorphisms ( chapter 6). In addition, we assessed whether a common CETP 
promoter polymorphisms was associated with the first step of HDL metabolism, 
cholesterol efflux (chapter 7). In this subset we also determined whether CETP in 
blood and the transfer it acts in are the (sole) explanation for the association between 
the CETP polymorphisms and HDL cholesterol (chapter 8). Hence, apart from the 
associations of common CETP polymorphisms with HDL cholesterol and cardiac 
disease outside a clinical setting, we attempted to clarify the interrelation between 
CETP gene variation, HDL and cardiac disease from a metabolic perspective. 
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Abstract 
Insulin resistance and type 2 diabetes mellitus are generally accompanied by low 
HDL cholesterol and high plasma triglycerides, which are major cardiovascular risk 
factors. This review describes abnormalities in HDL metabolism and reverse 
cholesterol transport, i.e. the transport of cholesterol from peripheral cells back to the 
liver for metabolism and biliary excretion, in insulin resistance and type 2 diabetes 
mellitus. 
Several enzymes including lipoprotein lipase (LPL), hepatic lipase (HL) and 
lecithin:cholesterol acyltransferase (LCAT), as well as cholesteryl ester transfer 
protein (CETP) and phospholipid transfer protein (PLTP), participate in HDL 
metabolism and remodelling. LPL hydrolyses lipoprotein triglycerides, thus providing 
lipids for HDL formation. HL reduces HDL particle size by hydrolysing its 
triglycerides and phospholipids. A decreased post-heparin plasma LPL/HL ratio is a 
determinant of low HDL2 cholesterol in insulin resistance. The esterification of free 
cholesterol by LCAT increases HDL particle size. Plasma cholesterol esterification is 
unaltered or increased in type 2 diabetes mellitus, probably depending on the extent of 
triglyceride elevation. Subsequent CETP action results in transfer of cholesteryl esters 
from HDL towards triglyceride-rich lipoproteins, and is involved in decreasing HDL 
size. An increased plasma cholesteryl ester transfer is frequently observed in insulin 
resistant conditions, and is considered to be a determinant of low HDL cholesterol. 
PLTP generates small pre P-HDL particles that are initial acceptors of cell-derived 
cholesterol. Its activity in plasma is elevated in insulin resistance and type 2 diabetes 
mellitus in association with high plasma triglycerides and obesity. In insulin 
resistance, the ability of plasma to promote cellular cholesterol efflux may be 
maintained consequent to increases in PLTP activity and pre P-HDL. However, 
cellular cholesterol efflux to diabetic plasma is probably impaired. Besides, cellular 
abnormalities that are in part related to impaired actions of ATP binding cassette 
transporter I and scavenger receptor class B type I are likely to result in diminished 
cellular cholesterol efflux in the diabetic state. Whether hepatic metabolism of HDL­
derived cholesterol and subsequent hepatobiliary transport is altered in insulin 
resistance and type 2 diabetes mellitus is unknown. 
Specific CETP inhibitors have been developed that exert major HDL cholesterol 
raising effects in humans and retard atherosclerosis in animals. As an increased 
CETP-mediated cholesteryl ester transfer represents a plausible metabolic 
intermediate between high triglycerides and low HDL cholesterol, studies are 
warranted to evaluate the effects of these agents in insulin resistance- and diabetes­
associated dyslipidaemia. 
Key words: Insulin resistance, type 2 diabetes mellitus, high density lipoproteins, 
reverse cholesterol transport, lecithin: cholesterol acyltransferase, cholesteryl ester 
transfer protein, phospholipid transfer protein, lipases. 
HDL metabolism and reverse cholesterol transport 























ATP binding cassette transporter I 
apolipoprotein 
cholesteryl ester transfer protein 
endothelial lipase 
enzyme-linked immunoabsorbent assay 
free fatty acid 
high density lipoproteins 
hepatic lipase 
lecithin: cholesterol acyltransferase 
low density lipoproteins 
endothelial lipase gene 
HDL particle that only contains apo A-I 
HDL particle that contains both apo A-I and apo A-II 
lipoprotein lipase 
LDL receptor-related protein 
lipid transfer inhibitor protein (apo F) 
phospholipid transfer protein 
reverse cholesterol transport 
scavenger receptor class B type I 
triglyceride-rich lipoproteins 
very low density lipoproteins 
21 
22 Chapter 2 
Introduction 
Dyslipidaemia represents one of the most important risk factors for cardiovascular 
morbidity and mortality. 1 An inverse relationship between plasma high density 
lipoprotein (HDL) cholesterol and atherosclerosis was already described in the J 950's 
2, but the importance of this relationship was only realised in I 975.3 Many subsequent 
studies have emphasised that low HDL cholesterol is associated with an increased 
cardiovascular risk.4 Current opinion is that next to high LDL cholesterol and low 
HDL cholesterol levels, high plasma triglycerides should be regarded as a risk factor 
for the development of cardiovascular disease.5 
Insulin sensitivity can be defined as a measure of the capacity of insulin to exert 
its biological effects on insulin-sensitive tissues. Insulin resistance that relates to 
whole-body glucose metabolism refers to the ability of insulin to lower blood glucose, 
consequent to either decreased cellular glucose uptake or increased hepatic glucose 
output. Insulin resistance is a harbinger of type 2 diabetes mellitus and is 
pathogenetically linked to an increased risk of cardiovascular events.6 The insulin 
resistance syndrome originally included hyperinsulinaemia, impaired glucose 
tolerance, hypertension, increased plasma triglycerides and decreased HDL 
cholesterol.7 Later, other features were added such as visceral adiposity, small dense 
LDL, exaggerated postprandial lipaemia, increased plasma plasminogen activator 
inhibitor-I and decreased sex hormone binding globulin levels8 Hypertension9 and 
impaired fibrinolysis10 possibly contribute to increased cardiovascular risk. Above all, 
a major cause of coronary heart disease associated with insulin resistance is 
dyslipidaemia, hallmarked by low HDL cholesterol and high plasma triglycerides.6; 1 1  
Importantly, low HDL cholesterol remains an independent cardiovascular risk factor 
once type 2 diabetes mellitus has developed. 12 
The cardioprotective role of HDL is thought to be related at least in part to the 
role of HDL in reverse cholesterol transport (RCT), the process by which cholesterol 
is removed from peripheral cells and transported to the liver for metabolism and 
excretion in the bile. 13; 14 In addition, HDL has important anti-oxidative and anti­
inflammatory properties 1 5; 16  and may prevent adhesion of monocytes to the 
endothelial cells. 1 7  
This review focuses on the causes of low HDL cholesterol, and on alterations in 
HDL metabolism and RCT in insulin resistance and type 2 diabetes mellitus. 
Furthermore, recently developed therapeutic strategies to raise HDL cholesterol are 
discussed. 
High density lipoprotein metabolism under normolipidemic circum­
stances 
HDL comprise a heterogeneous class of lipoproteins with a density > 1 .063 g/ml.18;19 
HDL particles contain various apolipoproteins (apo's) of which apo A-I and apo A-II 
are qualitatively the most abundant.20 In humans, liver and intestine are important 
sources of apo A-I, whereas apo A-II is predominantly produced by the liver.18•20 
Some HDL also contain apo E. HDL can be subdivided according density in HDL2, 
the less dense subfraction and HDL3.
18 Both HDL2 and HDL3 contain apo A-1, and 
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migrate with a-mobility on electrophoresis. 19 These HDL subfractions can also be 
differentiated according to their apolipoprotein composition in HDL particles that 
only contain apo A-I {LpA-1) and particles that contain apo A-I as well as apo A-II 
{LpA-VA-Il). 19:io A small fraction of HDL particles are lipid poor and very small 
sized. 1 3 Most of these particles show pre P-mobility on electrophoresis and are 
designated as pre P-HDL, which can be further subdivided in pre p 1-, pre Pi- and pre 
PrHDL. 13: 1 9  These discoidal, nascent HDL particles contain apo A-1, as well as some 
phospholipids. 1 3;1 8;1 9  
HDL formation is regarded to begin with pre P-HDL that are produced by liver 
and intestine as well as extracellularly during the metabolism of triglyceride-rich 
lipoproteins and HDL remodelling. 1 3; ia : i9:2 1 As these particles mature they become 
spherical with a-electrophoretic mobility with HDL2 originating from HDL3• 1 3; 1 9•2 1  
HDL particles are constantly remodelled as a result of many interrelated processes. As 
described below, several enzymes including lipoprotein lipase, hepatic lipase, the 
recently discovered endothelial lipase and lecithin: cholesterol acyltransferase, as well 
as lipoprotein transfer proteins including cholesteryl ester transfer protein and 
phospholipid transfer protein are involved in HDL metabolism. 
Lipoprotein lipase (LPL): LPL is predominantly present in adipose tissue, 
skeletal muscle and heart.22 After synthesis by parenchymal cells, LPL is transferred 
to endothelial cells and bound to heparan sulphate proteoglycans.22 LPL hydrolyses 
triglycerides contained within lipoproteins. During the process of chylomicron and 
very low density lipoprotein (VLDL) triglyceride hydrolysis, surface fragments are 
transferred to maturing HDL.1 8 Adipose tissue LPL mRNA expression as well as its 
activity are positively correlated with postprandial plasma triglyceride excursions.23 
Genetic lipoprotein lipase deficiency associates with severe 
hypertriglyceridaemia and with very low HDL cholesterol levels,24 whereas the LPL­
variant Ser447Stop is associated with high LPL activity and high HDL 
cholesterol. 24:25 
Hepatic lipase (HL): HL is produced in hepatic cells, and is active at the surface 
of hepatic endothelial cells.24:26 By hydrolysing HDL triglycerides as well as HDL 
phospholipids, HL contributes to the metabolism of HDL.19:24:26 HL has the ability to 
generate pre P-HDL from spherical HDL,27 and is involved in the generation ofHDL3 
from HDL2•24;27 A high activity of HL as measured in post-heparin plasma is 
associated with lower HDL cholesterol and smaller HDL particles.24 Apo A-II may 
stimulate HL activity which is possibly due to a greater affinity of HL towards apo A­
II compared to apo A-I.20•28 
Genetic HL deficiency results in a moderately elevated plasma HDL 
cholesterol 1 9;24 and larger HDL particles24• A common polymorphism in the HL gene 
promoter is associated with low HL activity, high HDL cholesterol and triglyceride 
enrichment of all lipoprotein classes.26 
Endothelial lipase (EL): EL is a recently discovered lipase. Its gene, the 
endothelial lipase gene {LIPG), is predominantly expressed in endothelial cells but 
also in other tissues.29:3o In vivo studies in mice reveal that EL shows primarily 
phospholipase activity and relatively little triglyceride lipase activity.29:3o One study 
showed that a high degree of EL overexpression in mice liver results in a decrease in 
HDL cholesterol and apo A-I.3 1  In LIPG transgenic mice an inverse relationship 
between HDL and EL-expression was found.30 Therefore, it is possible that EL is a 
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physiological regulator in HDL metabolism, but much research is necessary to 
characterise its exact role. 
Lecithin: cholesterol acyltransferase (LCAT): LCA T is mainly secreted by the 
liver,32 is particularly active on pre PrHDL and catalyzes the transfer of 2-acyl 
groups from lecithin or phosphatidylethanolamine to free (unesterified) 
cholesterol. 13;24 The LCAT reaction, which requires apo A-I as cofactor, thereby 
results in the generation of cholesteryl ester molecules that by their hydrophobic 
nature are retained in the core of HDL particles. As a consequence, new unesterified 
cholesterol molecules, either derived from triglyceride-rich lipoproteins or from 
peripheral cells, can be transferred to the surface of HDL particles, causing an 
increase in HDL size. As HDL grows, the affinity of LCAT for the HDL surface 
lessens. Eventually, large spherical HDL2 that contain little or no LCAT are 
generated. 13;33 The cholesterol esterification reaction in plasma is determined by the 
activity of LCA T, i.e. the amount of active LCAT in plasma, as well as by the plasma 
triglyceride concentration,34 although manoeuvres that decrease plasma triglycerides 
do not necessarily affect plasma cholesterol esterification.35 In humans, plasma LCAT 
activity is positively correlated with the HDL2 as well as with the LpA-I/A-11 level but 
not with HDL3 and LpA-1.33 With higher concentrations of apo A-II, LCAT reactivity 
seems to be diminished.2o;zs;36 Moreover, plasma cholesterol esterification has been 
shown to be a determinant of the HDL cholesteryl ester concentration.37 
Familial LCAT deficiency is due to mutations in the LCA T  gene that leads to a 
total loss of catalytic activity of this enzyme.32 This disease is associated with 
markedly reduced HDL cholesterol and apo A-I levels.32 Intriguingly, it is unusual for 
patients with familial LCA T deficiency to develop premature coronary 
atherosclerosis. 32 Nonetheless, accelerated atherosclerosis has been described in 
patients with fish eye disease, which is caused by mutations in the LCAT gene that 
result in a partial loss ofLCAT activity.32 
Cholesteryl ester transfer protein (CETP): In contrast to species such as mice 
and rats, human and rabbit plasma contains CETP.38 This lipid transfer protein 
enables the mass transfer and exchange of cholesteryl ester and triglyceride molecules 
among lipoproteins. 1 3;39;4o Liver and fat tissue appear to be important sources of 
circulating CETP in man.40 Between lipoprotein particles with a high cholesteryl ester 
content, such as spherical HDL as well as LDL, and triglyceride-rich lipoproteins this 
neutral lipid transfer process results in a net gain of triglycerides and a net loss of 
cholesteryl ester in HDL and LDL, with reciprocal changes in triglyceride-rich 
lipoproteins. 19;22;3941 Between HDL and LDL exchange of neutral lipids 
predominates, and there is little mass.39 Consequent to this process, the HDL 
cholesteryl ester concentration is decreased, whereas the HDL triglyceride content is 
increased. Since triglyceride molecules are larger than cholesteryl ester molecules, 
HDL size is increased. Subsequent HDL triglyceride hydrolysis by HL results in 
smaller sized, cholesteryl ester poor HDL, although CETP by itself is able to reduce 
HDL size.27 CETP and HL are, therefore, considered to act in concert in HDLrHDL3 
remodelling. Likewise, the process of neutral lipid transfer between LDL and 
triglyceride-rich lipoproteins (TRL) results in triglyceride-rich LDL that are 
remodelled to small dense LDL by lipase action.42 Importantly, cholesteryl ester 
transfer should be considered to provide a metabolic intermediate between high 
plasma triglycerides and low HDL cholesterol.39.43-45 Furthermore, neutral lipid 
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transfer enhances the accumulation of cholesterol m chylomicrons, VLDL and 
intermediate density lipoproteins, especially when clearance of triglyceride-rich 
lipoproteins is diminished. I3;39;4o Of note, LPL-mediated lipolysis is thought to 
enhance cholesteryl ester transfer from HDL to VLDL by facilitating transfer of free 
fatty acids (FF A) to the VLDL surface.40;46 The cholesteryl ester transfer reaction is 
not only determined by the amount of active CETP in plasma ( designated CETP 
activity) but also by the constellation of cholesteryl ester donor (predominantly HDL) 
and acceptor (triglyceride-rich) lipoproteins. 37;39;43;45;47 Large-sized triglyceride-rich 
lipoproteins are better acceptors of HDL-derived cholesteryl ester than small-sized 
triglyceride-rich lipoproteins,45 whereas the rate of cholesteryl ester transfer is 
positively correlated with the phospholipid and unesterified cholesterol content in 
VLDL.39 In normolipidaemia, the concentration of triglyceride-rich lipoproteins 
provides a driving force for net cholesteryl ester transfer, and the cholesteryl ester 
transfer rate is determined by the triglyceride-rich lipoprotein concentration.43 In 
severe hypertriglyceridaemia, in contrast, the amount of active CETP becomes rate 
limiting 43• In tum, cholesteryl ester transfer with HDL that contain apo A-I and apo 
A-II is lower than that with HDL containing only apo A-I.28 There is a strong positive 
correlation between plasma CETP concentration and CETP activity.48"50 In addition, 
the amount of active CETP in plasma may also be affected by a lipid transfer inhibitor 
protein (LTIP), recently identified as apo F.5 1  LTIP is associated with LDL and may 
preferentially suppress the neutral lipid transfer process between LDL and other 
lipoprotein particles.52 Thus, cholesteryl ester transfer from HDL towards 
triglyceride-rich lipoproteins may be enhanced, thereby fine tuning CETP-mediated 
neutral lipid transfer. Apo C-I is another protein with CETP activity inhibiting 
properties. In normolipidaemic plasma, this apolipoprotein has been demonstrated to 
diminish CETP activity in a concentration dependent manner with high efficiency.53 
HDL cholesterol levels are 3 to 6 fold elevated in genetic CETP deficiency.54 In 
this situation plasma cholesterol and triglycerides are only slightly increased. HDL2 is 
elevated, and these particles are enormously large. LDL particles are small and 
heterogeneous.54 Expectedly, HDL is cholesteryl ester rich and triglyceride depleted, 
whereas VLDL and LDL are triglyceride rich and cholesteryl ester poor.54 Genetic 
CETP deficiency may impair cellular cholesterol efflux,55 despite elevated HDL 
cholesterol, and may lead to decreased cholesterol esterification.55 The diminished 
cellular cholesterol efflux in genetic CETP deficiency could accelerate 
atherosclerosis. 55 However, data concerning human CETP deficiency are confusing, 
with some but not all studies showing accelerated atherosclerosis.38;54;56 Of various 
biallelic CETP polymorphisms, the intronic TaqIB polymorphism (B 1 82) has been 
most extensively studied.57;58 This polymorphism is closely linked to the -629 NC 
polymorphism and to a tetranucleotide repeat in the CETP gene promoter.59;60 The B2 
allele is associated with higher HDL cholesterol, larger HDL particles, and lower 
plasma CETP activity and mass.57;58;6 1 ;62 Interestingly, this TaqIB polymorphism may 
interact with environmental factors such as alcohol use, smoking, obesity and insulin­
dependent diabetes mellitus, and gender on HDL cholesterol.63-66 The B2 allele may 
lower coronary artery risk.57;6 1 ;62;66 Another common polymorphism is the I405V 
mutation.58 The less frequent V allele is related to higher HDL cholesterol and lower 
plasma CETP concentration and activity.58;67 Remarkably, the V allele may be 
associated with higher risk for cardiovascular disease compared to wildtype I allele. 67 
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Another CETP gene variant (R45 l Q) is reported to affect plasma CETP activity, 
intima media thickness in men and cardiovascular risk in women.68 
Phospholipid transfer protein (PL TP): Plasma from humans contains a second 
lipid transfer protein, designated PLTP. PLTP is synthesised in liver, lung and adipose 
tissue but its main source in human plasma is still unknown.69 PLTP facilitates 
phospholipid and free cholesterol transfer between lipoproteins during lipolysis, 70 and 
may promote cholesteryl ester transfer towards triglyceride-rich lipoproteins.37;40 
Moreover, PLTP is able to convert HDL in larger and smaller particles.71;72 During 
this HDL remodelling, pre �-HDL particles are generated that act as initial acceptors 
of cell-derived cholesterol. 13;14; 1 9;73;74 Remarkably, human plasma PLTP activity is not 
correlated with PL TP mass at least when assayed using monoclonal capture 
antibodies.75 Indeed, evidence is accumulating that in humans circulating PLTP is 
only in part active.76 
Figure 1.1. Effects of lipases, lecithin: cholesterol acyltransferase and lipid 



















HDL: high density lipoproteins; TRL: triglyceride-rich lipoproteins; FC: free cholesterol; PL: 
phospholipids; LPL: lipoprotein lipase; HL: hepatic lipase; LCA T: lecithin: cholesterol acyltransferase; 
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Human genetic PLTP deficiency has not been unequivocally described as yet, 
nor is the effect of PLTP polymorphisms on lipoprotein metabolism clearly 
delineated. 
Figure 2. 1 schematically shows the effects of Ii pases, LCA T and lipid transfer 
proteins on HDL remodelling and figure 2.2 depicts the CETP-mediated process of 
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As alluded to later, many 
of the changes in HDL 
metabolism that occur in 
insulin resistance and type 
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on the pathogenesis of 
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Figure 2.2. The cholesteryl ester transfer protein­
mediated process of neutral lipid transfer between 
high density /ipoproteins, triglyceride-rich 
/ipoproteins and low density lipoproteins in 
normolipidaemia 
LOI. 
HDL: high density lipoproteins; TRL: triglyceride-rich 
lipoproteins; LDL: low density lipoproteins; CE: cholesteryl 
ester; TG: triglycerides; CETP: cholesteryl ester transfer protein; 
L TIP: lipid transfer protein inhibitor protein. Dotted arrows 
indicate stimulating effect of CETP on CE and TG transfer. 
Dotted arrows with a cross indicate inhibiting effect of L TIP. 
Long arrows indicate CE and TG transfer. There is less CE and 
TG transfer between HDL and LDL (thinner arrows) than 
between HDL and TRL and between LDL and TRL. 
28 Chapter 2 
clearance is delayed in type 2 diabetes mellitus.8 1 Increased plasma triglycerides are 
due to elevated VLDL triglycerides which are 1 .5 3 times higher in type 2 diabetes 
mellitus. The magnitude of this increase depends on the co-occurrence of obesity and 
the degree of glycaemic control.80 Plasma triglycerides are not higher in adequately 
controlled type 2 diabetic patients with similar insulin sensitivity compared to healthy 
subjects.82 HDL cholesterol is 10-20% lower in unselected type 2 diabetic patients, 
which is mainly due to a decrease in HDLi and to some extent in HDL3 .
80;83 The low 
HDL cholesterol in type 2 diabetes mellitus is partly due to a decrease in HDL 
cholesteryl ester and is accompanied by higher HDL triglycerides.35;37 This decrease 
in HDL cholesteryl ester/triglyceride ratio is more pronounced in obese type 2 
diabetic patients.84 Furthermore, even when metabolic control is adequate, free 
cholesterol and phospholipids on the HDL surface are decreased, resulting in an 
altered viscosity.85 Moreover, both decreases in LpA-I concentration but not in LpA­
I/A-11,86 as well as decreases in LpA-I/A-11 but not in LpA-I87 have been documented 
in type 2 diabetes mellitus. These discrepancies are probably attributable to 
differences in methodology as well as to the extent of hypertriglyceridaemia. 86 Pre P­
HDL levels are reported to be elevated in hypertriglyceridaemic states,88;89 but 
surprisingly there are no reports comparing pre P-HDL in unselected type 2 diabetic 
patients with healthy subjects. In type 2 diabetic patients matched with healthy 
subjects for HDL cholesterol, we found no significant increase in pre P-HDL 
formation.90 
Lipoprotein lipase: LPL activity can be measured in post-heparin plasma, as 
well as in adipose tissue and muscle. Post-heparin plasma LPL activity is probably 
affected by insulin resistance as such and by the diabetic state. Plasma LPL activity is 
reported to be decreased in insulin resistant subjects without diabetes,91 although the 
difference with insulin sensitive subjects did not always reach significance.82 Early 
studies showed decreased LPL activities in post-heparin plasma and in type 2 diabetes 
mellitus.92 More recently, we observed a lower post-heparin plasma LPL activity in 
adequately controlled, insulin resistant type 2 diabetic subjects compared to type 2 
diabetic patients with relatively normal insulin sensitivity.82 In that study, no 
difference was observed in LPL activity between type 2 diabetic patients and non­
diabetic subjects with a similar degree of insulin sensitivity.82 A decreased LPL 
activity has been documented in adipose tissue from type 2 diabetic patients,84 
although the insulin resistance- and diabetes-associated lowering of adipose tissue 
LPL activity has been questioned.93 Muscle LPL activity is negatively related to both 
plasma triglycerides and to the degree of insulin resistance.93 
Hepatic lipase: Hepatic lipase (HL) is also measured in post-heparin plasma. 
Post-heparin HL activity correlates positively with insulin resistance in non-diabetic 
subjects,94 and in type 2 diabetic patients82:95_ Therefore, hyperinsulinaemia may 
underlay enhanced HL activity, which results in low HDL cholesterol. However, 
insulin administration decreases HL activity.95 Thus, the effects of insulin resistance 
and of short-term exogenous hyperinsulinaemia on the HL activity should be 
discerned. 
A decreased post-heparin plasma LPL/HL ratio has been observed in insulin 
resistant subjects without and with diabetes.82:91 Such a decreased LPL/HL ratio is a 
determinant of low HDL2 cholesterol.
9 1  
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Endothelial lipase: As yet, no data are available with respect to possible 
abnormalities in EL in insulin resistance and type 2 diabetes mellitus. 
Lecithin: cholesterol acyltransferase: Established methods for assaying 
cholesterol esterification in total plasma include measurement of changes in plasma 
free cholesterol mass after incubation of plasma96 and detection of radiolabelled 
cholesteryl ester after plasma incubation with radiolabelled free cholesterol.97 Such 
assays depend on the chemical composition of the substrate lipoproteins as well as on 
the amount of active LCAT, and reflect the actual situation in vivo. 97 Plasma LCAT 
activity can also be measured with exogenous substrate assays.98 The effect of 
endogenous plasma lipoprotein substrates is minimised, so that plasma LCAT activity 
level reflects the amount of active protein. Accordingly, LCAT activity assayed by 
these latter methods are strongly correlated with its plasma concentration,98 which can 
be measured with specific immunochemical assays. 99 The terms plasma cholesterol 
esterification and LCAT activity are frequently used interchangeably. Obviously, one 
should discern between these two types of assay systems. We use the terms plasma 
cholesterol esterification and LCAT activity to indicate cholesterol esterification and 
LCAT activity per se, respectively. Plasma cholesterol esterification is unaltered 1oo; I O I  
or increased37;102 in type 2 diabetic patients. Since plasma triglycerides determine the 
rate of cholesterol esterification,34;3 the absence of higher plasma triglyceride levels 
in type 2 diabetes mellitus compared to healthy subjects in some of these reports 101 
may explain at least in part this discrepancy. Plasma cholesterol esterification is 
increased in insulin resistant type 2 diabetic patients compared to insulin sensitive 
healthy subjects, reflecting the relationship between insulin sensitivity and plasma 
triglyceride levels.82 Plasma LCAT activity is reported to be increased in in insulin 
resistant subjects without diabetes 1 1  and in type 2 diabetic subjects37 but in the latter 
study the difference disappeared after excluding hypertriglyceridaemic patients.37 
Cholesteryl ester transfer protein: Endogenous assay systems assess 
cholesteryl ester transfer between HDL particles and apo B-containing lipoproteins by 
measurement of changes in lipoprotein cholesteryl ester after incubation of plasma 
under conditions of LCAT inhibition, or by measurement of changes in specific 
radioactivity of cholesteryl ester donor or acceptor lipoproteins. Exogenous assays 
measure plasma CETP activity as transfer of radiolabelled cholesteryl ester between 
LDL and HDL. 103 Exogenous substrates, i.e. is LDL or HDL, are added in excess, 
minimising the effect of endogenous lipoproteins on plasma CETP activity 
measurement. Plasma CETP activity assayed this way is strongly correlated with 
CETP mass.48;49 Clearly, the results obtained from endogenous and exogenous 
substrate assays provide different information about the process of cholesteryl ester 
transfer. We use the results from endogenous and exogenous substrate assays to 
designate plasma CETP activity and cholesteryl ester transfer, respectively. Plasma 
cholesteryl ester transfer is found to be increased in insulin resistant subjects without 
diabetes compared to insulin sensitive individuals.82 With one exception 104 plasma 
cholesteryl ester transfer either between HDL and VLDL + LDL or between HDL and 
VLDL is elevated in adequately controlled type 2 diabetic patients with moderately 
elevated triglycerides compared to healthy subjects.37; ios; I06 Plasma cholesteryl ester 
transfer, if evaluated, was positively correlated with plasma triglycerides in all these 
studies.37; I04; Ios While cholesteryl ester transfer from HDL to VLDL is enhanced, the 
transfer from HDL to LDL is decreased in type 2 diabetes mellitus. 105 The enhanced 
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cholesteryl ester transfer from HDL to VLDL is due to an increased ability of VLDL 
to accept cholesteryl ester from HDL. 106 Generally, there is no difference in plasma 
CETP activity between insulin sensitive and insulin resistant subjects, 1 1 and between 
type 2 diabetic and healthy subjects.37:s4: •04: ios; io7 Some data point to a slightly lower 
plasma CETP activity in type 2 diabetes mellitus. 108 These studies emphasise the 
importance of insulin resistance-related and diabetes-related changes in the 
constellation of cholesteryl ester acceptor lipoproteins to explain the enhanced plasma 
cholesteryl ester transfer. Plasma CETP activity is unaltered or decreases modestly 
after insulin infusion.84; i o?; ios In accord with increased cholesteryl ester transfer in 
hypertriglyceridaemia, plasma cholesteryl ester transfer decreases in parallel with a 
drop in plasma triglycerides after exogenous insulin.35 Finally, it is noteworthy that 
together with the plasma triglyceride concentration plasma CETP activity is a 
determinant of small dense LDL in type 2 diabetes mellitus. 109 
Phospholipid transfer protein: Plasma PL TP activity can be measured with 
radio-isotopes using a phospholipid vesicles-exogenous HDL system. 1 10 Plasma PL TP 
activity so assayed specifically reflects the amount of active PLTP.1 1 1 : 1 1 2 As yet, it 
appears that there is only a weak positive correlation between PL TP mass and activity 
when applying polyclonal rabbit antibodies against human PLTP.1 13 Plasma PLTP 
activity has been reported to be elevated84 in type 2 diabetic patients in association 
with high plasma triglycerides and obesity.37 Likewise, when comparing insulin 
resistant with insulin sensitive subjects without diabetes mellitus, a higher plasma 
PLTP activity is related to insulin resistance in men84:94 and in women only1 14• In 
another study, we found no increase in plasma PLTP activity in type 2 diabetic 
patients but they were matched for HDL cholesterol with healthy subjects. 1 1 5 Plasma 
PL TP mass, measured with polyclonal antibody ELISA is elevated in type 2 diabetes 
mellitus, 1 1 3 but we did not observe a higher plasma PLTP mass, measured with a 
monoclonal antibody ELISA, despite elevated plasma PLTP activity levels.50 So, 
there may be relatively more active PL TP in diabetic plasma. Interestingly, various 
studies reported relationships between high plasma PL TP activity, elevated plasma 
triglycerides37:s4; 105: 1 1 1 and indexes of obesity. 84; 1 1 1 ; 1 16; 1 17 Indeed, plasma PLTP activity 
is not elevated in type 2 diabetic patients with a relatively normal body mass 
index.84; 108 However, given the interrelationships between obesity, insulin resistance 
and high plasma triglycerides, it is difficult to discern between the independent effects 
of these parameters on PL TP regulation. Manoeuvres decreasing plasma FF A and 
triglycerides like insulin infusion and acipimox administration decrease PL TP 
activity.84; i os; i i s  In (obese) type 2 diabetic patients the drop in plasma PLTP activity 
after insulin appears to be blunted,84 suggesting that high plasma PLTP activity levels 
in insulin resistant states could be in part due to a diminished lowering by insulin. 
Conversely, an intravenous fat load raises plasma PLTP activity.94 Insulin resistance 
on lipid metabolism may be a common denominator for these interrelationships 
between the regulation of plasma FF A, triglycerides and PLTP activity but the 
responsible molecular mechanisms remain to be explained. Of interest, an increased 
HDL triglyceride content coinciding with high plasma triglycerides enhances pre �­
HDL formation.88; 1 18 Thus, high plasma triglycerides and PLTP activity levels 
possibly act together in promoting HDL conversion. 
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Figure 2.3 shows abnorrnalitities in HDL remodelling in relation to lipases, 
LCA T and lipid transfer proteins in insulin resistance and type 2 diabetes mellitus. 
Figure 2.4 illustrates alterations in the CETP-mediated process of neutral lipid 
transfer in insulin resistance and type 2 diabetes mellitus. 
Figure 2.3. Effects of lipases, lecithin: cholesterol acyltransferase and lipid 
transfer proteins on altered high density lipoprotein remodelling in insulin 
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HDL: high density lipoproteins; TRL: triglyceride-rich lipoproteins; FC: free cholesterol; PL: 
phospholipids; LPL: lipoprotein lipase; HL: hepatic lipase; LCA T: lecithin: cholesterol 
acyltransferase; CETP: cholesteryl ester transfer protein; PL TP: phospholipid transfer protein. 
TRL pool is increased (larger circle); pre P-HDL is depicted as increased (larger area) but note that 
data in insulin resistance and type 2 diabetes mellitus are limited; Both HDL2 and HDL3 are decreased 
but this is more pronounced for HDL2 (smaller circles) than for HDL1 (smaller circles). LPL­
mediated TRL hydrolysis is diminished resulting in less transfer of FC and PL from TRL to pre P­
HDL and spherical HDL (shorter dolled arrow and smaller arrow head). Stimulatory effects of HL 
and PL TP on HDL remodelling are increased (thicker dolled arrows). Effects of LCA T and CETP are 
depicted as unaltered. Pre P-HDL generation from HDL1, as well as HDL2 towards HDL3 remodelling 
are increased (thicker long arrows). 
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Fig11re 2.4. Abnormalities in cholesteryl ester transfer protein-mediated neutral 
lipid transfer between high density lipoproteins, triglyceride-rich lipoproteins and 
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HDL: high density lipoproteins; TRL: triglyceride-rich lipoproteins; LDL: low density lipoproteins; CE: 
cholesteryl ester; TG: triglycerides; CETP: cholesteryl ester transfer protein; LTlP: lipid transfer protein 
inhibitor protein. 
TRL pool is increased (larger circle); HDL CE is decreased (smaller circle); LDL size is decreased 
(smaller circle) consequent to enhanced CE and TG transfer with TRL and subsequent triglyceride 
hydrolysis. CETP activity is depicted as unchanged (dotted arrows); L TIP action is depicted as 
unchanged (dotted arrows) with a question mark since there are no data in insulin resitance and type 2 
diabetes mellitus. There is more CE and TG transfer between HDL and TRL (thicker arrows) and 
between LDL and TRL (thicker arrows), and less CE and TG transfer between HDL and LDL (thinner 
arrows). 
Reverse cholesterol transport 
That HDL has important cardioprotective properties is undisputed.3;2 1 ;119 One of the 
anti-atherogenic properties of HDL is exerted by its function to scavenge peripheral 
tissue-derived cholesterol in the RCT pathway.120 Indeed, infusion of heterologous or 
acetylated LDL increases circulating HDL cholesterol in rabbits, suggesting that these 
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lipoproteins are able to clear LDL-derived cholesterol from tissues.121 Two lines of in 
vivo evidence directly indicate that in mammals a system exists, which is capable of 
effectively removing cholesterol from the arterial wall. This evidence also indicates 
that HDL has this ability, thereby retarding or even reversing atherosclerosis. Firstly, 
cholesterol fluxes were studied in the aortic intima-media of normolipidaemic humans 
who underwent aortic valve replacement and were free of visible atherosclerosis.122 
Applying infusion of homologous radiolabelled plasma, the mean cholesterol turnover 
time in the aortic intima-media layer amounted to I .  7 years, providing a measure of 
cholesterol influx.122 In comparison with the mean age of 62 years of the study 
subjects these observations indicate that removal of cholesterol must be a major 
determinant of aortic tissue cholesterol content. Secondly, it was demonstrated that 
weekly HDL infusions in rabbits during the last 30 days of a 90 days cholesterol 
feeding period reduces aortic cholesterol content by 55% and atherosclerotic lesion 
area by 50%. 1 23 Thus, thers is direct in vivo evidence exists that HDL administration 
does not only inhibit progression but also reverses established atherosclerosis. 
Although HDL is cardioprotective,3;2 1 ;1 19 it is important to realise that the level of 
circulating HDL cholesterol cannot be regarded as a measure of the dynamics of HDL 
cholesterol transport and thus will not necessarily indicate the efficacy of HDL­
mediated RCT. HDL cholesterol elevations could, therefore, reflect diminished HDL 
clearance and, hence, an impaired RCT.1 19 Conversely, low HDL cholesterol could in 
theory also be attributable to increased HDL removal in terms of hepatic cholesterol 
metabolism and biliary excretion. 
It is commonly thought that the RCT pathway consists of the following different 
steps: efflux of cholesterol from peripheral cells to extracellular acceptors, mainly pre 
P-HDL (i), subsequent LCAT-mediated esterification of free cholesterol within HDL 
contributing to HDL remodelling (ii), direct uptake of HDL-derived cholesterol by the 
liver (iii, a), indirect uptake of HDL-derived cholesteryl ester by the liver via CETP­
mediated transfer to apo B-containing lipoproteins (iii, b), and metabolism of 
cholesterol in the liver, followed by biliary excretion (iv). 
Efflux of cholesterol from peripheral cells to extracellular acceptors (i): 
Cholesterol efflux out of plasma membranes of peripheral cells to extracellular 
acceptors can occur through various mechanisms including fast specific energy­
dependent and passive slow diffusion-type processes. 1 9;28 Apo A-I on pre P 1-HDL 
promotes cellular cholesterol efflux. Its unique conformation on these particles13 
allows for both mechanisms.28 However, pre �1-HDL is not essential for cholesterol 
efflux out of fibroblasts and macrophages in vitro. 124 Also, scavenger receptor class 
B type I (SR-BI) 1 4;125 and ATP binding cassette transporter 1 (ABCAl )19;126 seem to 
be important in fast specific cholesterol efflux. SR-BI can promote free cholesterol 
efflux by a mechanism where cell surface-acceptor binding is relatively 
unimportant. 14 ABCAI is a key factor in intracellular lipid transport and in 
subsequent transmembrane lipid flux to extracellular apo A-I by forming an aqueous 
pore on the cell surface.126 Besides apo A-I, apo A-II is complexly involved in cellular 
cholesterol efflux. LpA-I/A-II particles only induce non-specific cholesterol efflux,28 
accounting for the reduced efflux to such particles.20;28; 1 27 Apo A-II binds well to SR­
BI,20;127; 128 and may negatively modulate SR-BI-mediated cholesterol efflux in 
vitro. 1 27 In contrast, Apo A-II enhances efflux after binding to ABCAI .127 
Furthermore, Apo A-II may stimulate HL activity in vitro28 and is able to displace 
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Apo A-I from HDL, thereby contributing to the generation of pre fl-HDL.20 It seems 
that Apo A-II could, therefore, have both cellular cholesterol efflux inhibiting and 
stimulating properties. 
LCAT-mediated esterification of free cholesterol within HDL and IIDL 
remodelling (ii): Cell-derived free cholesterol, contained within pre 13-HDL­
particles, is subsequently esterified by LCA T, allowing pre 13-HDL to become ex.­
migrating HDL3• 13 Cholesteryl ester is more hydrophobic than free cholesterol and 
migrates away from the HDL surface, enabling uptake of other free cholesterol 
molecules. 13 The LCAT reaction was initially hypothesised to be the rate limiting step 
in the RCT pathway. 1 20;129 It is now clear that LCAT is able to impede cellular 
cholesterol influx rather than to stimulate efflux. 1 30; 13 1 Moreover, the plasma 
cholesterol esterification rate is not correlated with the efflux of radiolabelled 
cholesterol from Fu5AH cells, 1 32 a cell line that expresses SR-BI but hardly any 
ABCA I .  As outlined earlier and depicted in figure 2. 1 ,  enlargement of HDL requires 
acceptance of more phospholipids and apolipoproteins, whereas further lipid loading 
results in HDL2 generation.
1 8  
Direct uptake of HDL-derived cholesterol by the liver (iii, a): Direct hepatic 
removal of HDL-derived cholesterol involves interaction with several receptors on the 
hepatocyte cell membrane. SR-BI stimulates uptake of HDL. In a proposed process 
called selective transcytosis, 133 HDL particles bind reversibly to SR-B1 14; 125 leading to 
selective transfer of cholesteryl ester into the cellular cholesterol pool. 133 SR-BI­
mediated cholesteryl ester uptake is impaired in apo A-I knock-out mice/28 and is 
diminished with LpA-1/A-II compared to LpA-1 particles. 134 Apo E may increase SR­
BI-mediated selective cholesterol uptake. 135 HL enhances the binding of HDL to SR­
BI, 136 thereby indirectly promoting uptake of HDL cholesterol in liver.24;27; 137 HDL 
also binds to a recently described apo A-I receptor, which is the ectopically expressed 
j3-chain of ATP synthase, 1 38 resulting in generation of extracellular ADP and in 
subsequent endocytosis. This endocytosis does not involve SR-BI or ABCA l .  138 The 
importance of this receptor for hepatic removal of HDL-derived cholesterol is not 
known. 
Indirect uptake of HDL-derived cholesteryl ester by the liver via CETP­
mediated transfer to apo B-containing lipoproteins (iii,b): The CETP-mediated 
cholesteryl ester transfer from HDL towards apo B-containing lipoproteins such as 
LDL and VLDL represents a second route transporting HDL-derived cholesterol to 
the liver. As cholesteryl ester mass transfer is most outspoken between HDL and 
triglyceride-rich lipoproteins,39 it is likely that HDL-derived cholesterol will be 
predominantly cleared by hepatocyte receptors that interact with chylomicron 
remnants, VLDL and VLDL remnants.41 ; 1 39-141 Its seems plausible that the interaction 
between LDL and its receptor plays a relatively minor role in RCT. VLDL is cleared 
via endocytosis by the LDL receptor,40 and by the LDL receptor-related protein 
(LRP), also designated as the VLDL receptor. 139 Chylomicron and VLDL remnants 
are also taken up in liver via the LRP. 139 The initial binding site may be formed by 
cell surface heparan sulfate proteoglycans. 140 Binding of VLDL is stimulated by HL 
and by LPL that acts as a ligand when contained within these lipoprotein particles but 
for subsequent degradation apo E is required. 140 The small fraction of HDL that 
contains apo E is also cleared via the LDL receptor and the LRP. 141  
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Note that in quantitative tenns the relative importance of the indirect route for 
hepatic uptake of HDL-derived cholesterol via apo B-containing lipoproteins vs. the 
direct route for hepatic uptake of cholesterol contained in HDL is not known. 
Metabolism of cholesterol in the liver, followed by biliary excretion (iv): 
Ultimately, cholesterol is excreted in the biliary tract, largely after conversion to bile 
acids. Microsomal cholesterol 7-cx-hydroxylase facilitates the first cholesterol 
conversion step in the Iiver. 142 After various subsequent hydroxylation and oxido­
reduction steps, chenodeoxycholic acid and cholic acid are fonned. Conjugation of 
these bile acids with taurine and glycine renders them more hydrophilic, facilitating 
their biliary excretion. Intestinal bacterial enzymes convert chenodeoxycholic acid 
and cholic acid in secondary bile acids, that can re-enter the circulating bile acid pool 
after reabsorbtion. Hepatic 7-cx-hydroxylase activity appears to be the rate limiting 
step for bile acid synthesis, providing a regulatory mechanism for hepatic cholesterol 
removal. 142 Interestingly, human PL TP overexpression in mice enhances the 
cholesteryl ester content of hepatic tissue and increases faecal bile acid excretion. 143 
Hepatobiliary cholesterol transport was found to be unaltered in experimental ABCAI 
deficiency. 144 
Figure 2.5 schematically depicts the RCT pathway under nonnolipidaemic 
circumstances. 
Reverse cholesterol transport in insulin resistance and type 2 diabetes 
mellitus 
Current knowledge is far from complete but it is likely that there are multiple 
abnonnalities in various steps of the RCT pathway in insulin resistance and type 2 
diabetes mellitus. 
Efflux of cholesterol from peripheral cells to extracellular acceptors (i): In 
general, the impact of metabolic disorders on cholesterol efflux to plasma can be 
studied in two ways. Firstly, the effect of extracellular acceptors on cellular 
cholesterol efflux can be evaluated while leaving the in vitro cell characteristics 
unaltered. Secondly, cells can be obtained from diseased subjects or be modified in 
vitro to document the effect of specific metabolic abnonnalities on cholesterol efflux 
at the cellular level. Cholesterol efflux from Fu5AH model cells, a widely used cell 
system, 14; 1 32 is positively correlated with HDL phospholipids, HDL cholesterol, apo 
A-I as well as with pre �-HDL. s9;9o;ii7: 132 Using these cells, it is suggested that 
cellular cholesterol efflux to plasma from insulin resistant subjects is maintained 
despite lower HDL cholesterol.89 This may be attributable to higher pre �-HDL 
fonnation in association with increased plasma triglycerides and plasma PL TP 
activities in insulin resistance. Elevated plasma triglycerides coincide with a relative 
increase in the HDL phospholipid content. 145 Since cell cholesterol efflux is positively 
related to HDL phospholipids,89 this may explain why cholesterol efflux from Fu5AH 
cells to hypertriglyceridaemic plasma can be unaltered. 145 Although these data suggest 
that low HDL cholesterol does not necessarily imply an impaired first RCT step, 
cholesterol efflux from Fu5AH cells to plasma with low HDL cholesterol is reported 
to be diminished. 146 Importantly, the cell line used probably affects the extent and 
dynamics of cellular cholesterol efflux, as evidenced by different results when using 
Fu5AH cells compared to macrophage-like 1774 cells, a cell line that predominantly 
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Figure 2.5. Reverse cholesterol transport in normolipidaemia 
HDL: high density lipoproteins; LDL: low density lipoproteins; TRL: triglyceride-rich lipoproteins. 
FC: free cholesterol; CE: cholesteryl ester; HL: hepatic lipase; LCAT: lecithin: cholesterol 
acyltransferase; CETP: cholesteryl ester transfer protein; PL TP: phospholipid transfer protein; SR-BJ: 
scavenger receptor B-1; ABCA- 1 :  ATP-binding cassette transporter A I ;  LRP: LDL receptor-related 
protein; • other mechanisms including unmediated aqueous diffusion and apolipoprotein interactions 
with the plasma membrane. Note that only pre B-HDL as acceptor of cell-derived cholesterol is 
shown. The importance of the ectopically expressed B-chain of ATP synthase for removal of HDL­
associated cholesterol is not known (question mark). Long arrows indicate cholesterol transport 
routes. Dotted arrows indicate stimulatory effects of HL, LCA T and lipid transfer proteins. 
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expresses ABCA 1. 127:146 Cholesterol net transport from cultured fibroblasts to 
severely hyperglycaemic plasma may be impaired, an abnonnality which is reversed 
after blood glucose lowering with insulin. 147 Cholesterol efflux out of Fu5AH cells to 
diabetic plasma is also diminished.86;s9: 148 However, when comparing efflux from 
Fu5AH cells to plasma of diabetic and healthy subjects matched for HDL cholesterol, 
no differences in efflux appeared.9° Cellular cholesterol efflux is not correlated to 
plasma apo A-I in type 2 diabetic patients in contrast to healthy subjects.90 Instead, 
efflux out of Fu5AH cells is positively related to the plasma LpA-I/A-11 concentration 
in type 2 diabetes mellitus.86; 148 Decreased LpA-I/A-11 levels87 may, therefore, 
contribute to a lower cellular cholesterol efflux in type 2 diabetes mellitus. The effect 
of HDL glycation is controversial. In vitro glycation of HDL3 impairs cholesterol 
efflux from human skin fibroblasts. 149 The ability of glycated LpA-I to promote efflux 
out of Fu5AH cells is also diminished. 1so However, no effect of HDL3 glycation on 
cholesterol efflux out of mouse peritoneal macrophages was observed. 1 s 1 
Concerning cell-related changes on cholesterol efflux, supraphysiological 
concentrations of insulin impair cellular HDL binding as well as HDL-mediated 
cholesterol efflux from fibroblasts in vitro, suggesting that very high levels of insulin 
decrease the first step in RCT. 1s2 Moreover, it has been shown that advanced 
glycation end products, as accumulating in the diabetic state, may interfere with SR­
BI mediated cholesterol efflux in vitro. 12s;ISJ Furthennore, when 1774 macrophages 
are incubated with unsaturated FF A, in order to mimic elevated FF A levels as 
observed in insulin resistance and type 2 diabetes mellitus, cellular cholesterol efflux 
is decreased, consequent to diminished cellular ABCA I expression.154 In peritoneal 
macrophages from insulinopenic diabetic mice, ABCAI mRNA expression is 
markedly decreased. iss This abnonnality is reversed by adding insulin, but is unlikely 
due to an effect of insulin itself. 156 In both studies, co-incubation with saturated FF A 
had no effect on cellular ABCAI abundancy nor on cellular cholesterol efflux. 1 s4; Is6 
ABCA I mRNA expression in circulating mononuclear cells from type 2 diabetic 
patients is reduced compared to healthy subjects. 1ss 
Taken together, these findings suggest that cholesterol efflux from peripheral 
cells to plasma is impaired in the diabetic state, consequent to lipoprotein acceptor 
changes and to cellular abnormalities. In insulin resistance, however, the ability of 
plasma to stimulate cellular cholesterol efflux may be unaltered. In this situaton, it is 
uncertain whether cellular abnonnalities, consequent to hyperinsulinaemia and FF A 
elevations, will result in a diminished cholesterol removal. 
LCAT-mediated esterification of free cholesterol within HDL and HDL 
remodelling (ii): As described earlier and depicted in Figure 2.3, several mechanisms 
are probably involved in altered HDL remodelling in insulin resistance and type 2 
diabetes mellitus. Pre P-HDL fonnation may be increased as a result of higher plasma 
PLTP and HL activities, HDL triglyceride enrichment and enhanced PLTP-mediated 
phospholipid transfer from the enlarged triglyceride-rich lipoprotein pool to pre P­
HDL. 27:72:73: 1 18 Free cholesterol transport from this pool to HDL3 may be increased. 
Moreover, higher plasma PLTP and HL activities stimulate HDL2 towards HDL3 
remodelling. In view of the to some extent inconclusive data concerning plasma 
cholesterol esterification,37:82: 100- 102 we assume that the cholesterol esterification­
related effects on HDL remodelling are unchanged in insulin resistance and type 2 
diabetes mellitus. Furthennore, elevated plasma triglycerides in insulin resistance and 
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type 2 diabetes mellitus increase the cholesteryl ester transfer process out of HDL, 
thereby causing cholesteryl ester depletion and triglyceride enrichment of these 
particles.35;37 This effect could be accentuated by glycation of (apo) lipoproteins in 
diabetes, which may further enhance plasma cholesteryl ester transfer. 1 57 HDL 
catabolism is increased as a result of HDL triglyceride enrichment. 1 58 The 
consequence of all these abnormalities is a decreased HDL cholesterol which is more 
pronounced for HDL2 than for HDL3 • 83 
Direct uptake of HDL-derived cholesterol by the liver (iii, a): Apart from 
effects of changes in circulating HDL (subfraction) levels, the direct pathway of 
HDL-derived cholesterol binding and uptake in liver may be abnormal in insulin 
resistance and type 2 diabetes mellitus in vivo. Although SR-BI mRNA expression is 
unaltered in circulating mononuclear cells from type 2 diabetic patients, 1 55 selective 
HDL cholesteryl ester uptake via SR-Bl may be modified in type 2 diabetes mellitus. 
It is possible that high plasma HL activity as found in insulin resistance and type 2 
diabetes mellitus 1 1 ;82;95 stimulates HDL binding to SR-Bl. On the other hand, 
advanced glycation end products can inhibit SR-BI mediated selective HDL 
cholesteryl ester uptake in HepG2 cells by interference with intracellular 
processing. 1 53 However, the consequences for these apparently opposite effects of 
high plasma HL activity and of elevations in advanced glycation end products in 
diabetes on the dynamics and efficacy of SR-Bl-mediated HDL cholesteryl ester 
uptake in liver are still unknown. 
Indirect uptake of HDL-derived cholesteryl ester by the liver via CETP­
mediated transfer to apo B-containing lipoproteins (iii, b): Data concerning uptake 
of apo B-containing lipoproteins via the LDL receptor and the LRP in insulin 
resistance and type 2 diabetes mellitus are limited. Using HepG2 cells, LDL receptor­
mediated uptake and degradation of LDL obtained from hypertriglyceridaemic 
diabetic plasma is less effective than that of LDL isolated from plasma of non­
diabetic hypertriglyceridaemic subjects and that of in vitro glycated LDL. 159 
Moreover, the latter two LDL fractions bind less effective to this receptor than normal 
LDL. 1 59 Since LDL receptor mRNA expression in mononuclear cells from type 2 
diabetic patients is unchanged, 1 55 the diminished LDL receptor-mediated LDL 
degradation 159 may point to posttranslational modification of LDL receptor action. 
Insulin resistance-associated and type 2 diabetes mellitus-associated alterations in the 
LDL receptor pathway are possibly less important for RCT than abnormalities in the 
LRP pathway, because net cholesteryl ester mass transfer out of HDL is much greater 
to triglyceride-rich lipoproteins than to LDL.39 The scanty data concerning LRP­
mediated cholesterol uptake in insulin resistance and type 2 diabetes mellitus are 
inconclusive. LRP mRNA expression in skeletal tissue from type 2 diabetic patients is 
lower, 1 60 whereas its expression in mononuclear cells is unaltered. 1 55 Nonetheless, 
VLDL catabolism is probably impaired in type 2 diabetes mellitus as witnessed by a 
decreased fractional catabolic rate ofVLDL triglycerides and apo B in type 2 diabetes 
mellitus, 16 1  which is compatible with a decreased VLDL-mediated transport of HDL­
derived cholesteryl ester to the liver. 162 
Metabolism of cholesterol in the liver, followed by biliary excretion (iv): 
Early data have shown that cholesterol synthesis, faecal bile acid excretion and bile 
acid pool size are elevated during uncontrolled hyperglycaemia in type 2 diabetic 
patients. 163 However, the interpretation of these changes in terms of altered RCT is 
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unclear. To date no studies have evaluated hepatic cholesterol metabolism of HDL­
derived cholesterol and subsequent hepatobiliary cholesterol and bile acid transport in 
insulin resistance and type 2 diabetes mellitus. It is unknown whether elevated PL TP 
activity associated with these conditions affect this step in RCT, as demonstrated with 
experimental PL TP overexpression. 143 
Table 2. 1 summarises available data with respect to abnonnalities in RCT in 
insulin resistance and type 2 diabetes mellitus. 
Table 2.1. Abnormalities in reverse cholesterol transport in insulin resistance and 
type 2 diabetes mellitus 
Effiux of cholesterol from peripheral cells to extracellular acceptors 
Resulting/ram abnormalities in extracellular acceptors 
Insulin resistance may be unaltered 
Type 2 diabetes mellitus impaired 
Resulting/ram cellular abnormalities 
Insulin resistance 
Type 2 diabetes mellitus 
unknown 
impaired 
LCAT-mediated esterification of free cholesterol within HDL and HDL remodelling 
Insulin resistance 
Type 2 diabetes mellitus 
cholesterol esterification proposedly unchanged, multiple abnonnalities 
in HDL remodelling 
idem 
Direct uptake ofHDL-derived cholesterol by the liver 
Uptake of HDL-derived cholesterol via scavenger receptor class B type I 
Insulin resistance stimulatory effect of high hepatic lipase activity possible 
Type 2 diabetes mellitus stimulatory effect of high hepatic lipase activity possible; inhibitory 
effect of advanced glycation end products possible; net effect unknown 
Indirect uptake of HDL-derived cholesteryl ester by the liver via CETP-mediated transfer to apo B­
containing lipoproteins 
Via LDL-LDL receptor interaction 
Insulin resistance 
Type 2 diabetes mellitus 
Via TRL-LRP interaction 
Insulin resistance 
Type 2 diabetes mellitus 
unknown 
impaired LDL receptor-mediated LDL degradation 
unknown; effect of high hepatic lipase activity unknown 
possibly impaired as reflected by diminished VLDL catabolism 
Via TRL-LDL receptor interaction 
Insulin resistance 
TyPe 2 diabetes mellitus 
unknown 
unknown 
Metabolism of cholesterol in the liver, followed by biliary excretion 
Insulin resistance 
Type 2 diabetes mellitus 
unknown 
unknown 
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Strategies to inhibit plasma cholesteryl ester transfer and cholesteryl 
ester transfer protein activity 
As discussed earlier in this review CETP is able to lower cholesteryl ester in HDL and 
to raise cholesteryl ester in triglyceride-rich lipoproteins. Moreover, an enhanced 
cholesteryl ester transfer provides a plausible metabolic intermediate for the exchange 
between high plasma triglycerides and low HDL cholesterol as observed in insulin 
resistance and type 2 diabetes mellitus. Of interest, experimental data in rats 
transgenic for human CETP, show that CETP may be proatherogenic. 164 It is, 
therefore, of clinical relevance to ascertain the effects of lipid lowering drugs (statins 
and fibrates) on plasma cholesteryl ester transfer and CETP activity. Moreover, the 
effects of recent approaches to specificically inhibit CETP on HDL metabolism and 
on atherosclerosis will be outlined. 
Evidence for an effect of statin treatment on plasma cholesteryl ester transfer and 
CETP activity is derived from the following studies. In hypertriglyceridaemic 165 and 
combined hyperlipidaemic subjects, 166 LDL cholesterol lowering in response to 
atorvastatin is accompanied by a small decrease in plasma CETP activity. In familiar 
hypercholesterolaemia, pravastatin markedly decreases plasma cholesteryl ester 
transfer without affecting plasma CETP concentration. 167 A drop in plasma 
cholesteryl ester transfer after pravastatin treatment has also been demonstrated in 
type 2 diabetes mellitus. 168 Finally, simvastatin decreases plasma CETP concentration 
in normolipidaemic subjects, 169 whereas this treatment results in a non-significant 
decrease in plasma CETP activity in rabbits. 170 
In general, plasma CETP concentration remains unaltered after treatment with 
gemfibrozil or bezafibrate, 1 7 1 ; 1 72 whereas plasma CETP activity has been variably 
reported to decrease, 173- 1 75 to remain unchanged 1 76 or to increase slightly177 after 
fibrate treatment. Plasma cholesteryl ester transfer is lowered in response to 
gemfibrozil, bezafibrate and fenofibrate therapy, probably as a consequence of a fall 
in triglyceride-rich lipoproteins. 171 ; 174 A study in normolipidaemic subjects showed a 
diminished ability of HDL to provide cholesteryl esters for neutral lipid transfer after 
gemfibrozil. 176 
Plasma CETP activity can be specifically inhibited with chemical agents, 170; 178- 181 
and with antisense oligonucleotides. 1 82 Furthermore in rabbits, administration of 
CETP antibodies 1 83 and active vaccination against CETP 1 84 lower its activity in 
plasma. Chemical agents that specifically inhibit CETP include JTT-705, SC 7 1952 
and CGS 25 159. 1 70; 178-18 1  JTT-705 and SC 7 1952 act by forming disulphide bonds 
with Cys- 1 3  of CETP, 170:179; I S I  which is probably located near its neutral lipid binding 
site. 179 Orally administered CETP inhibitors increase apo A-I and HDL cholesterol 
with a greater rise in HDL2 than in HDL3, and decrease VLDL + LDL cholesterol in 
both rabbits170 and humans 1 81 • In rabbits, JTT-705 treatment decreases plasma CETP 
activity by 95%. 170 Of major importance, this treatment in rabbits inhibits progression 
of aortic atherosclerosis. 1 7° Furthermore, the ability of HDL to promote cholesterol 
efflux from J774 macrophages in vitro remains unaffected after JTT-705 treatment. 1 80 
In view of the rise in HDL cholesterol after CETP inhibitor and the efflux promoting 
effects of a high HDL cholesterol concentration, this suggests that JTT705 treatment 
may stimulate the first step of RCT. Treatment with this CETP inhibitor at a daily 
dose of 300 to 900 mg increases HDL cholesterol by 1 5  to 30% in a dose-dependent 
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fashion in healthy humans. 181 Plasma CETP activity is lowered by 3 7% after several 
weeks of daily treatment with 900 mg JTT-705 but CETP mass concentration is 
increased, which could be due to a diminished CETP clearance.181 In humans, plasma 
PL TP activity is unaffected by JTT-705 administration, indicating that this agent does 
not cross react with PLTP.181 The isoflavan derivative, CGS 25159, increases HDL 
cholesterol and HDL particle size in hamsters.178 Further data are needed to show its 
action in man. In rabbits, administration of antisense oligonucleotides against CETP 
targeted to liver inhibits CETP transcriptionally.182 As a result, plasma CETP activity 
and CETP concentration are decreased, and HDL cholesterol is increased.182 This 
approach also reduces the aortic atherosclerotic lesion area after 16 weeks on a 
cholesterol enriched diet.182 
Taken together, the above mentioned studies show that the effects of statins as 
well as fibrates on the cholesteryl ester transfer process are modest. Therefore, it will 
be of great clinical interest to combine these drugs with specific CETP inhibitors to 
reduce plasma cholesteryl ester transfer and to raise HDL more profoundly. Indeed, 
clinical trials with CETP inhibitors using surrogate end-points such as intima media 
thickness will soon be started. We propose that dyslipidaemia as occurring in insulin 
resistance and type 2 diabetes mellitus will become an important target for CETP 
inhibitor therapy. 
Conclusions and future research 
HDL cholesterol is decreased whereas HDL subfraction levels and HDL remodelling 
are altered in insulin resistance and type 2 diabetes mellitus in conjunction with high 
plasma triglycerides. These abnormalities are likely to be explained at least in part by 
a low post-heparin plasma LPL/HL ratio and by an increased CETP-mediated plasma 
cholesteryl ester transfer, a process that provides a metabolic intermdiate between low 
HDL cholesterol and high plasma triglycerides. Elevated plasma PLTP activity in 
association with high plasma triglycerides and obesity will affect HDL remodelling as 
well, including enhanced pre �-HDL formation. 
HDL plays a pivotal role in the anti-atherogenic RCT pathway, whereby 
cholesterol is transported from peripheral cells to the liver for metabolism and 
subsequent biliary excretion. Much has to be discerned about the exact defects and 
perhaps compensatory mechanisms that are operative in this pathway in insulin 
resistance and type 2 diabetes mellitus. Efflux of cholesterol from peripheral cells to 
extracellular acceptors is considered to represent the first step of RCT. In insulin 
resistance the ability of plasma to promote cellular cholesterol efflux may be 
maintained. It is uncertain whether insulin resistance leads to cellular abnormalities 
that affect cholesterol removal. In the diabetic state, it is likely that cellular 
cholesterol efflux is impaired as a result of changes in HDL subfraction levels as well 
as of cell-related defects. As yet, data with respect to abnormalities in the uptake of 
HDL-derived cholesterol by the liver (both directly and via CETP-mediated transfer 
to apo B-containing lipoproteins) and subsequent hepatic metabolism and biliary 
excretion in insulin resistance and type 2 diabetes mellitus are far from complete. 
Therefore, the extent to which these steps in RCT are abnormal in these common 
disorders is uncertain at present, and much research concerning hepatic metabolism of 
HDL-derived cholesterol as well as with respect to HDL dynamics in vivo is needed. 
42 Chapter 2 
One prom1smg new pharmacological approach to treat insulin resistance­
associated and diabetes-associated dyslipidaemia will be the administration of specific 
CETP inhibitors that have been recently demonstrated to raise HDL cholesterol to a 
relevant extent in normolipidaemic humans, and to retard atherosclerosis development 
experimentally. 
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Abstract 
Objectives. The cardioprotective effects of high density lipoproteins (HDL) are 
widely recognized but little is known about the strength of association between HDL 
cholesterol and prevalent myocardial infarction when its most abundant 
apolipoproteins (apos), apo A-I and apo A-II, are taken into account. Moreover, the 
relationships of HDL cholesterol and these apos with myocardial infarction may be 
different in men compared to women. 
Design. Cross-sectional population-based study. 
Setting. General PREVEND study population of the Dutch city of Groningen. 
Subjects and methods. In 6630 subjects (3306 women; 515 subjects with previous 
myocardial infarction; the others without cardiovascular diseases), HDL cholesterol, 
serum apo A-I and apo A-II were measured. 
Results. HDL cholesterol (P < 0.01 )  and apo A-I (P < 0.05) were lower in men and 
women (P < 0.001 and P < 0.05) with myocardial infarction compared to subjects 
without cardiovascular disease, but apo A-II was only lower in men with myocardial 
infarction (P < 0.001 ). Multiple logistic regression analyses demonstrated that in men 
the strongest inverse association with myocardial infarction was found for apo A-II, 
followed by apo A-1. This relationship with apo A-II remained after adjustment for 
HDL-related clinical factors and HDL cholesterol. In contrast, in women no inverse 
association of myocardial infarction with apo A-II was observed after adjustment for 
these factors. Linear regression analyses revealed that for a given apo A-I and apo A­
II level, HDL cholesterol was higher in women. 
Conclusions. This cross-sectional study suggests that the interrelationships of HDL 
cholesterol, apo A-I and apo A-II with myocardial infarction differ between men and 
women which may be due to gender-dependent effects on HDL composition. It is 
proposed that the prospectively determined cardiovascular risk attributable to low 
HDL cholesterol, apo A-I and apo A-II needs to be determined separately in both 
genders. 
Key words: apolipoprotein A-1, apolipoprotein A-II, high density lipoprotein, gender, 
cardiovascular disease. 
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Introduction 
An inverse relationship between the HDL cholesterol level and cardiovascular disease 
has been observed both in cross-sectiona1 1 -8 and prospective studies9- 14 HDL particles 
are heterogeneous in apolipoprotein content, size, and lipid composition. 
Apolipoprotein A-I (apo A-I) and apolipoprotein A-II (apo A-II) are the most 
abundant apolipoproteins (apos) making part of HDL particles.15 HDL particles can 
be divided in LpA-I that contain only apolipoprotein A-I, and LpA-1/A-II that carry 
both apo A-I and apo A-II. HDL particles can also be divided according to density in 
the less dense and larger HDL2 and the more dense and smaller HDL3, and according 
to size by NMR spectroscopy. 16 




6 have been shown to correlate negatively with cardiovascular disease, although 
not all reports demonstrated significant differences for apo A-17; , o  or apo A-11 12• 
Importantly, the relationships between HDL or HDL-related apos and cardiovascular 
disease, is confounded by gender differences in levels of (apo)lipoproteins as well as 
in the incidence of cardiovascular disease. HDL cholesterol is lower in men than in 
women13; 1 7-21 , as is apo A-I 1 9;2 1 -25 and LpA-I18;2 1 ;22;24, although some studies did not 
reveal gender differences in ar,o A-1
18
;
26 or LpA-1 1 9• In contrast, serum levels of apo 
A-I1�2-24;26;27 and LpA-I/A-II1 ;l9;2 1 ;22;24 may not differ between sexes. It is largely 
unknown whether there are gender-dependent differences in the interrelationships of 
HDL cholesterol and HDL-related apos with cardiovascular disease. Few studies 
regarding the relationship of HDL cholesterol with cardiovascular disease took the 
apo A-I level into consideration.8; 14 Only one study corrected for both apo A-I and 
apo A-II in evaluating the association of HDL cholesterol with cardiovascular disease, 
but this relationship was not determined in men and women separately.2 
Therefore, the aim of the current study was to evaluate the interrelationships of 
apo A-I, apo A-II and HDL cholesterol with previous myocardial infarction among 




The database used for this study consists of a cross-sectional sample of 8592 
Groningen inhabitants, participating in the PREVEND ("Prevention of REnal and 
Vascular ENd stage Disease") study. Details of the protocol have been described 
elsewhere.28 In short, the PREVEND study investigates vascular and renal damage in 
the general population. The study was approved by the local medical ethics 
committee. All participants gave written informed consent. 
The interrelation between HDL-C, apo A-I and apo A-II may be different in 
coronary heart disease, peripheral vascular disease and cerebrovascular disease and 
could be modified by the severity of coronary heart disease. Therefore, this study 
compares subjects with a proven myocardial infarction with subjects without any 
evidence of cardiovascular disease. Subjects with missing values of serum apo A-I, 
apo A-II or HDL cholesterol (n=565) were excluded, leaving a data set of 8027 
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part1c1pants. Overall, 5 1 5  subjects were diagnosed with previous myocardial 
infarction, as evidenced from either a history of hospital admission for myocardial 
infarction (n = 256) and/or from ECG changes characteristic for myocardial infarction 
(n = 35 1  ). Participants without myocardial infarction, but with major cardiac 
ischaemia, peripheral vascular disease and cerebrovascular disease were excluded (n 
=1397), leaving 61 1 5  subjects with no evidence of previous or existing cardiovascular 
disease. 
Study protocol 
The screening program consisted of two visits to the out-patient clinic.28 The medical 
history focussed on previous hospital admission for myocardial infarction or 
cerebrovascular accident. The questionnaire included information with respect to 
alcohol use but not concerning physical activity. The use of lipid lowering drugs was 
recorded and it was estimated that statins were most widely used (> 90% of lipid 
lowering drug prescription). However, individual subject data concerning the use of 
either statin or fibrate therapy were considered to be insufficiently precise to allow for 
separate analysis for the type of lipid lowering drugs. Body mass index (BMI) was 
calculated as the ratio between weight and height squared (kg/m2). Waist/hip ratio 
was the waist circumference divided by the hip circumference. Blood pressure was 
measured in the supine position, using an automatic Dinamap XL Model 9300. Blood 
pressure was calculated as the mean of the last two measurements of both visits. 
During the second and the fifth min, the blood pressure of the left ankle and the right 
ankle were measured. Thereafter, the mean of both ankle-brachia! indexes was 
calculated from the ratio of ankle pressure and the accompanying arm pressure. After 
1 5  min rest, blood samples were taken. Urinary albumin excretion was assessed as the 
mean of two 24h urine collections. 
Definitions 
Myocardial infarction was documented if ECG detected myocardial infarction by 
Minnesota code 1 - 1 - 1  to 1 -2-8, and/or if the participant had a history of hospital 
admission for myocardial infarction.29 Prior hospitalisations because of myocardial 
infarction are obtained using questionnaires. ECG patterns are regularly used in 
epidemiological studies to detect myocardial infarction according to thoroughly 
evaluated methods.30-33 Major ischaemia was defined by Minnesota code 4-1 ,  4-2, 5-
1, or 5-2. Peripheral vascular disease was defined as an ankle-brachia! index lower 
than 0.9 or when medical history revealed previous peripheral arterial surgery.34 
Cerebrovascular disease was considered present if hospital admission due to stroke 
was documented. Using the WHO criteria of 1 999, diabetes mellitus was diagnosed if 
fasting plasma glucose level was 7.0 mmol/1 or higher, or if the participant used blood 
glucose-lowering drugs.35 Hypertension was defined, according to the Dutch general 
practitioner's standard, as a systolic blood pressure of at least 1 40 mmHg or a 
diastolic blood pressure of at least 90 mmHg or the use of antihypertensive drugs. 36 
Micro- or macroalbuminuria was defined as a urinary albumin excretion greater than 
30 mg/24h. 
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Laboratory methods 
Venous blood was collected after an overnight fast. Glucose was measured in freshly 
obtained plasma. For other measurements serum samples were stored at -20°C until 
analysis. Serum total cholesterol and plasma glucose were assessed using Kodak 
Ektachem dry chemistry (Eastman Kodak, Rochester, New York, U.S.A.). HDL 
cholesterol was measured with a homogeneous method (direct HDL, no. 7D67, 
AEROSET™ System, Abbott Laboratories, Abbott Park, IL 60064, USA). In this 
assay system, HDL and apo B-containing lipoproteins are complexed with one 
reagent, followed by solubilising HDL particles by another reagent.37 Serum 
triglycerides were measured enzymatically. Serum apo A-I, apo A-II and apo B were 
determined by nephelometry applying commercially available reagents for Dade 
Behring nephelometer systems (BN II, Dade Behring Marburg, Germany; apo A-I test 
kit, code no. OUED; apo A-II test kit, code no. OQBA, apo B test kit, code no. 
OSAN).38;39 Intra and inter assay coefficients of variation of apo A-I, apo A-II and 
HDL cholesterol were all < 5%. 
Statistical analysis 
StataSE 8 was used for data analysis. Data are expressed as mean ± SD or in median 
(interquartile range). Between group differences were compared with student's t-tests 
or by Wilcoxon rank-sum tests where appropriate. Chi-square analysis was used to 
compare frequencies between groups. 
Odds ratios (with 95% confidence intervals) of various multiple logistic 
regression models were calculated in men and women separately, evaluating the 
relationships of apo A-I, apo A-II and HDL cholesterol with myocardial infarction, 
without (model I )  and with adjustment for clinical variables which influence HDL 
cholesterol (models 2). Further analyses included combined adjustment for these apos 
and/or for HDL cholesterol (model 3, 4, 5). Sex differences in HDL composition were 
evaluated using linear regression analysis, after adding interaction terms of gender 
with apo A-I, apo A-II, HDL cholesterol and triglycerides. 
In defining myocardial infarction, at first both questionnaire and ECG patterns 
were combined, because the questionnaires might miss silent infarctions, and because 
ECGs occasionally return to normal patterns after the occurrence of a myocardial 
infarction. Secondly, the analyses were repeated for myocardial infarction hospital 
admissions according to the questionnaire, and compared with subjects without such a 
history. A two-sided P-value below 0.05 was considered to be significant. 
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Table 3.1. Characteristics of the study population 
Men Women 
MI No CVD MI 
N 341 2983 1 74 
Age (yrs) 603·'±) J .9 49'±12.4 533±13.3 Hypertension (%) 55.53 32.6' 47.73 Diabetes (%) 9.93 3.4b 8.83 
Lipid lowering drugs (%) 29.43,b 2.7 1 5.73 Smoking (%) 43. 1  44.2 44.7 Micro- or macroalbuminuria (%) 36.83•' 1 6.2' 1 6.72 
Serum total cholesterol (mmol/1) 5.54 1± 1 . 14 5 .67'± 1 . 10 5.69±1 .07 HDL cholesterol (mmol/1) I . I  I 2·'+0.30 1 . 1 6'±0.32 1 .383+0.39 Serum triglycerides (mmol/1) usi,b 1 .27' 1 .223 
( 1 .00-2.00) (0.90-1 .92) (0.88- 1 .69) Serum apo B (g/1) 1 .08±0.33 l .07'±0.29 I .07'±0.3 1 Serum apo A-I (g/1) 1 .261·'±0.23 I .30'±0.25 1 .44 1±0.29 Serum apo A-II (g/1) 0.3 1 83·b±0.064 0.338'±0.061 0.339±0.069 
HDL cholesterol / apo A-I 0.882·' ±0. 1 9  0.92'±0.43 0.97'±0.28 (mmol/ ) 
Data are given in mean±SD, median (interquartile range) or %. 
Myocardial infarction (Ml) vs no cardiovascular disease (no CVD) in men and women. 
BMI, body mass index; WHR, waist/hip ratio. 1. 2, 3 P S0.05, <0.01 and <0.001 ,  respectively, from men or women without CVD. a. h, c P <0.05, <0.01 and <0.00 1 ,  respectively, from women with or without CVD. 
Results 
Clinical characteristics, serum lipids and apolipoproteins 
No CVD 
3 1 32 
47±1 1 .8 





5.56± 1 . 1 5  
1 .50±0.40 
1 .03 





Clinical characteristics, serum lipids and apos of the men and women with myocardial 
infarction and without cardiovascular disease are summarized in table 3. I .  In men and 
women with myocardial infarction, triglycerides were higher, whereas HDL 
cholesterol and apo A-I were lower compared to subjects without cardiovascular 
disease. Apo A-II levels were lower in men with myocardial infarction than in men 
without cardiovascular disease, but not different between women with myocardial 
infarction and women without cardiovascular disease. Men with myocardial infarction 
used lipid lowering drugs more frequently than men without cardiovascular disease 
and their total cholesterol was lower. Both groups of men had higher triglycerides and 
lower HDL cholesterol, apo A-I and apo A-II levels than both groups of women. The 
HDL cholesterol/apo A-I ratios in myocardial infarction subjects proved to be lower 
than in subjects without cardiovascular disease as well as in men compared to women. 
Relationships of apo A-I, apo A-II, HDL cholesterol with myocardial infarction 
Tables 3.2, 3.3 and 3.4 show the associations of apo A-I, apo A-II and HDL 
cholesterol with myocardial infarction in men and in women separately. In men, apo 
A-I was negatively associated with myocardial infarction (table 3.2). After addition of 
apo A-II, or of both apo A-II and HDL cholesterol, this association disappeared. 
When HDL cholesterol was added alone, a negative trend of apo A-I with myocardial 
infarction remained. In women, apo A-I and myocardial infarction were negatively 
associated in the unadjusted model, but this association was no longer apparent after 
Apo A-I, apo A-II, HDL-C and MI 
Table 3. 2. Odds ratios of myocardial infarction (Ml) for each 0. 5 g/l increase in 
apo A-I in men and in women 
Odds ratio of MI, by men 
apo A-I, steps of 0.5 g/1 
OR (95% Cl) 
Model I 0.76 (0.61-0.96) 
Model 2 0.7 1  (0.54-0.93) 
Model 3 0.93 (0.63-1 .38) 
Model 4 0.72 (0.50-1 .03) 
Model 5 1 .00 (0.6 1-1 .63) 








OR (95% CI) 
0.77 (0.59-1 .00) 
0.81 (0.61-1 .09) 
0.81 (0.55-1 .20) 
1 .02 (0.69-1 .5 1 )  
1 .09 (0.65-1 .82) 
p 
0.05 




Model 2: odds ratio of MI for apo A-1, adjusted for HDL-related clinical factors (age, waist/hip ratio, 
diabetes, lipid lowering drugs, smoking and alcohol consumption). 
Model 3, 4 and 5: odds ratios of Ml for apo A-1, with additional adjustment for HDL-related clinical 
factors and for apo A-II (model 3), for HDL cholesterol (model 4) and for the combination of both 
(model 5). 
Table 3. 3. Odds ratios of myocardial infarction (Ml) for each 0. 1 g/1 increase in 
apo A-II in men and in women 
Odds ratio of MI, by 
apo A-II, steps of 0. 1 g/1 
men 
OR (95% Cl) 
Model 1 0.59 (0.49-0.7 1 )  
Model 2 0.7 1  (0.57-0.88) 
Model 3 0.74 (0.53-1 .02) 
Model 4 0.73 (0.57-0.92) 
Model 5 0.73 (0.52-1 .0 1) 








OR (95% Cl) 
0.8 1 (0.65-1 .02) 
0.89 (0.69-1 . 1 5) 
1 .0 1  (0.72-1.41) 
0.97 (0.74-1 .27) 







Model 2: odds ratio of MI for apo A-II, adjusted for HDL-related clinical factors (age, waist/hip ratio, 
diabetes, lipid lowering drugs, smoking and alcohol consumption). 
Model 3, 4 and 5: odds ratios of MI for apo A-II, with additional adjustment for HDL-related clinical 
factors and for apo A-I (model 3), for HDL cholesterol (model 4) and for the combination of both 
(model 5). 
Table 3.4. Odds ratios of myocardial infarction (Ml) for each 0.5 mmol/1 increase 
in HDL cholesterol in men and in women 
Odds ratio of MI, by men 
HDL cholesterol, steps of0.5 
mmol/1 
OR (95% Cl) P 
Model 1 0.75 (0.62-0.91 )  0.00 
Model 2 0.82 (0.65-1.03) 0.09 
Model 3 0.98 (0.73-1 .33) 0.90 
Model 4 0.93 (0.73-1 . 19) 0.57 
Model 5 0.93 (0.69-1 .26) 0.65 
Model I: odds ratio of MI for HDL cholesterol, unadjusted data. 
women 
OR (95% CI) 
0.67 (0.54-0.82) 
0.77 (0.6 1-0.97) 
0.76 (0.56-1 .03) 
0. 78 (0.61-0.99) 







Model 2: odds ratio of Ml for HDL cholesterol, adjusted for HDL-related clinical factors (age, 
waist/hip ratio, diabetes, lipid lowering drugs, smoking, alcohol consumption). 
Model 3, 4, 5: odds ratios of MI for HDL cholesterol, with additional adjustment for HDL-related 
clinical factors and for apo A-I (model 3), for apo A-II (model 4) and for the combination of both 
(model 5). 
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adjustment for any of the variables (3. 2). In men, significant and nearly significant 
negative associations of apo A-II with myocardial infarction were found in all models 
(table 3.3). In contrast in women, apo A-II was not significantly associated with 
myocardial infarction in any of the models (table 3.3). The negative association 
between HDL cholesterol and myocardial infarction in men was no longer significant 
after adjustment (table 3.4). In women, HDL cholesterol was negatively associated 
with myocardial infarction in 
most models. Notably, the 
models did not essentially 
change when the presence of 
micro- of macroalbuminuria 
was taken into account ( data 
not shown). Moreover, odds 
ratios of all models m 
menopausal women did not 
differ statistically from odds 
ratios in premenopausal 
women (data not shown). 
Correlation analyses 
To evaluate whether the 
observed gender differences 
in the associations of HDL­
related variables with 
myocardial infarction could 
be explained by lower serum 
triglyceride levels in women, 
the relationship of HDL 
cholesterol with serum 
triglycerides were compared 
between men and women. 
As shown in figure 3. 1, HDL 
cholesterol was higher in 
women for a given 
triglyceride level. 
Furthermore, for a given apo 
A-I (figure 3.2) and apo A-II 
(figure 3.3) level, HDL 
cholesterol was higher in 
women than in men. Thus, 
women had a higher content 
of cholesterol m HDL 
particles relative to apo A-I 
and apo A-II compared to 
men. 
Figure 3.1. Relationship of serum triglyceride 
levels with HDL cholesterol in men and in women 




.,g .  �------=----..,.. 
§ 0 ...__�����-� 
0 1 2 3 4 5 6  
Triglycerides (mmol/1) 
_ : Men, R = -0.42, P < 0.00 I ,  n = 3324, 
HDL cholesterol "' 1 .33 - 0. 1 1  * triglycerides; 
___ : Women: R =  -0.40, P <  0.00 1 ,  n = 3306, 
HDL cholesterol = 1 .76 - 0.22 * triglycerides. 
Difference in intercept: P < 0.00 I ;  difference in slope: P < 
0.00 1 
Figure 3.2. Relationship of serum apo A-I levels 
with HDL cholesterol in men and in women 




_g l  
§ 0 
0 2 
Apo A-I (g/1) 
_ : Men, R = 0.69, P <  0.00 1 ,  n = 3324, 
HDL cholesterol = 0.02 + 0.88 * apo A-I; 
: Women: R = 0.67, P < 0.00 I ,  n = 3306, 
HDL cholesterol = 0. 1 2  + 0.93 * apo A-1. 
3 
Difference in intercept: P < 0.00 I ;  difference in slope: ns 
Apo A-I, apo A-II, HDL-C and MI 59 
Myocardial infarction hospitalisation according to questionnaire 
In addition to the results based 
on the combined definition, the 
logistic analyses were repeated 
for myocardial infarction 
hospital admissions only. A 
total of 208 men and only 48 
women had reported 
hospitalisation for myocardial 
infarction. In both genders 
hospitalised myocardial 
infarction patients had stronger 
derangements in risk factors 
than infarcted subjects 
identified by admission and/or 
abnormal ECG readings (table 
3.5). 
Table 3.6 shows the 
models for myocardial 
infarction hospitalisation. In 
men, negative associations of 
apo A-I with hospitalisation 
Figure 3.3. Relationship of serum apo A-II levels 
with HDL cholesterol in men and in women 
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0,0 0,2 0,4 0,6 
Apo A-II (g/1) 
_ : Men, R = 0.43, P < 0.00 1 ,  n = 3324, 
HDL cholesterol = 0.42 + 2 . 19  • apo A-II; 
: Women: R = 0.33, P < 0.00 I ,  n = 3306, 
HDL cholesterol = 0.80 + 1 .98 • apo A-II. 
0,8 
Difference in intercept: P < 0.00 I; difference in slope: ns 
Table 3.5. Characteristics of the study population according to hospitalisations for 





Lipid lowering drugs (%) 
Smoking (%) 
Micro- or macroalbuminuria (%) 
Serum total cholesterol (mmol/J) 
HDL cholesterol (mmol/1) 
Serum triglycerides (mmol/1) 
Serum apo B (g/1) 
Serum apo A-I (g/1) 
Serum apo A-II (g/1) 











5.501 ,b± l . l  7 
1 .053·'+0.28 
1 .423 
( 1 .05-2. 1 7) 
1 .09±0.30 
l .243·b±0.23 
0.3 1 03±0.060 
0.853•0±0.l 8 
No MI hosp 







5.67'± 1 . 1 0  
l . 1 6'±0.3 1 
1 .27' 





Data are given in mean±SD, median (interquartile range) or %. 
Women 
Ml hosp No MI hosp 
48 3257 
63.83±8.3 47. 1 ± 1 1 .9 




6.032± 1 . 1 4  5.56± 1 . 1 4  
1 .292±0.42 
1 .523 
( 1 .25-2.27) 











Hospitalisation for myocardial infarction (MI hosp) vs no Hospitalisation for myocardial infarction (no 
MI hosp) in men and women. BM!, body mass index; WHR, waist/hip ratio. 1 , 2. i P :50.05, <0.01 and <0.001 ,  respectively, from men or women without hospitalisation for 
myocardial infarction. 
a.b,, P <0.05, <0.0 1 and <0.001 ,  respectively, from women with or without hospitalisation for 
myocardial infarction. 
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for myocardial infarction were shown to be similar to models for the combined 
outcome (table 3.2). In women, odds ratios for apo A-I were 0.60 or less in all models 
(table 3.6), considerably smaller than in table 3.2. 
Even fully adjusted apo A-II models showed negative associations with 
hospitalisations for myocardial infarction in men (table 3 .6), as was also shown in 
models for the combined outcome measure of table 3.3. In women models 1 and 2 
suggested negative associations of apo A-II and hospitalisation for myocardial 
infarction (table 3.6), while no negative associations in models 1 and 2 were observed 
for the combined outcome (table 3.3). After adjustment for apo A-I and HDL this 
association disappeared (table 3.6). 
Table 3.6. Odds ratios of hospitalisation/or myocardial infarction (Ml hosp) for 
apo A-I, apo A-II and HDL cholesterol (HDL-C) in men and in women 
Odds ratio of MI hosp men Women 
OR (95% Cl) P OR (95% Cl) P 
Models for apo A-I, 




Models for apo A-II. 




Models for HDL-C, 
steps of0.5 mmol/13 
0.6 1 (0.46-0.82) 0.00 1 0.54 (0.33--0.88) 
0.55 (0.38--0.80) < 0.0 1 0.53 (0.29--0.95) 
1 .04 (0.53 2.07) 0.90 0.60 (0.22-1 .60) 
0.48 (0.38--0.60) < 0.00 1 0.59 (0.39---0.90) 
0.64 (0.47---0.86) < 0.01  0.69 (0.40- 1 . 1 8) 
0.74 (0.47-1 . 18) 0.21 0.96 (0.46--2.00) 
Model 1 0.52 (0.40---0.68) < 0.001 0.48 (0.3 1---0. 73) 
Model 2 0.54 (0.38--0. 75) < 0.001 0.69 (0.43-1 . 1 1 )  
Model 5 0.59 (0.38--0.92) 0.02 0.88 (0.48-1 .60) 1 Odds ratios of hospitalisation for MI for each 0.5 g/1 increase in apo A-I, 










3 odds ratios of hospitalisation for MI for each 0.5 mmol/1 increase in HDL cholesterol. 
Models I :  odds ratio of hospitalisation for MI, unadjusted data. 
Models 2: odds ratio of hospitalisation for MI, adjusted for HDL-related clinical factors (age, 
waist/hip ratio, diabetes, lipid lowering drugs, smoking and alcohol consumption). 
Models 5: odds ratios of hospitalisation for MI, with additional adjustment for HDL-related clinical 
factors, including apo A-I, apo A-II and HDL cholesterol. 
HDL cholesterol models for myocardial infarction hospitalisation of men did 
show small or smaller odds ratios than in the combined definition, also when HDL 
cholesterol levels were adjusted for apo A-I and apo A-II (table 3.4, table 3.6). In 
hospitalised women no negative association with hospitalised myocardial infarction 
patients was observed in the model adjusted for apo A-I and apo A-II (table 3.6), 
while all models for HDL cholesterol showed negative associations or trends with the 
combined outcome based on reported myocardial infarction and/or myocardial 
infarction patterns on ECG (table 3.4). 
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Discussion 
To our knowledge, this study is the first to adjust the association of HDL cholesterol 
with myocardial infarction for both apo A-I and apo A-II, and to evaluate these 
relationships in men and women separately. Two aspects of this study are novel. 
Firstly, our data clearly show that apo A-II is inversely correlated with myocardial 
infarction in men, independently of clinical factors influencing HDL and of the HDL 
cholesterol concentration itself. Secondly, in women HDL cholesterol instead of apo 
A-II was most negatively associated with myocardial infarction. Our study, therefore, 
strongly suggests that the inverse interrelationships of HDL cholesterol and its major 
apolipoproteins with myocardial infarction are different in men compared to women. 
One of the anti-atherogenic properties of HDL is assumed to be exerted by its 
role in reverse cholesterol transport, i.e. the process by which cholesterol returns from 
peripheral cells to hepatocytes for excretion in the bile.40:41 Whereas there is little 
doubt about the cardioprotective role of apo A-I, 14;6;8:12·14 the relationship of apo A-II 
with cardiovascular diseases is still debated. 15:42:43 In a complex manner apo A-II may 
affect several steps in the reverse cholesterol transport pathway, making it of interest 
to evaluate the extent to which circulating apo A-II levels are associated with 
cardiovascular disease. The present study shows that apo A-II is inversely associated 
with myocardial infarction in men, even after adjustment for HDL cholesterol and apo 
A-I. This suggests that the overall influence of apo A-II may be cardioprotective, at 
least in men. 
Apart from higher concentrations of HDL cholestero111·19:21 ·25 and apo A-r22 in 
women compared to men, 19:21 :23·25 levels of HDL subparticles are also different. 
Women have more HDL2 cholesterol
44 than men and their HDL particles appear to be 
larger, at each level of serum triglycerides,25 which is consistent with the present 
finding that HDL cholesterol was higher in women, also when the lower triglyceride 
level in women was taken into account (figure 3. 1). Moreover, the larger HDL 
particles in women contain more cholesterol per apo A-I and per apo A-II.22:23:27 
Indeed, we found that women had a higher HDL cholesterol/apo A-I ratio (table 3.1) 
and a higher content of cholesterol in HDL particles relative to apo A-I (figure 3.2) 
and apo A-II (figure 3.3). 
The presently documented different associations of HDL cholesterol, apo A-I 
and apo A-II with myocardial infarction in men compared with women, as found in 
our primary analyses, may in part be explained by differences in HDL subfraction 
levels, i.e. a greater HDL size25 and more LpA-I particles relative to LpA-I/A­
II18:21:22:24 in women. Consequent to these differences in HDL subfractions, the higher 
content of cholesterol in HDL relative to apo A-I and apo A-II in women could limit 
the importance of apo A-I and apo A-II compared to HDL cholesterol in their 
association with myocardial infarction. Notably, HDL size is abnormal in patients 
with coronary artery disease in such a way that smaller HDL particles are increased 
and larger HDL particles are decreased.4547 In our study, myocardial infarction was 
associated with a lower HDL cholesterol/apo A-I ratio in both genders (table 3.1). 
Collectively, it can be hypothesized that the higher content of cholesterol in HDL per 
apo A-I in women and in subjects without cardiovascular disease may reflect a more 
efficacious cellular cholesterol removal, contributing to larger HDL particles. 
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A clinically relevant question is whether serum apo A-I or apo A-II measurement 
can replace the determination of HDL cholesterol in cardiovascular risk assessment. 12-
14;48 With the limitations inherent to a cross-sectional study design, our data suggest 
that such replacement does not yield similar information about cardiovascular risk in 
men compared to women. 
Additional analyses based on hospitalisation for myocardial infarction 
In addition to the analyses regarding combined outcome, the analyses were repeated 
for models on hospital admission for myocardial infarction only. Characteristics of 
control groups based on both definitions did not differ. In contrast, all risk factors 
were more severely abnormal in hospitalised myocardial infarction patients than in 
patients with myocardial infarction according to the combined definition, except for 
smoking and the HDL cholesterol / apo A-I ratio. Noteworthy, risk factors for 
myocardial infarction were at least as unfavourable in female hospitalised myocardial 
infarction patients as in hospitalised men, but in analyses based on the combined 
definition women with previous myocardial infarction appeared to have more 
favourable risk factors than men. Negative odds ratios for hospitalisation for 
myocardial infarction were similar or more pronounced in men than odds ratios for 
the combined definition of myocardial infarction. In women, it is precarious to 
compare the effect of both definitions on odds ratios of apo A-I, apo A-II and HDL 
cholesterol because of the small number of women which were hospitalised for 
myocardial infarction. 
The Minnesota Code classification system is an established definition which has 
been developed in order to provide a standardized outcome, offering comparability 
between epidemiological studies towards coronary heart disease.49;so In this study 
Minnesota Codes were assigned by a computer program (MC-MEANS, Modular 
ECG Analysis System) rather than visually, because MC-MEANS has been proven to 
be more sensitive and more reliable.33 To our knowledge Minnesota Codes have not 
been compared with prevalent clinical outcomes. Therefore, the magnitude of 
agreement between Minnesota Codes for myocardial infarction and clinical 
myocardial infarction is at least to some extent uncertain. Furthermore, silent 
myocardial infarctions missed by medical history can be detected by Minnesota 
Codes for myocardial infarction. On the other hand, a proportion of prevalent 
myocardial infarctions have ECG patterns which resolve after therapy,5 1 and will thus 
be missed when only ECG-data are used to detect prevalent myocardial infarction. 
Therefore, both Minnesota Codes suggesting myocardial infarction and reported 
hospitalisations for myocardial infarction are used in this study. 
The definition of cases did not show distinctive influence on models of apo A-I 
and apo A-II in men. Although, HDL cholesterol in men was negatively associated in 
all models with hospitalisation for myocardial infarction while not in models in men 
adjusted for apo A-I and/or apo A-II according to the combined definition. Due to the 
small number of hospitalised women, their models on myocardial infarction 
hospitalisation were insufficiently reliable to determine interrelationships with apo A­
I, apo A-II and HDL cholesterol in women. 
Taken together, we observed that in men the models based on only 
hospitalisation for myocardial infarction are consistent with analyses based on based 
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on the combination of hospitalisation for myocardial infarction and myocardial 
infarction patterns on ECG. 
Conclusion 
In conclusion, the present cross-sectional study demonstrates that the association of 
myocardial infarction with HDL cholesterol and its most abundant apolipoproteins 
with myocardial infarction is different in men compared to women. In men, but not in 
women, myocardial infarction is most strongly associated with apo A-II. These 
gender-dependent differences suggest that the prospectively assessed cardiovascular 
risk attributable to low HDL cholesterol, apo A-I and apo A-II needs to be determined 
in both genders separately. 
Acknowledgements 
S.E. Borggreve is supported by the Netherlands Heart Foundation (grant 2001 .005). This study is 
financially supported by the Jan Komelis de Cock Foundation, Groningen, The Netherlands. We thank 
Dade Behring (Marburg, Germany) for supplying equipment (Behring Nephelometer II) and analytes for 
the determination of apolipoproteins and other metabolites. We thank J.J. Duker and J. van der Wal­
Haneveld (laboratory assistants) for their concise and elaborate work. 
The PREVEND Study Group consists of: P.E. de Jong, G.J. Navis, R.T. Gansevoort, A.H. Brantsma, 
Department of Nephrology, University Medical Centre Groningen. D. de Zeeuw, W.H. van Gilst, J.W. 
Brinkman, Department of Clinical Pharmacology, University Medical Centre Groningen. R.O.8. Gans, 
S.J.L. Bakker, A.J. Smit, A.M. van Roon, Department of Medicine, University Medical Centre Groningen. 
D.J. van Veldhuisen, H.L. Hillege, F.W. Asselbergs, C.A. Geluk, Department of Cardiology, University 
Medical Centre Groningen. B.H.R. Wolffenbuttel, R.P.F. Dullaart, S.E. Borggreve, Department of 
Endocrinology, University Medical Centre Groningen. V. Fidler, J.G.M. Burgerhof, Department of 
Epidemiology and Statistics. L.T.W. de Jong-van den Berg, M.J. Postma, J. van den Berg, Department of 
Pharmaco-Epidemiology. J.H.J. Muntinga, Department of Medical Physiology. D.E. Grobbee, Department 
of Epidemiology, Julius Center, Utrecht. 
References 
( I )  Genest JJ Jr, Bard JM, Fruchart JC, et al. Plasma apolipoprotein A-1, A-II, B ,  E ,  C-lll 
containing particles in men with premature coronary artery disease. Atherosclerosis 
1 991 ;90 : 149- 157. 
(2) Suring JE, O'Connor GT, Goldhaber SZ, et al. Decreased HDL2 and HDL3 cholesterol, apo A-I 
and apo A-II, and increased risk of myocardial infarction. Circulation 1 992;85 :22-29. 
(3) Syvlinne M, Kahri J, Virtanen KS, et al. HDLs containing apolipoproteins A-I and A-II (LpA-
1:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes 
mellitus. Circulation 1 995;92:364-370. 
(4) O'Brien T, Nguyen TT, Hallaway BJ, et al. HDL subparticles and coronary artery disease in 
NIDDM. Atherosclerosis 1996; 1 2 1  :285-29 I .  
(5) Uiterwaal CSPM, Witterman JCM, Stiphout WAHJ van, et al. Lipoproteins and apolipoproteins 
in the young and familial risk of coronary atherosclerosis. Atherosclerosis 1 996;127:235-244. 
(6) Miwa K, Yoshida N, Nakagawa K, et al. High-density lipoprotein particles are large in patients 
with variant angina. Cardiovasc Res 1 998;37:729-737. 
(7) Asztalos BF, Roheim PS, Milani RL, et al. Distribution of apoA-1-containing HDL 
subpopulations in patients with coronary heart disease. Arterioscler Thromb Vase Biol 
2000;20:2670-2676. 
(8) Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk - apolipoprotein AI as 
an independent risk factor. Atherosclerosis 200 1 ; 155 : 165-1 70. 
(9) Stensvold I, Urda) P, Thurmer H, et al. High-density lipoprotein cholesterol and coronary, 
cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur 
Heart J 1 992; 1 3 : 1 1 55- 1 1 63. 
64 
( 10) 
( 1 1 )  
( 1 2} 
( 13) 
( 14) 
( 1 5) 
( 1 6) 
( 17) 
( 18) 
( 1 9) 
(20) 










(3 1 )  
Chapter 3 
Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of 
ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. 
Circulation I 996;94:273-278. 
Assmann G, Schulte H, Eckardstein A von, et al. High density lipoprotein cholesterol as a 
predictor of coronary heart disease. The PROCAM experience and pathophysiological 
implication for reverse cholesterol transport. Atherosclerosis 1 996; 124:S 1 1 -S20. 
Sweetnam PM, Bolton CH, Downs LG, et al. Apolipoproteins A-1, A-II and B, lipoprotein(a) 
and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest 2000;30:947-956. 
Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and 
improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective 
study. Lancet 200 1 ;358:2026-2033. 
Sharett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from 
lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B ,  and HDL 
density subfractions. The atherosclerosis risk in communities (ARIC) study. Circulation 
200 1 ; 104: 1 108- 1 1 13. 
Tailleux A, Duriez P, Fruchart JC, et al. Apolipoprotein A-II, HDL metabolism and 
atherosclerosis. Atherosclerosis 2002; 164: 1 - 13. 
Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance 
spectroscopy. Clin Lab 2002;48: 17 1 - 180. 
Haffner SM, Applebaum-Bowden D, Wahl PW, et al. Epidemiological correlates of high 
density lipoprotein subfractions, apolipoproteins A-1, A-II, and D, and lecithin cholesterol 
acyltransferase. Effects of smoking, alcohol, and adiposity. Arteriosclerosis 1 985;5: I 69-1 77. 
Roche D, Migueres ML, Lequang NT, et al. Concentrations of high-density lipoprotein 
subfraction HDL2 and lipoprotein A-I in a random population of healthy subjects. Clin Chem 
1991 ;37:2 1 1 1 -21 13. 
Tilly-Kiesi M, Lichtenstein AH, Joven J, et al. Impact of gender on the metabolism of 
apolipoprotein A-I in HDL subclasses LpAI and LpAI:AII in older subjects. Arterioscler 
Thromb Vase Biol 1997;17:35 13-35 18. 
Calhoun HM, Taskinen MR, Otvos JD, et al. Relationship of phospholipid transfer protein 
activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 
I diabetes. Diabetes 2002;5 I :3300-3305. 
Couillard C, Bergeron J, Despres JP, et al. Apolipoprotein AI- and AI:AII-containing 
lipoproteins in white men and women of the HERITAGE family study: associations with 
metabolic risk profile variables. Metabolism 2003;52: 1 530- 1 536. 
Jkewaki K, Zech LA, Kindt M, et al. Apolipoprotein A-II production rate is a major factor 
regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-1 and LpA-1:A-II 
in normolipidemic humans. Arterioscler Thromb Vase Biol 1 995; 1 5:306-312. 
Duverger N, Rader D, Brewer HB Jr. Distribution of HDL containing apoA-1 without apoA-II 
(LpA-1) in normolipidemic men and women. Arterioscler Thromb 1994; 14: 1 594- 1 599. 
Lyu L-C, Yeh C-Y, Lichtenstein AH, et al. Association of sex, adiposity, and diet with HDL 
subclasses in middle-aged Chinese. Am J Clin Nutr 200 I ;74:64-7 1 .  
Freedman DS, Otvos JD, Jeyarajah EJ, et al. Sex and age differences in lipoprotein subclasses 
measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem 
2004;50: 1 189-1200. 
Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and 
coronary heart disease. Am J Med l 997;103:1 52-162. 
Ohta T, Hattori H, Murakami M, et al. Age- and sex-related differences in lipoproteins 
containing apoprotein A-1. Arteriosclerosis I 989;9:90-95. 
Pinto-Sietsma SJ, Janssen WMT, Hillege HL, et al. Urinary albumin excretion is associated 
with renal functional abnormalities in a non-diabetic population. J Am Soc Nephrol 
2000; 1 1 : 1 882- 1 888. 
Stuveling EM, Bakker SJ, Hillege HL, et al. C-reactive protein modifies the relationship 
between blood pressure and microalbuminuria. Hypertension 2004;43:791 -796. 
Bruyne MC de, Kors JA, Hoes AW, et al. Diagnostic interpretation of electrocardiograms in 
population-based research: computer program research physicians, or cardiologists? J Clin 
Epidemiol I 997;50:947-952. 
Kottke TE, Daida H, Bailey KR, et al. Agreement and coding reliability of the minnesota and 
mayo electrocardiographic coding systems. J Electrocardiol 1 998;3 I :303-31 2. 
Apo A-1, apo A-II, HDL-C and MI 65 
(32) Diercks GFH, Boven AJ van, Hillege HL, et al. Microalbuminuria is independently associated 
with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The 
PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 
2000;21 : 1 922-1927. 
(33) Kors JA, Crow RS, Hannan PJ, et al. Comparison of computer-assigned Minnesota Codes with 
the visual standard method for new coronary heart disease events. Am J Epidemiol 
2000; 1 5  I :790-797. 
(34) Meijer WT, Grobbee DE, Hunink MMG, et al. Determinants of peripheral arterial disease in the 
elderly. The Rotterdam Study. Arch Intern Med 2000; 1 60:2934-2938. 
(35) World Health Organization DoNDS. Report of a WHO Consultation. Definition of metabolic 
syndrome in definition, diagnosis and classification of diabetes mellitus and its complications. 
1999;32. 
(36) Walma EP, Thomas S, Grundmeyer HGLM, et al. NHG-standaard hypertensie (derde 
herziening). Huisarts Wet 2003;46:435-449. 
(37) Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: 
from ultracentrifugation to homogenous assays. Clin Chem 200 I ;47: 1 579-1 596. 
(38) Steinmetz J, Tarallo P, Fournier B, et al. Reference limits of apolipoprotein A-I and 
apolipoprotein B using an !FCC standardized immunonephelometric method. Eur J Clio Chem 
Clio Biochem 1995;33:337-342. 
(39) Ceme D, Ledinski G, Kager G, et al. Comparison of laboratory parameters as risk factors for the 
presence and the extent of coronary or carotid atherosclerosis: the significance of apolipoprotein 
B to apolipoprotein all ratio. Clio Chem Lab Med 2000;38:529-538. 
(40) Miller NE, Ville A La, Crook D. Direct evidence that reverse cholesterol transport is mediated 
by high-density lipoprotein in rabbit. Nature 1 985;3 14 : 109-1 1 1 . 
(4 1 )  Barter PJ, Rye KA. High density Iipoproteins and reverse cholesterol transport. Curr Opin 
Lipidol I 993;4:2 1 0-2 1 7. 
(42) Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, et al. Role of apo A-II in lipid metabolism 
and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 200 I ;42: I 727-
1 739. 
(43) Borggreve SE, Vries R de, Dullaart RPF. Alterations in high-density lipoprotein metabolism and 
reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of Iipolytic 
enzymes, Iecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clio Invest 
2003;33: 1 05 1 - 1 069. 
(44) Clifton PM, Noakes N, Nestel PJ. LDL particle size and LDL and HDL cholesterol changes 
with dietary fat and cholesterol in healthy subjects. J Lipid Res 1 998;39: 1 799-1 804. 
(45) Syviinne M, Ahola M, Lahdenpera S, et al. High density Iipoprotein subfractions in non-insulin­
dependent diabetes mellitus and coronary artery disease. J Lipid Res I 995;36:573-582. 
( 46) Freedman DS, Otvos JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by 
proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler 
Thromb Vase Biol 1 998; 1 8: 1046- 1 053. 
(47) Asztalos BF, Cupples A, Demissie S, et al. High-density Iipoprotein subpopulation profile and 
coronary heart disease prevalence in male participants of the Framingham Offspring Study. 
Arterioscler Thromb Vase Biol 2004;24:2 1 8 1 -2 1 87. 
(48) Vries R de, Borggreve SE, Dullaart RPF. Role of Iipases, Iecithin:cholesterol acyltransferase 
and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin 
resistance and type 2 diabetes mellitus. Clio Lab 2003;49:601-613 .  
(49) Blackbum H. Electrocardiographic classification for population comparisons. The Minnesota 
Code. J Electrocardiol 1 969;2:5-1 0. 
(50) Antman E, Bassand JP, Klein W, et al. Myocardial infarction redefined--a consensus document 
of The Joint European Society of Cardiology/American College of Cardiology Committee for 
the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969. 
(5 1 )  Petrina M ,  Goodman SG, Eagle KA. The 12-Iead electrocardiogram as a predictive tool of 
mortality after acute myocardial infarction: current status in an era of revascularization and 
reperfusion. Am Heart J 2006; 1 52: I 1 - 1 8. 

Chapter 4 
High plasma cholesteryl ester transfer 
protein levels may favour reduced 
incidence of cardiovascular events 
in men with low triglycerides 
Susanna E. Borggreve; Hans L. Hillege; Geesje M Dallinga-Thie; Paul E. de Jong; 
Bruce HR. Wolffenbuttel; Diederik E. Grobbee; Arie van Toi; Robin P.F. Dullaart; 
on behalf of the PREVEND Study Group 
Eur Heart J. 2007;28:1012-8. 
68 Chapter 4 
Abstract 
Aims: High cholesteryl ester transfer protein (CETP) concentrations are associated with 
increased risk of cardiovascular disease (CVD) in subjects with high triglycerides. We 
determined the relationship of plasma CETP with incident CVD in a population with 
relatively low triglycerides. 
Methods and Results: A nested case-control study was performed in men participating in 
the prospective PREVEND study, after exclusion of cardiovascular disease (CVD), 
diabetes mellitus and lipid lowering drugs use at baseline. Plasma CETP was measured in 
l 1 1  men who developed a cardiovascular event (cases) during follow-up and in l 1 6  
controls who remained free of CVD. Fasting total cholesterol (P < 0.001 )  and triglycerides 
(P < 0.001 )  were higher, HDL cholesterol was lower (P = 0.001), but CETP was similar in 
cases and controls (P = 0.39). Cox proportional hazards regression analysis showed that 
CVD risk tended to be lower with higher plasma CETP after adjustment for age and lipids 
(hazard ratio 0.84; 95 % CI 0.69- 1 .03, P = 0.10). Plasma CETP was lower in cases than in 
controls (P = 0.05) with triglycerides :S 1 .38 mmol/l (median), but not with higher 
triglycerides. The age-adjusted hazard ratio for CVD was 0.46 (95 % CI 0.24 - 0.90) in 
men with triglycerides � 1 .38 mmol/1 and CETP > 2.26 mg/I (median) compared to men 
with similarly low triglycerides and CETP � 2.26 mg/I. With higher triglycerides, the 
hazard ratio for CVD was similar in both CETP categories. 
Conclusions: Relatively high plasma CETP may favour reduced CVD risk in the context of 
low triglycerides. 
Key words: CETP mass, cardiovascular disease, triglycerides, prospective, case-control 
study 
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Introduction 
Cholesteryl ester transfer protein (CETP) plays a pivotal role in HDL metabolism in 
humans, as evidenced by the markedly elevated HDL cholesterol levels in subjects with 
genetic CETP deficiency, 1 -3 and the strong increase in HDL cholesterol in response to 
pharmacological CETP inhibition.4;5 This lipid transfer protein enables the transfer of 
cholesteryl esters from HDL towards very low and low density lipoproteins (VLDL and 
LDL), while triglycerides are transferred in the opposite direction.6;7 As a result of CETP 
action, HDL cholesterol is decreased, the cholesterol content in VLDL is increased and the 
generation of small dense LDL particles is enhanced, particularly in 
hypertriglyceridaemia. 7-10 
Despite intensive research, the potential impact of CETP on cardiovascular disease is 
still debated. On the one hand, the CETP-mediated cholesteryl ester transfer process 
contributes to an atherogenic lipoprotein profile, and species which naturally lack CETP 
such as rats are relatively resistant to diet-induced atherosclerosis. 1 1 On the other hand, the 
cholesteryl ester transfer process provides an additional route for delivery of HDL-derived 
cholesteryl esters to the liver via VLDL and LDL.7;9;Io;i2- 14 Moreover, intracellular CETP 
could directly promote cholesterol removal from peripheral cells, 15 and circulating CETP is 
involved in the generation of small !�id poor pre �-HDL particles that act as initial 
acceptors of cell-derived cholesterol.6; 1 ; !6- 1 8  In addition, CETP is present in hepatocytes 
and may directly stimulate hepatic uptake of cholesteryl esters from HDL. 19 Thus, CETP 
may beneficially affect reverse cholesterol transport, i.e. the pathway whereby cholesterol 
is removed from peripheral cells to the liver where it is metabolized and excreted in the 
bile.6; 10; 14 
Importantly, one prospective case-control study has shown that the plasma CETP 
concentration is a predictor of cardiovascular disease but only in subjects with high plasma 
triglycerides. 20 We have recently observed that the rate of plasma cholesteryl ester transfer, 
rather than the plasma CETP concentration per se, is an independent detenninant of intima 
media thickness, a well accepted marker of subclinical atherosclerosis.2 ' Since plasma 
cholesteryl ester transfer is detennined by both the plasma triglyceride level, reflecting the 
constellation of VLDL particles that accept cholesteryl esters from HDL, and the CETP 
concentration, these findings are consistent with the notion that CETP may indirectly 
increase cardiovascular risk, in the context of higher triglyceride levels. Collectively, these 
findings strongly suggest that the plasma triglyceride level modifies the effect of circulating 
CETP on cardiovascular risk. 
The primary objective of our study was to detennine the impact of plasma CETP on 
incident cardiovascular disease, in a population with relative low triglycerides.22 As 
secondary objective, we detennined the relation of CETP with cardiovascular risk in the 
context of relatively lower and higher triglyceride levels. To this end we carried out a 
prospective nested case-control study among men participating in the PREVEND 
("Prevention of REnal and Vascular ENd stage Disease") project. 
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Methods 
Study design and participants 
We performed a nested case-control study among subjects participating in the PREVEND 
cohort. This study investigates vascular and renal damage in a predominantly Caucasian 
population. Details of the study have been described elsewhere.23 In summary, in 1997-
1998, all inhabitants of the city of Groningen, aged 28 - 75 years, were sent a short 
questionnaire on demographics and cardiovascular morbidity and a vial to collect an early 
morning urine sample. Altogether, 40,856 subjects responded (47.8 %). Pregnant women 
and diabetic subjects using insulin were excluded. All participants with urinary albumin 
concentration > 10 mg/I were invited to our clinic together with randomly selected subjects 
with a urinary albumin concentration < 10 mg/I. So, the PREVEND Study consists of a 
population enriched with subjects with microalbuminuria. The study population was 
comprised of 8,592 subjects who completed the total screening program. The study was 
approved by the local medical ethics committee. All participants gave written informed 
consent. 
Both HDL cholesterol and the plasma CETP level have been reported to be lower in 
men than in women.24;25 This strongly suggest that the effect of CETP action on HDL 
differs between sexes, making it necessary to evaluate the effect of plasma CETP on 
cardiovascular disease in men and women separately. Since it was anticipated that the event 
rate was low in women, we decided to carry out the present study in men only. Only men 
with a negative history of myocardial infarction, major ischaemia, percutaneous 
transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) at 
baseline were selected. Information regarding the use of antihypertensive, blood glucose 
lowering and lipid lowering drugs, smoking and alcohol consumption ( categorized as < 1 
and � 1 U/day) was obtained using a check-list as described.23 Body mass index (BMI) was 
calculated as the ratio between weight and height squared (in kg/m2). Waist circumference 
was measured on bare skin between the tenth rib and the iliac crest. Hypertension was 
characterized as systolic blood pressure � 140 mmHg or diastolic blood pressure � 90 
mmHg26 or the use of antihypertensive drugs. Men with diabetes mellitus, defined as 
fasting plasma glucose � 7.0 mmol/1 or the use of glucose lowering agents, use of lipid 
lowering drugs and with urinary albumin excretion > 300 µg/min, were excluded. 
The combined end-point of our study was incident cardiovascular disease (CVD), 
defined as death from CVD (ICD-10 IO0-l02, l05-115, 120-128, 130-152, 160-189, 195-199), 
hospitalisation for myocardial infarction (ICD-10 121, 122), percutaneous transluminal 
coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG). From the time of 
inclusion in the study, the vital status of the participants was checked through the municipal 
register. The cause of death was obtained by linking the number of the death certificate to 
the primary cause of death as coded by a physician from the Central Bureau of Statistics 
(CBS, Voorburg/Heerlen, The Netherlands). Causes of death were coded according to the 
tenth revision of the International Classification of Diseases (ICD-10). Information on 
myocardial infarction, PTCA and CABG was obtained from national hospital information 
system (Prismant, Utrecht, The Netherlands). Cases were men who had an event in the 
period from the date of the outpatient clinic baseline assessment to 31 December 2003, or 
31 December 2002 until which date information regarding specific causes of death follow 
up information was available. 
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In total, 129 men who had an event until sensus date were identified. An equal number 
of male control subjects was randomly selected from the whole baseline study cohort after 
exclusion of those men who developed cardiovascular event. Baseline plasma samples of 
sufficient quality for CETP measurement from 111 out of 129 cases, and from 1 16 out of 
129 control subjects were available. There were no differences in clinical characteristics as 
well as in plasma lipids and apolipoproteins (apos) between the men whose plasma CETP 
level was available (n = 227) compared to the men in whom CETP was lacking (n = 3 1, 
data not shown), except that men without information on CETP were older (61.9 ± 10.5 vs 
52.5 ± 12.2 years, P < 0.001) and had a lower urinary albumin excretion (5.2 (4.4 - 13.9) vs 
13.6 (7.9 - 23.8) µg/min, P < 0.001). 
Laboratory methods 
Blood samples were taken after 15 min rest. Plasma glucose was measured shortly after 
blood sampling. Plasma was obtained by centrifugation at 4°C, and the samples were stored 
at -80°C until analysis. HDL cholesterol was measured with a homogeneous method (direct 
HDL, AEROSET™ System, Abbott Laboratories, Abbott Park, USA).27 Triglycerides were 
measured enzymatically. Total cholesterol and plasma glucose were assessed using Kodak 
Ektachem dry chemistry (Eastman Kodak, Rochester, New York, U.S.A.). Apo A-I and apo 
B were determined by nephelometry applying commercially available reagents for Dade 
Behring nephelometer systems (BN II, Dade Behring Marburg, Germany).28;29 Urinary 
albumin concentration was determined by nephelometry (Dade Behring Diagnostic, 
Marburg, Germany). The mean of two 24 h urine collections was used to determine urinary 
albumin excretion. 
Plasma CETP concentration was analysed using a double-antibody sandwich ELISA.30 
A combination of monoclonal antibodies TPl and TP2 was employed as coating antibodies 
and monoclonal antibody TP20, labeled with digoxigenine, as the secondary antibody. 
CETP control samples were validated by Dr. R.M. McPherson, Montreal Canada, using a 
radioimmunoassay. 
Statistical analyses 
Stata SE 8, SPSS 12 and Excel were used for data analysis. Data are expressed as mean ± 
SD or in median (interquartile range). Between group differences were compared with 
Student's t-test and by Mann-Whitney analyses where appropriate. X2 analysis was used to 
compare frequencies between groups. A list of factors was created which could be 
associated with the exposure (CETP concentration) under study, and a list was made of 
factors which were likely to be associated with the outcome. For many potential 
confounders an association with CETP and the outcome could not be established. An 
association between CETP concentration and potential confounders in this study was only 
suggested regarding lipid parameters (not shown). The relation between CETP and 
potential confounders and the incidence of CVD was analysed with the use of Cox 
proportional hazards models. Hazard ratios for continuous risk factors were standardised, 
thus expressing the risk associated with a 1-SD increase in the continuous risk factors. All 
Cox proportional hazards models were age or mutually adjusted. The assumption of 
proportionality of hazards was checked by means of Schoenfeld residuals using procedure 
stphtest in ST AT A, which is based on the methods described by Grambsch and Themeau. 
No severe deviations from parallelism were evident. The assumption of linearity was 
checked graphically by studying the smoothed martingal residuals from the null model 
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plotted against the covariate variables. The l inearity assumptions were satisfied. In a 
secondary analysis the subjects were also grouped according to the median triglyceride and 
the median CETP level to determine the effect of CETP on CVD risk in the context of 
lower and higher triglycerides. In these models hazard ratios were adjusted for age. Since 
our cohort consisted of a random sample of subjects with <IO mg/I of urinary albumin 
concentration and all subjects with > IO  mg/I of urinary albumin, risk estimates were also 
calculated by adding the selection parameter as an effect modifier interacting with the 
variables for CETP and plasma l ipids. A two-sided P-value � 0.05 was considered to be 
significant. 
Results 
Median follow-up was I 021 (interquartile range, 581 1579) days in men who developed 
CVD (cases) and 2020 ( 1 930 - 21 13) days in men who remained free of CVD (controls). 
Table 4. 1 shows clinical and laboratory characteristics of 1 1 1  cases and 1 16 controls. Cases 
were older and had a higher BMI, waist circumference and urinary albumin excretion. 
There were more smokers among men with incident CVD and they had hypertension more 
frequently. Total cholesterol, non-HDL cholesterol, triglycerides and apo B levels were 
higher, whereas HDL cholesterol and apo A-I were lower in cases than in controls. Plasma 
CETP levels were not significantly different between the two groups. 
Table 4.1. Baseline clinical characteristics, plasma lipids, apolipoproteins (apos) 
and cholesteryl ester transfer protein (CETP) mass in men who developed 
cardiovascular disease (cases) and in men who remained free of cardiovascular 
disease (controls) 
Cases 
(n - 1 1 1 )  
Age (years) 58.0 ± 10.3 
BMI (kg/m2) 27.5 ± 3.9 
Waist (cm) 97.9 ± 10.6 
Cigarette smokers (%) 55.0 
Alcohol users (> I per day, %) 65.8 
Hypertension (%) 55.5 
Urinary albumin excretion (µg/min) 1 8. 1  
(9.7 36.3) 
Total cholesterol (mmol/1) 6.25 ± 1 . 1 2  
Non-HDL cholesterol (mmol/1) 5.20 ± 1 . 1 8  
HDL cholesterol (mmol/1) 1 .05 ± 0.35 
Triglycerides (mmol/1) 1 .6 1  
( I . I  I - 2.38) 
Apo B (g/1) 1 .24 ± 0.38 
Apo A-I (g/1) 1 .24 ± 0.28 
CETP mass (mg/I) 2.34 ± 0.80 
Controls 
(n = 1 1 6) 
47.2 ± 1 1 .5 
25.7 ± 3 . 1  





(6.4 - 1 7.2) 
5.60 ± 1 .04 
4.39 ± I . J O  
1 .20 ± 0.34 
1 . 1 7  
(0.84 - 1 .64) 
1 .07 ± 0.26 
1 .33 ± 0.22 
















As shown in table 4.2, Cox proportional hazards regression analysis with plasma lipids 
and CETP levels showed that plasma total cholesterol, HDL cholesterol and triglycerides 
were significant determinants of age-adjusted incident CVD. In a mutually adjusted model, 
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age-adjusted incident CVD was also independently determined by HDL cholesterol and 
plasma triglycerides, while there was now a trend for lower risk with higher CETP levels. 
Table 4.2. Effect of plasma lipids and cholesteryl ester transfer protein (CETP) 
concentration on incident cardiovascular disease by Cox proprotional hazard 
regression analysis 
HR (95% CJ) p HR (95% CI) p 
Age-adjusted Mutuall� adjusted 
Total cholesterol 1 .26 0.20 1. 1 8  0. 1 2  
(1 .04- 1 .52) (0.96 - 1 .46) 
HDL cholesterol 0.66 < 0.001 0.7 1 0.01 
(0.53- 0.82) (0.54 - 0.92) 
Ln triglycerides 1 .43 < 0.001 1 . 1 6  0.26 
(1 . 1 9 - 1 .72) (0.90- 1 .48) 
CETP 0.88 0.21 0.84 0. 10 
{0.73-1 .07} {0.69 - 1 .03} 
Hazard ratios (HR) are given per I SD increase in plasma lipids and CETP values. Left column 
shows HRs adjusted for age only. Right column shows mutually, including age, adjusted HR 
To determine whether the plasma CETP level influences CVD risk in the context of 
lower or higher triglycerides, we compared plasma CETP between men who remained free 
of CVD and men who developed CVD, stratified according to the median triglyceride level 
( 1 .38 mmol/1) of the whole study population (n = 227). In men with triglycerides � 1 .38 
mmol/1, plasma CETP was lower in men who developed CVD (2.10 ± 0. 76 mg/I) than in 
men who remained free of CVD (2.40 ± 0.79 mg/I, P = 0.05). In contrast, in men with 
triglycerides > 1.38 mmol/1, there was no difference in CETP between cases (2.49 ± 0.90 
mg/I) and controls (2.47 ± 0.81 mg/I, P = 0.89). 
To further evaluate the effect of CETP on CVD risk, the study population was divided 
in four groups according to the median triglyceride level and the median plasma CETP 
level of the entire study population (2.26 mg/I). As shown in table 4.3, the percentage of 
subjects who developed CVD was lower in men with lower triglyceride and higher CETP 
levels compared to men with lower triglyceride and lower CETP levels, but there were no 
significant differences in any clinical characteristics and plasma (apo)lipoproteins between 
these subgroups. There were, however, no differences in the percentage of men who 
developed CVD, nor in clinical characteristics and plasma (apo)lipoprotein levels in the 
subgroup with higher triglyceride and higher CETP levels compared to the subgroup with 
higher triglyceride and lower CETP levels (table 4.3). Men with triglycerides > 1.38 mmol/1 
had higher total cholesterol, non-HDL cholesterol and apo B as well as lower HDL 
cholesterol and apo A-I levels (P � 0.001 for all), but plasma CETP mass was not 
significantly different (n = 113, 2.47 ± 0.84 mg/I) compared to men with triglycerides �1.38 
mmol/1 (n = 114, 2.30 ± 0.79 mg/I, P = 0.10). 
As shown in table 4.4 at lower plasma triglyceride levels, the age-adjusted hazard ratio 
for incident CVD was decreased to 0.46 (95% CI 0.24 - 0.90, P = 0.03) in men with higher 
CETP levels compared to men with lower CETP. After additional adjustment for smoking, 
urinary albumin excretion, hypertension and use of alcohol, this hazard ratio was 0.49 (95% 
CI 0.25 - 0.97, P = 0.04). In contrast, no significant effect of the CETP level on incident 
CVD was observed in men with triglycerides above the median value (HR: 1.00 (95 % CI 
0.63-1.58, P = 0.98). 
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Table 4.3. Incidence of cardiovascular disease (CVD), baseline clinical characteristics, 
plasma lipids and apolipoproteins (apos) and cholesteryl ester transfer protein (CETP) 
mass according_ to e_lasma trig_ly__cerides CTG2 and CETP Subgroup I Subgroup 2 P of Subgroup 3 Subgroup 4 P of 
difference difference 
TG S. 1 .38 TG S. 1 .38 TG > 1 .38 TG > 1 .38 
mmol/1, mmol/1, mmol/1, mmol/1, 
CETP :::_ 2.26 CETP > 2.26 CETP :::_ 2.26 CETP > 
mg/I, mg/I, mg/I, 2.26 mg/I, 
n = 58 n = 55 n = 56 n = 58 
Incident CVD (% 44. 1 23.6 0.02 63.6 63.8 0.99 
of sub·ects 
Age (years) 52.2 ± 14.0 50.4 ± 12.7 0.47 53.9 ± 10.5 53.4 ± I I . I  0.83 
BMI (kg/m2) 25.9 ± 3.9 25. 1 ± 2.5 0.2 1 27.8 ± 4.0 27.5 ± 3.2 0.7 1 
Waist (cm) 92.5 ± 10.9 90.7 ± 8.4 0.33 99.3 ± 1 0.5 97.2 ± 9.5 0.25 
Cigarette smokers 39.0 40.0 0.9 1 56.4 48.3 0.39 
(%) 
Alcohol users (> I 79.3 69. 1 0.2 1 67.3 63.8 0.70 
unit per day, %) 
Hypertension (%) 33.9 38.2 0.63 49. 1 50.9 0.85 
Urinary albumin 12.2 9.7 0 . 15  1 5.0 16.9 0.91 
excretion {�!imin) (7.3 - 23.8) (6.4 - 1 5.8) (9.7 - 3 1 .0) (8.0 - 36.2) 
Total cholesterol 5.27 ± 0.9 1 5.55 ± 1 .02 0. 13 6 .37 ± 1 .07 6.49 ± 1 .02 0.56 
(mmol/1) 
Non-HDL 4.00 ± 0.92 4.26 ± 1 .04 0. 16  5.35 ± I .OS 5.55 ± 1 .03 0.3 1 
cholesterol 
(mmol/1) 
HDL cholesterol 1 .27 ± 0.36 1 .29 ± 0.37 0.77 1 .02 ± 0.26 0.94 ± 0.26 0 . 10 
(mmol/1) 
Triglycerides 0.96 0.98 0.89 1 .88 2 . 10  0.36 
(mmol/1) (0.79 - 1 . 14) (0. 77 - 1 . 1 7) {1 .61 - 2.54) { 1 .63 - 2.80) 
Apo B (g/1) 0.96 ± 0.20 1 .04 ± 0.25 0.06 1 .27 ± 0.33 1 .33 ± 0.37 0.42 
Apo A-I (g/1) 1 .33 ± 0.25 1 .37 ± 0.23 0.42 1 .22 ± 0.29 1 .22 ± 0.20 0.89 
CETP (m!il) 1 .69 ± 0.33 2.95 ± 0.58 < 0.00 1 1 .83 ± 0.32 3.09 ± 0.70 < 0.001 
Table 4.4. Age-adjusted hazard ratios (HRs) for incident cardiovascular disease 











(0.24 - 0.90) 
1 .39 











1 .38 0.2 1 3.00 0.001 1 .00 
(0.84 2.29) ( 1 .59- 5.64) (0.63 - 1 .58) A, B, C: HRs calculated with group I ,  2 and 3 as reference group, respectively. 
p 
0.98 
Subgroup I :  TG S. 1 .38 mmol/1, CETP s_ 2.26 mg/I; subgroup 2: TG s_ 1 .38  mmol/1, CETP > 2.26 
mg/I; subgroup 3: TG > 1 .38  mmol/1, CETP :::_ 2.26 mg/I; subgroup 4: TG > 1 .38 mmol/1, CETP > 2.26 
mg/I. 
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We also analysed the data making use of another strategy of dichotomising of the 
distribution of plasma CETP and triglycerides, i.e. the highest quartile of CETP vs a 
combination of the three lowest quartiles of CETP and the lowest quartile of triglycerides 
vs the highest quartiles of triglycerides, as well as by stratifying below and above a plasma 
triglyceride level of 1 .7 mmol/1 which was the median value in the EPIC-Norfolk study.20 
Both age-adjusted analyses showed similar trends that the hazard ratio was lowest in the 
subgroup with high CETP and low triglyceride levels compared to low triglycerides and 
low CETP; HR: 0.30 (95% CI 0.07- 1 .3 1 ,  P = 0. 1 1 ) and HR: 0.6 1 (95% CI 0.37- 1 .04, P = 
0.07), respectively. Furthermore, we also conducted an analysis using plasma CETP and 
plasma triglycerides as continuous variables, and calculated the interaction term. In this 
analysis the interaction between CETP and triglycerides was not significant (P = 0.21, age­
adjusted). 
Finally, it was explored whether the preferential inclusion of subjects with elevated 
levels of urinary albumin concentration in the PREVEND cohort affected the relationship 
between plasma lipids and CETP levels on incident CVD. The procedure for participating 
in PREVEND did not materially alter the results, and no significant interaction was 
observed. 
Discussion 
The present prospective nested case-control study is the first that is focussed on the 
association of circulating CETP concentration with incident CVD in a population with 
relatively low fasting plasma triglycerides. Plasma CETP mass was not different in cases 
compared to control subjects, and Cox proportional hazards regression analysis 
demonstrated that cardiovascular risk tended to be lower with higher CETP levels after 
adjustment for age and lipid parameters. Thus, our study shows that a higher plasma CETP 
level is not associated with increased cardiovascular risk in men with relatively low 
triglycerides. Further analysis suggested that in men with triglyceride levels below the 
median value of the whole study group, a high plasma CETP level was associated with a 
reduced incidence of CVD compared to the risk observed in subjects with similarly low 
triglycerides but low CETP mass levels. Among men with lower triglycerides, the 
association of high plasma CETP with reduced CVD risk at lower could not be explained 
by differences in clinical characteristics, nor by differences in plasma lipid levels between 
men with higher compared to lower CETP levels. These findings remained after adjustment 
for well accepted clinical cardiovascular risk factors such as smoking, hypertension, urinary 
albumin excretion, as well as alcohol consumption. 
Median fasting plasma triglycerides amount to 1 . 1 4  mrnol/1 in the whole P REVEND 
population,22 a value which closely corresponds with the level of 1. 1 7  mmol/1 in the 
presently studied control subjects. In a meta-analysis of surveys in which the effect of HDL 
cholesterol and CETP gene variation on cardiovascular risk was determined, the median 
triglyceride level was reported to vary between 0.9 mrnol/1 and 1 .7  mmol/1 across 
populations.31 This underscores that plasma triglycerides are relatively low in the 
PREVEND cohort, but it is also evident that such a degree of triglyceridaemia is not unique 
in comparison with other cohorts. In the EPIC-Norfolk study, the detrimental effect of 
plasma CETP on cardiovascular risk was limited to those subjects in whom plasma 
triglycerides (in part of the population measured in the non-fasting state) were greater than 
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1 .7 mmol/1.20 In the present study, the median triglyceride level was 1 .38 mmol/1 in cases 
and control subjects combined. In view of this difference in triglycerides between the 
present report and the EPIC-Norfolk study, we consider our results to be complementary 
rather than contradictory with that survey.2° Furthermore, close inspection of the graphical 
data from the EPIC-Norfolk study suggests that there may indeed have been a tendency 
towards a reduced cardiovascular risk in association with a high CETP mass in subjects 
with triglycerides below 1 .7 mmol/1. In our study, the hazard for incident CVD was not 
increased in men with higher triglycerides and higher CETP levels compared to men with 
higher triglycerides and lower CETP. This lack of association of CVD risk with circulating 
CETP at triglycerides above the median value of the whole study population could again be 
attributable to relatively low triglyceride levels (median, 2.0 mmol/1) even in those subjects, 
but also to insufficient statistical power. Taken the EPIC-Norfolk study and our data 
together, it is tempting to speculate that there may be a U-shaped relationship between 
circulating CETP and CVD risk, such that there is a beneficial effect of CETP on CVD at 
low triglycerides, which disappears at intermediate triglyceride levels and changes into a 
deleterious effect at high triglycerides. 
In view of the multiple roles of CETP in lipoprotein metabolism, there is an ongoing 
debate about the putative pro- or anti-atherogenic effects of circulating CETP in humans.32-
34 Our population-based study suggests that high plasma CETP levels could protect against 
cardiovascular disease in men with the lowest triglyceride levels. Among other possible 
mechanisms this potentially beneficial effect of CETP at low triglycerides may be 
explained by assuming that a certain rate of cholesteryl ester transfer from HDL towards 
VLDL and LDL is necessary for an effective reverse cholesterol transport pathway.32 In 
this regard it is important that in normolipidaemic subjects the major route for delivery of 
HDL-derived cholesteryl esters to the liver is via apo B-containing lipoproteins, whereas 
there is little net transport of cholesteryl esters to the liver directly via HDL. 13 These kinetic 
data support the notion that the CETP-mediated cholesteryl ester transfer process 
substantially contributes to the reverse cholesterol transport pathway in humans in vivo. 
Moreover, although equivocal results have been reported concerning the association of 
common CETP gene variations with cardiovascular risk,3 1 ;35;36 (partial) genetic CETP 
deficiency is reported to be related to increased cardiovascular risk in the context of 
intermediate HDL cholesterol levels.2 
Certain methodological aspects of our study need to be considered. Firstly, in order to 
avoid heterogeneity in cardiovascular end-points as much as possible, we decided to 
include only subjects who died from cardiovascular diseases, as well as subjects who 
suffered from proven myocardial infarction or in whom coronary intervention was 
performed during follow-up. Consequently, the number of cases was rather low in the 
present survey. Secondly, we included only men (for reasons see Methods section). 
Therefore, our results cannot be extrapolated to women. Thirdly, this study was performed 
in a cohort in which subjects with elevated urinary albumin excretion were preferentially 
included. However, this is very unlikely to have affected the interpretation of our results, 
because neither controlling for our study design nor adjustment for urinary albumin 
excretion did have any effect on the reduced hazard ratio for cardiovascular disease 
observed in men with lower triglycerides and higher CETP levels. Finally, the division of 
the subjects in subgroups according to median plasma triglyceride and CETP mass levels of 
the entire study population is somewhat arbitrary. Using plasma CETP and plasma 
triglycerides as continuous variables a non-significant interaction term was found. 
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However, also when plasma CETP and triglycerides were dichotomised using combinations 
of different quartiles, and when dichotomised using the median value of triglyceride levels 
as found in the EPIC-Norfolk study, similar results were observed.20 Our findings need to 
be confirmed in further prospective studies. Moreover, the cut-off levels presented in this 
study should not be interpreted in absolute terms. 
The present findings may have practical implications. Firstly, our results raise the 
possibility that measurement of plasma CETP mass could be valuable for cardiovascular 
risk assessment in men with low triglycerides. Secondly, our results would suggest that 
CETP inhibitor treatment is not beneficial in subjects with low triglycerides and high CETP 
levels. 
In conclusion, this study supports the hypothesis that the plasma CETP level can 
modulate the effect of triglycerides on cardiovascular risk. In men with the lowest 
triglycerides a relatively high CETP level may favour reduced cardiovascular risk. 
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Abstract 
Context: The -629A-C cho/estery/ ester transfer protein (CETP) promoter poly­
morphism is a determinant of HDL cholesterol, probably via an effect on plasma 
CETP. The TaqIB polymorphism of the CETP gene is in strong linkage disequilib­
rium with this promoter variant, and its effect on HDL cholesterol has been suggested 
to be modified by obesity and hyperinsulinaemia. 
Objectives: Because the CETP-mediated cholesteryl ester transfer out of HDL is 
stimulated by high serum triglycerides, we hypothesised that the effect of the -
629A-C CETP promoter polymorphism on HDL cholesterol is modified by the 
triglyceride level, rather than by obesity or insulin resistance. 
Design: In 7083 non-diabetic subjects of the PREVEND population, the CETP -
629C-A promoter polymorphism, HDL cholesterol, serum triglycerides, body mass 
index, waist circumference and insulin resistance (HOMAir) were determined. Serum 
apolipoprotein A-I was available in 6948 subjects. The TaqIB polymorphism was 
also assessed. 
Setting: The study was set in the general community. 
Results: HDL cholesterol and serum apolipoprotein A-I were on average 0. 1 4  mmol/1 
and 0.05 g/1 higher in -629AA (22.9 %) compared to -629CC (26.8%) homozygotes 
(P < 0.001 for both). This genotype effect on HDL cholesterol was on average 0. 1 5  
mmol/1 in the lowest triglyceride tertile but only 0.08 mmol/1 i n  the highest triglyc­
erides tertile (P < 0.01 ). Multiple regression analysis showed that HDL cholesterol by 
the CETP promoter variant (P < 0.00 I ), gender (P < 0.00 I ), triglycerides (P < 0.001 ), 
and interactions between triglycerides and genotype (P < 0.05), between triglycerides 
and gender (P < 0.05) and between genotype and gender (P < 0.05), independently 
from waist, HOMA;., alcohol use, age and use of lipid-lowering drugs. The TaqIB 
polymorphism also interacted with triglycerides on HDL cholesterol. The-629C-A 
promoter polymorphism did not interact with obesity and HOMA;, on HDL choles­
terol. 
Conclusions: The HDL cholesterol raising effect of the CETP -629A allele is dimin­
ished with higher triglycerides, which may be explained by a predominant effect of 
triglyceride-rich lipoproteins over circulating CETP itself on cholesteryl ester transfer 
out of HDL with rising triglycerides. 
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Introduction 
The cardioprotective role of high density lipoproteins (HDL) is widely accepted. 1 ;2 
The anti-atherosclerotic effect of HDL is commonly ascribed to its role in reverse 
cholesterol transport, i.e. the process by which cholesterol is removed from peripheral 
cells and transported to the liver for metabolism and excretion in the bile.3;4 Choles­
teryl ester transfer protein (CETP) is important for HDL metabolism because this 
lipid transfer protein enables the transfer of cholesteryl esters from HDL towards 
triglyceride-rich lipoproteins and low-density lipoproteins, thereby contributing to 
low HDL cholesterol.3;5-7 Elevated plasma CETP levels may be associated with an 
increased cardiovascular risk in subjects with high serum triglyceride levels.8 On the 
other hand, this cholesteryl ester transfer process provides a potentially beneficial 
pathway for delivery of HDL-derived cholesteryl esters to the liver via apolipoprotein 
(apo) B-containing lipoproteins.6 Consequently, the role of this process in atheroscle­
rosis development is still debated.9·w 
Evidence is accumulating that common polymorphisms in the CETP gene influ­
ence HDL cholesterol levels. The TaqIB polymorphism in intron I of the CETP gene 
has been most widely studied, and a recent meta-analysis showed a large difference in 
HDL cholesterol between B 1B 1 and B2B2 homozygotes. 1 1  This strong genetic effect 
is explained at least in part by an association of plasma CETP levels with this poly­
morphism, 1 1 · 1 5  and it is of relevance that the TaqIB polymorphism is closely linked to 
the -629C-+A promoter polymorphism in the CETP gene. 15; 16 This promoter poly­
morphism modulates CETP gene transcriptional activity in vitro. 16 Importantly, it has 
been documented that this variant rather than the TaqIB polymorphism is involved in 
regulating plasma CETP levels. 17  Several studies, performed mostly in Caucasian 
subjects, have suggested that the effect of the TaqIB CETP polymorphism on HDL 
cholesterol may be modified by gender 1 8•20 and environmental 1 9;2 1  factors. For reasons 
that are not clear at present, obesity and hyperinsulinaemia could also modulate the 
effect of this polymorphism on HDL cholesterol, in such a way that this effect may be 
diminished in obese 13;22 and hyperinsulinaemic individuals22• Because raised triglyc­
eride levels result in an enhanced transfer of cholesteryl esters out of HDL,7 the de­
scribed modulations of CETP gene effect on HDL cholesterol by obesity and hyper­
insulinaemia could be explained by elevated serum triglycerides. We therefore hy­
pothesised that the effect of the -629C-+A promoter polymorphism in the CETP 
gene on HDL cholesterol is modified by the serum triglyceride level, rather than by 
obesity or insulin resistance. 
The aim of the present study was to investigate whether the influence of the 
CETP -629C-+A promoter polymorphism on HDL cholesterol is modulated by se­
rum triglycerides, independently from other clinical determinants of HDL cholesterol. 
The relationships of HDL cholesterol with the TaqIB CETP gene variants and of se­
rum apo A-1, the major HDL-associated apolipoprotein, with these polymorphisms 
were also studied. 
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Methods 
Study population 
Inhabitants of the city of Groningen participating in the PREVEND ("Prevention of 
REnal and Vascular ENd stage Disease") study were studied. Details of the protocol 
have been described elsewhere. 23 In short, the PREVEND study investigates vascular 
and renal damage in the general population. The study was approved by the local 
medical ethics committee. All participants gave written infonned consent. 
The present study is focussed on the effects of CETP gene polymorphisms in 
conjunction with clinical variables and serum triglycerides on HDL cholesterol and 
serum apo A-1. Therefore, participants who were not genotyped, subjects with miss­
ing values for HDL cholesterol or triglycerides, as well as subjects who were not 
examined after an overnight fast were excluded. Diabetic patients were also excluded, 
leaving 7083 subjects. A second database (n = 6948) was used to evaluate detenni­
nants of apo A-1, with similar exclusion criteria. 
Study protocol 
Information regarding the use of lipid lowering drugs, smoking, alcohol consumption 
(categorized as < I and ::::: 1 U/day) and hospital admission for myocardial infarction 
was obtained, using a check-list as described.23 Body mass index (BMI) was calcu­
lated as the ratio between weight and height squared (in kg/m2). Waist circumference 
was measured on bare skin between the tenth rib and the iliac crest. After 1 5  min rest, 
blood samples were taken. 
Definitions 
Diabetes mellitus was diagnosed if fasting plasma glucose level was ::::: 7.0 mmol/1,24 
or if the participant used blood glucose-lowering drugs. Myocardial infarction was 
documented if ECG detected a myocardial infarction by Minnesota code 1 - 1 - 1  to 1 -2-
8, and/or if the participant had a history of hospital admission for myocardial infarc­
tion. In women, postmenopausal status was defined as absence of menstruation for 
more than a year or use of honnone replacement therapy for postmenopausal condi­
tions. The homeostasis model assessment index for insulin resistance (HOMA;,) was 
quantified as fasting insulin (mU/1) x fasting glucose (mmol/1) I 22.5.25 
Laboratory methods 
Serum samples were stored at -20°C until analysis. Plasma glucose was measured 
shortly after blood sampling. Insulin levels were assessed using a microparticle en­
zyme immunoassay (AxSYM Insulin assay, Abbott Laboratories, Abbott Park, IL 
60064, USA). Serum triglycerides were measured enzymatically. Serum total choles­
terol and plasma glucose were assessed using Kodak Ektachem dry chemistry (East­
man Kodak, Rochester, New York, U.S.A.). HDL cholesterol was measured with a 
homogeneous method (direct HDL, no. 7D67, AEROSET™ System, Abbott Labora­
tories, Abbott Park, IL 60064, USA). In this assay system, HDL and apo B­
containing lipoproteins are complexed with one reagent, followed by solubilising 
HDL particles by another reagent.26 Serum apo A-I was determined by nephelometry 
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applying commercially available reagents for Dade Behring nephelometer systems 
(BN II, Dade Behring Marburg, Gennany; apo A-I test kit, code no. OUED).27;28 
Geno typing 
The -629C-+A promoter SNP was genotyped by two separate PCRs with allele spe­
cific primers: 5'-FAM-GCCCCAGCTGTAGGTAAAGTA was used as forward 
primer in both reactions. Reversed primer 5 ' -
GATATGCATAAAATAACTCTGGGT was used to amplify exclusively the A­
allele, resulting in a 188 basepair PCR product. Primer 5 '­
ttttGATATGCATAAAATAACTCTGGtG was used to amplify the C-allele. This 
latter primer has a four 5 '-T residues tail (lower case) to generate a discriminating 
PCR product of 1 92 bp of the C-allele and the second to last nucleotide (lower case 
"t") is a mismatch to improve specificity. After PCR cycling, using standard condi­
tions, samples were combined and separated on a MegaBACE I 000 sequencer (Am­
ersham Biosciences Benelux, Roosendaal, The Netherlands). Fragments were ana­
lysed with Genetic Profiler 2.0 software (Amersham Biosciences Benelux). 
The TaqIB was analysed using TaqMan-MGB probes and primers, designed 
through the Assay-by-Design service of Applied Biosystems (Applied Biosystems, 
Applera Nederland, Nieuwerkerk aan de IJssel). For the TaqIB SNP the forward 
primer sequence was 5 '-CCCCTAACCTGGCTCAGATC, the reversed primer se­
quence 5'-GCCAGGTATAGGGATITGTGTITGT, and the TaqMan-MGB probes 
were FAM-CCCTAACTTGAACCC and VIC-CCCTAACTCGAACCC. Assays were 
carried out according to the manufacturers recommendations on an ABI 7900HT ap­
paratus. 
Statistical Analysis 
Stata SE 8, SPSS 1 2  and Excel were used for data analysis. Data are expressed as 
mean ± SD or in median (interquartile range). Between-group differences of means 
were compared with ANOV A; medians were tested by K independent samples test. 
x2 analysis was used to compare frequencies between groups. Best curve fit for 
triglycerides, HOMA;, and waist was estimated by calculation using SPSS curve fit 
regression. These analyses showed that triglycerides, HOMA;, and waist against HDL 
cholesterol fitted best after natural logarithmic transfonnation. 
Multiple linear regression analyses were used to evaluate detenninants of HDL 
cholesterol and serum apo A-1. In these analyses the effects of the CETP promoter 
and the TaqIB CETP gene polymorphisms, triglycerides and clinical variables and of 
interactions of clinical variables and triglycerides with the CETP gene polymor­
phisms were evaluated. In these models, CC and B I B I  homozygotes (i.e. the CETP 
gene polymorphisms associated with the lowest HDL cholesterol and apo A-I levels) 
were used as reference group. In case of two variables comparing with one reference 
variable, a combined P value of both variables was calculated by Wald test in Stata 8. 
A two-sided P value < 0.05 was considered to be significant, except for interaction 
tenns, for which P values < 0. 10  were accepted. 
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Table 5.1. Population characteristics according to CETP -629C--+A promoter 
polymorphism (n = 7083). 
TaqIB B IB I (%) 
B I B2 (%) 
B2B2 (%) 















48.8 ± 1 2.4 
26.0 ± 4. 1  
88.0 ± 12.8 
2.08 ± 1 .60 
1 . 1 8  
(0.85 - I .  72) 
1 .26 ± 0.37 
1 .36 ± 0.28 
CA AA p 
(50.3%) (22.9%) 
1 4.9 3 . 1  < 0.001 
83. 1 22.3 
2 . 1  74.5 
50.5 48.6 0.41 
49.2 ± 12.7 49.4 ± 12.7 0.35 
26.0 ± 4.2 26. 1 ± 4.4 0.97 
88.4 ± 12.8 88.5 ± 1 3.5 0.44 
2. 1 0 ± 1 .82 2.23 ± 1 .9 1  0.02 
1 . 1 4  1 . 1 0  0.01 
(0.85 - 1 .65) (0.8 I - 1 .58) 
1 .33 ± 0.39 1 .40 ± 0.42 < 0.001 
1 .39 ± 0.29 1 .4 1  ± 0.3 1 < 0.001 
BM!, body mass index; HOMA;., homeostasis model assessment index; TG, triglycerides, HDL-C, high 
density lipoprotein cholesterol; apo A-1, apolipoprotein A-1. 
Results 
As shown in table 5. 1 ,  with respect to the CETP promoter polymorphism 26.8% of 
individuals were genotyped as -629CC, 50.3% as -629CA and 22.9% as -629AA. 
The genotype distribution was in Hardy-Weinberg equilibrium (P > 0.9). The CETP -
629C--+A was in strong linkage disequilibrium with the TaqIB polymorphism (D'= 
0.941 , P < 0.001 ). There were no differences in gender distribution, age, BMI and 
waist circumference among the CC, CA and AA allele carriers (table 5. 1 ). In the 
whole group, 6.0 % of the subjects had a history of myocardial infarction, 6. 1 % used 
lipid lowering drugs, 33.8 % were smokers, 59.5% consumed � 1 Unit of alcohol / 
day, and 40.2% of the women were postmenopausal. The prevalences of previous 
myocardial infarction, use of lipid lowering drugs, postmenopausal status, alcohol 
intake, and current smoking as well as urinary albumin excretion were also not differ­
ent among the three CETP promoter genotype groups (data not shown). HOMA" was 
slightly higher in AA genotype carriers (table 5. 1 ). HDL cholesterol and serum apo 
A-I levels were on average 0. 1 4  mmol/1 and 0.05 g/1 higher in AA genotype carriers 
compared to CC genotype carriers. Serum triglyceride levels were slightly lower in 
AA genotype carriers. 
Analysis of HDL cholesterol, apo A-I and triglycerides, according to the TaqlB 
CETP polymorphism showed that HDL cholesterol was 1 .27 ± 0.37, 1 .34 ± 0.40 and 
1 .40 ± 0.41 mmol/1, and that apo A-I was 1 .36 ± 0.28, 1 .39 ± 0.29 and 1 .41 ± 0.31 g/1 
in B 1 B 1 ,  B 1 B2 and B282 carriers, respectively (P < 0.001 for both). 
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Table 5.2. Effect of CETP -629C----+A promoter polymorphism and other variables on 
HDL cholesterol (n = 7083) 
Model 1 Model 2 Model 3 
Variable p p 
CA vs CC, Pl  < 0.001 < 0.001 0.07 
AA vs CC, p2 0 . 15  
TG (In, mmol/l) -0.30 < 0.001 -0.34 < 0.001 -0.25 
Male gender -0.26 < 0.00 1 -0.26 < 0.001 -0.24 
CA x TG, PI -0.05 } 0.02 -0.05 } 0.03 -0.04 
AA x TG, P2 -0.04 -0.03 -0.02 
CA x male, P I  0.00 
} 
< 0.05 0.00 
AA x male, P2 -0.04 -0.04 
TG x male (mmol/l) 0.07 < 0.00 1 0.03 
Homair -0.05 
[In, mU.mmol/(12 x 22.5)] 
Waist (In, cm) -0.47 
Alcohol use (< I u/day vs 0. 1 1  
� I u/da 
HDL cholesterol (mmol/1) was adjusted for age and lipid lowering drugs in all models. 
The natural logarithm of triglycerides (TG), HOMA,, and waist are used. 
p 
< 0.00 1 
< 0.00 1 
< 0.00 1 




< 0.00 1 
< 0.00 1 
< 0.00 1 
CETP -629CC genotype carriers were used as the reference group. Interaction terms of genotype with TG, 
gender and ofTG with gender are shown. Interaction terms are evaluated by Wald test. 
As shown in table 5.2, HDL cholesterol was independently determined by the 
CETP -629C----+A promoter polymorphism, triglycerides, and gender as well as by the 
interaction of CETP genotype with triglycerides, after adjustment for age and the use 
of lipid lowering drugs (model 1 ). Menopausal status did not affect these relation­
ships (P = 0.30; data not shown). The negative �-coefficients of this interaction term 
indicate that the HDL cholesterol raising effect of the A allele was diminished with 
higher levels of triglycerides. When men and women were analysed separately, simi­
lar trends concerning the CETP promoter polymorphism-triglyceride interaction were 
found (data not shown). Moreover, when lipid lowering drug users were excluded (n 
= 434), the interaction of the CETP promoter polymorphism with triglycerides on 
HDL cholesterol remained significant (Wald test P = 0.04). Model 2 shows that a 
significant interaction of this CETP gene polymorphism with gender on HDL choles­
terol was also present, in such a way that the HDL-raising effect of the A allele was 
greater in women, without a significant effect of the postmenopausal status (P = 
0.16). The positive interaction term of triglycerides with male gender on HDL choles­
terol indicates that the inverse relation of HDL cholesterol with the triglyceride level 
is less steep in men than in women. In model 2, the interaction of the CETP -
629C----+A promoter polymorphism with triglycerides remained significant. Finally, 
the interaction of the CETP promoter polymorphism with triglycerides was still sig­
nificant after additional adjustment for HOMAin waist circumference and the amount 
of alcohol consumption (model 3) and further adjustment for smoking (data not 
shown). In models that included the CETP promoter polymorphism, serum triglyc­
erides, gender and alcohol use or smoking, we did not observe interaction between 
smoking or use of alcohol and the CETP -629C----+A promoter polymorphism on HDL 
cholesterol (Wald test for interaction P > 0.50 for both). 
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When the TaqlB CETP gene polymorphism was used as genetic determinant of 
HDL cholesterol, similar findings were noted with respect to the interaction of 
triglycerides with the TaqIB genotypes (table 5.3). 
Table 5.3. Effect of CETP TaqJB polymorphism and other variables on HDL choles-
terol [n = 70832 
Model I Model 2 Model 3 
Variable p p p 
B IB2 vs BIBI ,  Pl  O.o? } < 0.001 0.09 } < 0.001 0.08 < 0.001 8282 VS BIBI ,  p2 0. 12  0. 1 4  0. 1 5  
TG (In, mmol/1) -0.30 < 0.001 -0.34 < 0.001 -0.26 < 0.001 
Male gender -0.26 < 0.001 -0.26 < 0.001 -0.23 < 0.001 
B I B2 x TG, P l  -0.05} 0.0 1 -0.04 } 0,03 -0.04 } 
0.05 
B282 x TG, p2 -0.04 -0.03 -0.02 
8 I B2 x male, P l  -0.02 } 0. 1 7  -0.02 } 
0. 1 7  
8282 x male, p2 -0.04 -0.04 
TG x male (mmol/1) O.Q7 < 0.001 0.04 0.01 
Homa,, [In, mU.mmol/(12 x -0.05 < 0.001 
22.5)] 
Waist (In, cm) -0.47 < 0.001 
Alcohol use (< I u/day vs ;e: 0. 1 1  < 0.001 
I u/da 
HDL cholesterol (mmol/1) was adjusted for age and lipid lowering drugs in all models. 
The natural logarithm of triglycerides (TG), HOMA., and waist are used. CETP TaqIB B IB I  genotype 
carriers were used as the reference group. Interaction terms of genotype with TG, gender and of TG with 
gender are shown. Interaction terms are evaluated by Wald test. 
Table 5.4 shows that apo A-I levels are determined by the CETP -629C-+A 
promoter and TaqIB polymorphisms. However, the interaction of these CETP poly­
morphisms with triglycerides did not independently affect serum apo A-1. 
Notably, models with each CETP polymorphism, waist, HOMAi, or insulin level 
and the interactions of these variables with CETP genotypes did not reveal significant 
interactions of waist, HOMAir or serum insulin with CETP genotypes on HDL cho­
lesterol (data not shown; Wald test for interactions P > 0.30), except for an interac­
tion between the TaqIB polymorphism and waist (Wald test P = 0.06). 
Table 5.4. Effect of CETP 629C-+A promoter and of TaqIB polymorphism and 
other variables on apo A-I, after adjustment for age and lipid lowering drugs 
Model -629C-+A promoter Model TaqIB 
Variable 
(n = 6948) (n � 6948) 
p 
CA vs CC, P l  
AA vs CC, P2 
TG (In, mmol/1) 
Male gender 
CA X TG, PI 
AA x TG, �2 
0.04 } < 0.00 1 B I B2 vs BIB l , Pl  0.04 } < 0.001 0.05 B2B2 VS B IB I ,  p2 0.06 
-0.06 < 0.00 1 TG (In, mmol/1) -0.06 
-0. 1 8  < 0.00 I Male gender -0. 1 8  
-0.02 } 0.59 8 1 82 x TG, PI -0.01 } -0.00 B I  82 x TG, �2 -0.00 




The natural logarithm of triglycerides (TG) is used. CETP -629CC and CETP TaqlB B I B  I genotype carri­
ers were used as the reference group. Interaction terms of genotype with TG, gender and of TG with gender 
are shown. Interaction terms are evaluated by Wald test. 
CETP gene variation, HDL cholesterol and triglycerides 91 
Figure 5.1 shows the unadjusted HDL cholesterol levels according to CETP -
629C---+A promoter genotypes across tertiles of serum triglycerides. In the tertile of 
lowest triglycerides (triglycerides < 0.94 mmol/1), the mean difference of HDL cho­
lesterol between the -629CC and the AA genotype carriers was 0. 15 mmol/1; whereas 
in the highest triglyceride tertile (triglycerides > 1.43 mmol/1) this difference was 
limited to 0.08 mmol/1 (P < 0.01). 
Figure 5.1. Effect of CETP -629C> A 
promoter polymorphism on HDL 










< 0.94 mmol/1 0.94 - 1.43 mmol/1 > 1.43 mmol/1 
Tertiles of serum triglycerides 






Mean difference in HDL cholesterol between 
CETP -629CC and -629AA homozygotes in 
lowest TG tertiles vs highest triglyceride fertile P < 
0.001. 
Discussion 
This population-based study demon­
strates that the influence of the -
629C---+A CETP promoter polymor­
phism on HDL cholesterol is dimin­
ished with rising serum triglycerides. 
Moreover, such a CETP gene­
triglyceride interaction on HDL cho­
lesterol was also present for the TaqIB 
polymorphism, which is known to be 
in strong linkage disequilibrium with 
the -629C---+A promoter variant. '5·17:29• 
34 In contrast, neither central obesity, 
determined by waist circumference, 
nor insulin resistance, documented as 
HOMAir, modified the influence of the 
-629C---+A promoter on HDL choles­
terol. The present data, therefore, indi­
cate that the level of circulating 
triglyceride-rich lipoproteins, as re­
flected by the triglyceride concentra­
tion, is central in modulating these 
genetic effects on HDL cholesterol. 
The present report provides in­
formation from the largest single cohort so far concerning the magnitude of the effect 
of the -629C---+A CETP promoter polymorphism on HDL cholesterol which was 
found to be 0. 14 mmol/1 between AA and CC homozygotes. The crude difference in 
HDL cholesterol between B2B2 and B IB I  homozygotes amounted to 0.13 mmol/1, 
which closely corresponds to values of 0. 11 to 0. 12 mmol/1, as retrieved by meta­
analyses. 1 1 :35 The associations between these polymorphisms and HDL cholesterol 
were still present after adjustment for serum triglycerides, obesity, alcohol use and 
insulin resistance, as inferred from HOMAir· In these meta-analyses
1 1
:
35 the effect the 
TaqIB CETP gene polymorphism on serum apo A-1 was not evaluated. Our study 
indicates that both CETP gene variants affect the serum apo A-I level as well, inde­
pendently from serum triglycerides. Significant differences in serum triglycerides 
levels and the degree of insulin resistance were found between -629AA and CC ho-
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diminished insulin sensitivity in AA allele carriers. We interpret these findings to be 
coincidental, as lower serum triglyceride levels usually coincide with lower HOMAi, 
values. Moreover, it cannot be easily explained how a direct or indirect effect of 
variation in the CETP gene could affect the serum triglyceride level or the degree of 
insulin resistance. 
Two relatively small studies with 220 1 3  and 18722 participants have previously 
suggested that obesity and hyperinsulinaemia may interact with the CETP TaqIB 
polymorphism on HDL cholesterol. In Taiwanese Chinese, the effect of CETP TaqIB 
variation on HDL cholesterol was diminished, i.e. not significant in obese and in hy­
pertriglyceridaemic subjects.36 A recently published meta-analysis reported that the 
serum triglyceride level does not influence the effect of this CETP gene polymor­
phism on HDL cholesterol.35 This discrepancy with the present report could be ex­
plained by heterogeneity between studies inherent to every meta-analysis, e.g. with 
respect to the median serum triglyceride level in each study, the overrepresentation of 
elderly subjects with coronary artery disease in this meta-analysis and the inclusion of 
subjects with diabetes in most studies. Moreover, in this meta-analysis, the influence 
of CETP gene variation on HDL cholesterol in relation to triglycerides was assessed 
by dichotomising triglycerides which may have masked relatively small effects. We 
consider the currently revealed interactions of the -629C-A CETP promoter variant 
and the TaqIB polymorphism with serum triglycerides on HDL cholesterol to be ro­
bust, in particular because these interactions remained present after adjustment for 
central obesity and insulin resistance. This is of interest because obesity is associated 
with higher plasma CETP levels.37;38 In our models, waist circumference rather than 
BMI was included, because the inverse relationship of HDL cholesterol with waist 
circumference was stronger than with BMI, and BMI did not affect HDL cholesterol 
independent from waist circumference. Of importance, previous studies suggest that 
the effect of the TaqIB CETP gene variant on HDL cholesterol is modified by gen­
der, 19;20 although such an interaction has not always been observed. 1 3;36 Our study 
shows that the effect of the CETP promoter polymorphism on HDL cholesterol is 
stronger in women than in men, irrespective of menopausal status. 
The CETP-mediated process of neutral lipid transfer results in a low content of 
cholesterol in HDL particles and a high cholesterol content in apo 8-containing lipo­
proteins, with reciprocal changes in lipoprotein triglycerides.5·7 Thus, enhanced trans­
fer of cholesteryl esters out of HDL provides a metabolic intermediate between high 
serum triglyceride levels and low HDL cholesterol.3941 The rate of cholesteryl ester 
transfer from HDL towards triglyceride-rich lipoproteins is determined by the circu­
lating amount of active CETP as well as by the composition and concentration of 
triglyceride-rich lipoproteins, with large-sized triglyceride-rich lipoproteins being the 
preferred cholesteryl ester acceptor lipoproteins.40;4245 The -629C-A CETP pro­
moter variant does not alter the molecular structure of this lipid transfer protein, but 
affects its circulating mass and, hence, the amount of active CETP in se­
rum. 1 1 ;  IJ;I4;I6; 1 7;2o;Jo A likely explanation of our results is that when triglycerides in-
crease, the CETP promoter variant and, hence, CETP levels could become less impor­
tant for the process of cholesteryl ester transfer compared with the concentration of 
triglyceride-rich lipoproteins. The lack of a CETP gene-triglyceride interaction with 
respect to serum apo A-I does not disregard this supposition, but instead underscores 
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that effects the constellation of triglyceride-rich lipoproteins on the cholesteryl ester 
transfer out of HDL primarily affect the HDL cholesterol content and only secondary 
the concentration of its major apolipoprotein, apo A-1. 
Both the serum CETP activity level46 and the CETP concentration 1 s are de­
creased by statin treatment, whereas small changes have been reported after fibrate 
therapy. 7 Statins were the most widely used lipid lowering drugs in our study popula­
tion, estimated to account for > 90% of lipid lowering drug prescriptions, and it was 
decided to adjust HDL cholesterol for the use of lipid lowering drugs in all multivari­
ate regression models. However, pharmacy-verified information regarding statin or 
fibrate treatment was not available for each participant, and we could not adjust sepa­
rately for the use of each type of lipid lowering drug. Of relevance, the interaction of 
the CETP promoter polymorphism with triglycerides on HDL cholesterol was also 
significant when all lipid lowering drug users were excluded from the analyses. Com­
plex alterations in the cholesteryl ester transfer process are present in the diabetic 
state.7 The specific activity of CETP, i.e. the level of active CETP divided by its con­
centration, is lower indicating that CETP is less active in the diabetic state.47 On the 
other hand, the cholesteryl ester transfer process may be enhanced by in vitro glyca­
tion of HDL.48 Therefore, subjects with type 2 diabetes mellitus were excluded from 
the present study. A possible limitation of our analysis is that data concerning physi­
cal activity were not available because this item was considered not precise enough 
when documented by questionnaire. 
What could be the practical consequences of the diminished effect of CETP gene 
variation on HDL cholesterol with high serum triglycerides? The Veteran Affairs 
HDL Intervention Trial has demonstrated that gemfibrozil treatment reduces the risk 
of cardiovascular diseases in subjects with low HDL cholesterol,49 and that the extent 
of risk reduction is predicted by the HDL cholesterol concentration attained during 
fibrate therapy.so Further analysis of this study demonstrated that even after stratifica­
tion according to the TaqIB CETP genotype, the HDL cholesterol response was quite 
variable across the CETP genotype groups.s1 From the present study, we surmise that 
more triglyceride lowering is required to achieve the same increase in HDL choles­
terol in -629CC compared with -629AA genotype carriers. Nonetheless, the possible 
consequences of this CETP gene-serum triglyceride interaction on HDL cholesterol 
for cardiovascular risk are unknown at present. 
In conclusion, the present study demonstrates that the effect of the -629C---+A 
CETP promoter polymorphism on HDL cholesterol was modified by the serum 
triglyceride level. In the lowest triglyceride tertile, this CETP gene effect amounts to 
0. 1 5  mmol/1, whereas this effect is limited to 0.08 mmol/1 in the highest triglyceride 
tertile. This CETP gene-triglyceride interaction on HDL cholesterol has consequences 
for the interpretation of genetic effects on the HDL phenotype, and could be of help 
to predict the effect of triglyceride lowering treatment on raising HDL cholesterol. 
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Abstract 
Background: Several cholestery/ ester transfer protein (CETP) polymorphisms 
affect HDL cholesterol, but the impact of CETP gene variants on incident coronary 
disease in the general population is uncertain after correction for their effect on HDL 
cholesterol. 
Design: We determined relationships between the CETP -629C---+A promoter (n = 
8 14 1 ), the TaqIB (n = 8289) and the 1405V (n = 8265) polymorphisms, serum lipids, 
C-reactive protein and clinical factors with incident coronary heart disease ( defined as 
death from or hospitalisation for myocardial infarction, ischaemic heart disease, or 
coronary intervention) during a median of 4.94 years follow-up. 
Subjects: A predominantly Caucasian general population was studied. 
Results: HDL cholesterol was 0.08 mmol/1 higher in -629A carriers than in -629CC 
homozygotes (P < 0.001 ). The unadjusted coronary hazard was 1 .26 [95% confidence 
interval (CI) 0.95 1 .68, P = 0. 1 1 ]  in A carriers compared to CC homozygotes, and 
increased to 1 .46 (95% CI 1 . 1 0  - 1 .95, P = 0.0 I )  after adjustment for HDL 
cholesterol. This effect remained after further adjustment for apolipoprotein A-I, 
triglycerides, C-reactive protein, age and gender. Likewise, the HDL cholesterol­
adjusted hazard ratio was also higher in AA than in CC homozygotes (hazard ratio, 
1 .72, 95% CI 1 .22 - 2.42, P < 0.01 ). Similar findings were obtained with the TaqIB 
polymorphism. The 405V allele was weakly associated with incident coronary heart 
disease after HDL cholesterol adjustment (P = 0.09). 
Conclusions: A common CETP promoter polymorphism, which beneficially 
contributes to higher HDL cholesterol, is paradoxically associated with increased 
incidence of coronary disease in the general population. Thus, CETP gene variation 
may affect coronary risk apart from the level ofHDL cholesterol. 
Key words: HDL, cholestery/ ester transfer protein gene, coronary disease, follow-up 
studies, population 
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Introduction 
The relationship between plasma high density lipoprotein (HDL) cholesterol and the 
risk of coronary artery disease is well established. 1 ;2 The cardioprotective role of HDL 
is commonly explained by its function in the reverse cholesterol transport pathway, 
whereby excess cholesterol is transported from vascular tissue back to the liver for 
metabolism and excretion in the bile.3-s The cholesteryl ester transfer protein (CETP) 
plays a pivotal role in HDL metabolism and in reverse cholesterol transport.6;7 CETP 
enables the transfer of cholesteryl esters from HDL particles towards very low density 
and low density lipoproteins (VLDL and LDL).4;6;7 As a result, HDL cholesterol is 
lowered by CETP action. Because the cholesteryl ester transfer process may stimulate 
reverse cholesterol transport by providing a route for delivery of HDL-derived 
cholesteryl esters to the liver via VLDL and LDL and the hepatic LDL receptor,7;8 it 
is currently debated whether circulating CETP may act in an atherogenic or even in an 
anti-atherogenic manner.6•9• 1 0 
Rare mutations causing CETP deficiency result in very high HDL cholesterol 
concentrations. 1 1 ; 12 Paradoxically, an increased prevalence of coronary disease has 
been reported in men with genetic CETP deficiency, despite their high HDL 
cholesterol levels. 1 1 ; 12 It has been suggested that large HDL particles occurring in 
genetic CETP deficiency do not have anti-atherogenic properties, 13 whereas LDL 
particles may have less affinity for their receptor. 14 CETP gene variants such as -
629C-+A, TaqIB and 1405V polymorphisms that affect HDL cholesterol are common 
in the general population. 15  The TaqIB variant is in almost complete linkage 
disequilibrium with the -629C-+A promoter polymowhism,
16
-
1 8 which directly 
modulates CETP gene transcriptional activity in vitro. 1 7; 1 The 1405V variant is also 
but to a lesser extent a determinant of circulating CETP. 1 5  Despite much study it is 
still unclear whether, how and under which circumstances these CETP gene variations 
affect coronary risk. The associations of the TaqlB polymorphism with coronary heart 
disease are inconsistent. 20-28 A meta-analysis has suggested that cardiovascular risk is 
decreased in TaqIB B2B2 homozygotes, i.e. the genotype which is associated with 
high HDL cholesterol levels.29 With some exceptions,26;30 cardiovascular risk was 
found to be unaffected by the CETP -629C-+A promoter polymorphism.22;2s;3i ;32 
Importantly, it remains uncertain whether an association of the TaqlB polymorphism 
with cardiovascular risk could be attributable to its effect on HDL cholesterol.29 
Moreover, as yet, all clinical end-point studies with the -629C-+A and the TaqIB 




32 were carried out men20;22;24-
6;3 1 ;33;
34 or in subjects with a cardiac history23;24;27;2s;3o;34 rather than in the general 
population. 
Therefore, we questioned how the -629C-+A promoter polymorphism may 
affect coronary heart risk in the general population when its effect on HDL 
cholesterol is taken into account. In the present study, the impact of the CETP -
629C-+A promoter polymorphism on incident coronary disease was determined in a 
population-based cohort. The effects of the TaqIB and the 1405V CETP gene variants 
were also assessed. 
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Methods 
Study population 
Inhabitants of the city of Groningen participating in the PREVEND ("Prevention of 
REnal and Vascular ENd stage Disease") study were studied. Details of the protocol 
have been described elsewhere.35 The PREVEND study is designed as a prospective 
longitudinal follow up study to evaluate the impact of baseline albuminuria level on 
cardiovascular36 and renal37 outcome in a predominantly Caucasian general 
population. The study was approved by the local medical ethics committee. All 
participants gave written informed consent. 
The present study is focussed on the effects of the CETP -629C-+A promoter 
polymorphism on coronary disease in a population of 8592 subjects. Therefore, 
participants who were not genotyped for -629C-+A (n = 451) were excluded, 
resulting in data of 8141 subjects. For similar reasons, analyses concerning the effects 
of the TaqIB and the 1405V polymorphisms were carried out in 8289 and in 8265 
subjects, respectively. 
Definitions 
All data were coded according to the International Classification of Diseases, Ninth 
Revision (ICD-9-CM), classification of diseases and the classification of 
interventions. The combined end-point of this study was defined as death from 
myocardial infarction (ICD-9 410) and ischaemic heart disease (ICD-9 411), and 
hospitalisation for myocardial infarction (ICD-9 410), ischaemic heart disease (ICD-9 
411 ), percutaneous transluminal coronary angioplasty (PTCA) and coronary artery 
bypass grafting (CABG). Vital status was evaluated through municipal register. 
Primary cause of death was obtained from the death certificates coded by Central 
Bureau of Statistics (CBS, Voorburg/Heerlen, The Netherlands). Morbidity data were 
registered from national registry of hospital discharge diagnoses (Prismant, Utrecht, 
The Netherlands). 
The first coronary heart event of each participant was used for analysis. Event­
free survival time for participants was defined as the period from the date of the 
outpatient clinic baseline assessment to the date of death, myocardial infarction, 
PTCA or CABG or from any cause until 31 December 2003, or 31 December 2002 
until which date information regarding specific causes of was available. If a person 
had moved to an unknown destination, the date on which the person was dropped 
from the municipal registry was used as census date. 
At baseline, information regarding the use of antihypertensive, anti-diabetic and 
lipid lowering drugs, smoking and alcohol consumption ( categorised as < l and ;;:: l 
U/day, i.e. < 10 and ::: 10 g/day) was obtained using a check-list as described.35 Body 
mass index (BMI) was calculated as the ratio between weight and height squared (in 
kg/m2). Waist circumference was measured on bare skin between the tenth rib and the 
iliac crest. Hypertension was characterised as systolic blood pressure ;;:: 140 mmHg or 
diastolic blood pressure ;;:: 90 mmHg or the use of antihypertensive drugs. 
Microalbuminuria was defined as urinary albumin excretion 30 - 300 mg/24 h.35 
Diabetes mellitus was diagnosed by fasting plasma glucose ;;:: 7.0 mmol/1, or use of 
anti-diabetic drugs. Myocardial infarction was documented if the participant had a 
history of hospital admission for myocardial infarction. 
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Laboratory methods 
Blood samples were taken after 15 min rest. Plasma glucose was measured shortly 
after blood sampling. Serum samples for lipid and apolipoprotein (apo) measurements 
as well as for C-reactive protein (CRP) assay were stored at -20 °C until analysis. 
EDT A-anticoagulated plasma samples for CETP and cholesteryl ester transfer (CET) 
measurement were frozen at -80 °c until assay in a sub-set of subjects. HDL 
cholesterol was measured with a homogeneous method (direct HDL, no. 7D67, 
AEROSET™ System, Abbott Laboratories, Abbott Park, IL 60064, USA). Serum 
triglycerides were measured enzymatically. Serum total cholesterol and plasma 
glucose were assessed using Kodak Ektachem dry chemistry (Eastman Kodak, 
Rochester, New York, U.S.A.). Serum apolipoprotein (apo) A-I was determined by 
nephelometry applying commercially available reagents for Dade Behring 
nephelometer systems (BN II, Dade Behring Marburg, Germany; apo A-I test kit, 
code no. OUED).38;39 CRP was also determined by nephelometry with a threshold of 
0. 175 mg/L (BNII, Dade Behring, Marburg, Germany). Urinary albumin 
concentration was determined by nephelometry (Dade Behring Diagnostic, Marburg, 
Germany). Albuminuria (UAE) is given as the mean of two 24 h urine excretions. 
Plasma CETP concentration was analysed using a double-antibody sandwich ELISA 
as described.4° CET was assayed using an isotope method.41 
Geno typing 
The -629C---+A promoter SNP and the TaqIB polymorphism were genotyped exactly 
as described.42 The CETP 1405 SNP was analysed using TaqMan-MGB probes and 
primers, designed through the Assay-by-Design service of Applied Biosystems 
(Applied Biosystems, Applera Nederland, Nieuwerkerk aan de IJssel, The 
Netherlands). For the 1405V SNP the forward primer sequence was 5 '­
CTCACCATGGGCATTTGATTGG, the reversed primer sequence 5 '­
CGGTGATCATTGACTGCAGGAA, and the TaqMan-MGB probes were FAM­
TCCGAGTCCGTCCAGA and VIC-CTCCGAGTCCATCCAGA. Assays were 
carried out according to the manufacturers recommendations on an ABI 7900HT 
apparatus. 
Statistical analyses 
Stata SE 8, SPSS 12 and Excel were used for data analysis. Hardy-Weinberg 
equilibria and linkage equilibrium were calculated using Excel.43 Data are expressed 
as mean ± SD or in median (interquartile range). Between group differences of means 
were compared with Student's t-test, medians with Mann-Whitney U test and 
frequencies with x2 analysis. x2 analysis was used to compare frequencies between 
groups. HDL cholesterol is lower in -629CC than in -629CA and -629AA 
subjects. 17; IS;42 For modelling, the association of the -629A allele (-629CA + -
629AA subjects combined and -629AA homozygotes alone) with event-free coronary 
heart disease survival was investigated using the CETP -629CC homozygotes as 
reference group. Likewise, the effects of the TaqIB and the 1405V polymorphism on 
coronary risk were evaluated using the B IB I  and the II homozygotes, i.e. the 
genotype groups with the lowest HDL cholesterol levels, as reference group. The 
effects of the CETP -629C---+A promoter, CETP TaqlB and CETP 1405V 
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polymorphism on coronary events were studied with Cox regression analysis, and 
hazard models were fit to test differences in survival. Proportional hazards 
assumptions were assessed by graphing the log-log(survival) and by testing the 
Schoenfeld residuals against time. Event-free survival data are plotted graphically. 
Our cohort consisted of a random sample of control subjects with <IO mg/I of urinary 
albumin and a selected sample of subjects with > 10 mg/I of urinary albumin. 
Therefore, risk estimates were calculated by adding the selection parameter as a 
confounder interacting with the CETP -629C-+A promoter, the TaqIB or the 1405V 
polymorphism in a secondary analysis. A two-sided P-value < 0.05 was considered 
significant. 
Results 
Baseline population characteristics 
Table 6. 1 shows baseline characteristics of the population according to the CETP -
629C-+A promoter polymorphism. The population consisted of 95.6% Caucasians. 
The promoter polymorphism was distributed in Hardy-Weinberg equilibrium (P > 
0.99) and the -629A allele frequency was 48%. No differences were observed in 
Table 6.1. Baseline e.oe.ulation characteristics (n = 81412 
CETP -629C->A eromoter eol�mo!Ehism 
cc CA AA CA + AA 
n (%} 2, 1 48 {26.4} 4, 1 22 {50.6} 1 ,871 {23.0) 5,993 {73.6} 
Male gender (%) 49.7 5 1 .3 49.9 50.9 
Age (years) 49. 1 ± 12.5 49.4 ± 1 2.7 49.6 ± 12.8 49.5 ± 12.8 
BM! (kg/m2) 26. 1 ± 4.2 26. 1 ± 4.2 26. 1 ± 4.4 26. 1 ± 4.3 
Waist (cm) 88.2 ± 1 2.8 88.8 ± 1 2.9 88.7 ± 13 .4 88.8 ± 13 . 1  
Hypertension (%) 3 1 .3 32.7 3 1 .8 32.4 
Systolic blood pressure (mmHg) 1 29 ± 20 1 29 ±  20 129 ± 20 1 29 ± 20 
Diastolic blood pressure (mmHg) 74 ± 1 0  74 ± 1 0  74 ± 1 0  74 ± 1 0  
Cigarette smokers (%) 36.5 38.4 37.5 38. 1 
Alcohol users, > I U/day (%) 59.3 59.0 59.3 59. 1 
Use of lipid lowering drugs (%) 5.3 4.8 4.0 4.5 
Diabetes (%) 3.4 4.0 4.0 4.0 
History of MI (%) 3.0 3.8 2.7 3.4 
Microalbuminuria (%) 14.0 1 3.4 14.4 1 3 .7 
Urinary albumin excretion 9.4 9.4 9.4 9.4 
(µg/min) (6.4 1 8.4) (6.3 1 6.9) (6.2 18.4) (6.3 - 1 7.3) 
CRP (mg/1) 1 .3 1  1 .26 1 .3 I 1 .27 
(0.55 - 2.98) (0.55 - 3.06) (0.57 -2.90) (0.56 - 2.98) 
HDL cholesterol (mmol/1) 1 .26 ± 0.37 1 .32 ± 0.39 1 .391 ± 0.42 1 .340 ± 0.40 
Non-HDL cholesterol (mmol/1) 4.34± 1 .2 1  4.36 ± 1 .2 1  4.26' ± 1 .20 4.33 + 1 .2 1  
Triglycerides (mmol/1) 1 .2 1  1 . 1 6  (0.85 1 . 1 2t 1 . 1 51 
(0.86 - 1 .75) - 1 .67) (0.83 - 1 .64) (0.85 - 1 .66) 
Apo A-I (g/1) 1 .36± 0.29 1 .38  ± 0.29 1 .4 1 1 ± 0.3 1 1 _398 ± 0.30 
To convert cholesterol from mmol/l to mg/di multiply by 38.7. To convert triglycerides from mmol/l to 
mg/di multiply by 88.6. One unit alcohol/day = 10 g alcohol/day. ·. t. ! P <0.05, <0.0 1 and <0.001 ,  respectively for difference between AA and CC. 
§, I P  <0.05 and <0.00 1 ,  respectively for difference between CA+AA and CC. 
MI, myocardial infarction; HDL, high density lipoprotein; apo, apolipoprotein. 
gender distribution, age, BMI, waist, prevalence of hypertension, systolic and 
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diastolic blood pressure, smoking, use of alcohol and lipid lowering drugs, prevalence 
of diabetes, previous myocardial infarction, prevalence of microalbuminuria and 
urinary albumin excretion between the -629CC and the -629A carriers as well as 
between the -629CC and -629AA homozygotes. HDL cholesterol and apo A-I were 
higher in -629A carriers and in -629AA homozygotes as compared with -629CC 
homozygotes. Triglycerides were slightly lower in -629A carriers and in -629AA 
homozygotes than in -629CC subjects. 
Table 6.2. Incidence of coronary heart disease per I 000 person years, 
according to deaths or hospital admission for myocardial infarction (Ml), 
ischaemic heart disease, percutaneous transluminal coronary angioplasty 
(PTCA) and coronary artery hYPass grafting (CABG) 
n (%) 
Total of person-years of follow-up 
Coronary disease (n) 
Coronary disease (n/ 1000 years) 
Subgroups of events: 
Death from MI or ischaemic heart 
disease (n/ 1000 years) 
MI (n/ 1000 years) 
Ischaemic heart disease (n/ 1000 
years) 
CABG (n/ 1000 years) 
PTCA (n/ 1000 years) 
CETP --629C->A promoter polymorphism 
CC CA AA CA + AA 
2148 4122 (50.6) 1 87 1  5993 
(26.4) (23.0) (73.6) 
1 1 ,45 1 22,0 1 1  9,978 3 1 ,988 
6 1  142 73 2 1 5  
5.3 6.5 7.3 6.7 
(4. 1  - 6.8) (5.5 - 7.6) (5.8 - 9.2) (5.9 - 7.7) 
0.3 0.3 0.6 
(0. 1 - 0.9) (0. 1 - 0.6) (0.3 - 1 .3) 
I �  2� 2� 
( 1 .0 - 2.5) (2.2 - 3.7) ( 1 .9 - 4. 1 )  
1 .8 1 .7 2.6 
( 1 .2 - 2.8) ( 1 .3 - 2.4) ( 1 . 8- 3.8) 
0.4 0.5 0.7 
(0.2 - 1 .0) (0.3 - 0.9) (0.3 - 1 .5) 
I . I  I . I  0.6 
(0. 7 - 2.0) (0. 7 - 1 .6) (0.3 - 1 .3} 
0.4 
(0.2 - 0.7) 
2.8 
(2.3 - 3 .5) 
2.0 
( 1 .6 - 2.6) 
0.6 
(0.4 - 0.9) 
0.9 
(0.7 - 1 .3) 
Data of first events are shown. The 95% CI are shown in parentheses 
Incident coronary disease and hazard models on -629C-A promoter polymorphism 
During a median follow-up of 4.94 years (range, 1 day - 6.3 years), and a total 
observation of 43,440 person-years, 276 subjects (3.4%) suffered a coronary event. 
Table 6.2 summarises the first coronary events according to the CETP -629C-A 
genotypes. As shown in model I (table 6.3), the hazard ratio (HR) for coronary 
disease was 26% higher -629A allele carriers than in -629CC homozygotes (P = 
0. 1 1  ). When the Cox survival function was adjusted for HDL cholesterol levels, -
629A carriers had a significantly 46% higher hazard ratio than -629CC subjects 
(model 2, table 6.3, and figure 6. 1). These increased hazard ratios for the -629A allele 
remained significant when confounders, apo A-I and triglycerides (model 3), and 
subsequently age, gender and CRP (model 4) were included. Additional adjustment 
for either use of alcohol, smoking, use of lipid lowering drugs, presence of diabetes 
mellitus, or history of myocardial infarction did not change the model. These 
parameters did not interact with the CETP genotype on coronary heart disease. When 
the models were repeated to obtain proportional hazards of AA vs CC homozygotes, 
similar results were obtained for model 2 [HR, 1 .72, 95 % confidence interval (CI), 
Table 6.3. Variation in CETP -629C-+A promoter polymorphism (-629CA+ AA versus -629CC) and other determinants of coronary heart 
disease evaluated by Cox proportional hazards analyses 
Model Model I 




HR 95% CI p 
Model 3 
HR 95% CI 
vs -629CC 1 .26 0.95 - 1 .68 0. 1 I 1 .46 I . IO - 1 .95 0.0 I 1 .53 1 . 1 3  - 2.08 
HDL cholesterol 0. 1 8  0. 12  - 0.26 < 0.00 I 0.40 0.23 - 0. 7 1  
(mmol/1) 
Apo A-I (g/1) 0.59 0.33 - I .  I 0 




CRP (In mg/I} 
HR, hazard ratio; 95% CI, 95% confidence intervals; HDL, high density lipoprotein; apo, apolipoprotein 
Model 4 
p HR 95% CI p 
< 0.01 I .40 1 .03 - 1 .90 0,03 
< 0.01 0.79 0.44 - 1 .40 0.42 
0.09 0.45 0.25 - 0.8 I 0.01 
< 0.001 1 .58 1 .2 1  - 2.07 0.001 
1 .07 1 .06 - 1 .08 < 0.001 
1 .9 1  1 .42 - 2.58 < 0.00 1 
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1.22 - 2.42; P = 0.01] and model 4 (HR, 1.53; 95% CI, 1.06 - 2.20; P = 0.02). The 
design of the study concerning enrichment of subjects with microalbuminuria did not 
alter the results. Moreover, no interaction of the sampling of the study population with 
the genotype on coronary risk was found (data not shown). 
TaqIB polymorphism was also in Hardy-Weinberg equilibrium (P > 0.99) and in 
almost complete linkage disequilibrium with the -629C-A polymorphism (D' = 
0.942, P < 0.001). The univariate hazard ratio of CETP TaqIB B2 allele on incident 
coronary disease was 1.31 (95% CI, 1.01 - 1.72; P = 0.04), as compared with B I B I  
homozygotes. The HDL-cholesterol-adjusted hazard ratio of the B2 allele was 1.51 
(95% CI, l . 16 - 1.98; P < 0.01). The hazard ratio was 1.62 (95% CI, 1.22 - 2. 15; P < 
0.01) after further adjustment for apo A-I and triglycerides, and 1.48 (95% CI, 1.12 -
1.97; P < 0.01) after subsequent age, gender, and CRP adjustment. Results were 
similar when the models were repeated to obtain proportional hazards of B2B2 vs 
BIBI  homozygotes (model 2: HR, 1.75; 95 % CI, 1.24 - 2.47; P < 0.00l )(model 4: 
HR, 1.58; 95 % CI, 1.10 - 2.27; P = 0.01). The sampling of the database did not alter 
the analyses with respect to the TaqIB polymorphism (data not shown). 
Figure 6.1. Association of HDL cholesterol-adjusted incident coronary disease 
with CETP -629C-A promoter polymorphism by Cox proportional hazards 
regression analysis (cf table 6.3, model 2). Numbers of subjects are given behind 
genotypes 
1 .00 -- -629CC 





IV · · .. 
C: . .. 
0 ... 
0 0.98 
. .. . u ... - .... 
0 .. .  
.c: 
... - ·· ··-... . "i 0.97 .. .. · · ·· · C: · · ··· . . .. 0 .. . 






0 1 2 3 4 5 6 
Years 
· 629 cc 2148 21 18  2090 2042 1 985 1709 290 
- 629 CA + AA  5993 5922 5829 5699 5535 4783 896 
106 Chapter 6 
Hazard models on 1405V polymorphism 
CETP I405V polymorphism was also in Hardy-Weinberg equilibrium (P > 0.99). The 
405V allele frequency was 3 1.7 %. Unlike the TaqlB, the I405V polymorphism was 
relatively weakly linked with the -629C-A polymorphism (D' = 0.554, P < 0.001). 
HDL cholesterol levels in 405W homozygotes (1.39 ± 0.42 mmol/1) and in 405V 
allele carriers (1.34 ± 0.4 1  mmol/1) were higher than in 40511 homozygotes ( 1.30 ± 
0.39 mmol/1; P < 0.001 for both). The univariate hazard ratio of CETP 405V allele on 
incident coronary disease was 1.16 (95% CI, 0.91 - 1.47; P = 0.24), whereas the 
HDL-adjusted hazard ratio was 1.23 (95% CI, 0.97 - 1.57; P = 0.09). After additional 
adjustment for apo A-I and triglycerides and after subsequently adjusting for age, 
gender and CRP as well, the hazard ratio of the 405V allele was 1.24 (95% CI, 0.97 
1.60; P = 0.09). The procedure of enrichment of the population with 
microalbuminuria again did not alter the analyses. 
CETP mass and CET 
In 226 men, plasma CETP mass and CET was measured. As expected, CETP mass 
decreased over the -629CC (2.95 ± 0.95 mg/I), -CA (2.27 ± 0.67 mg/I) and -AA (2. 15 
± 0.71 mg/I), as well as over the TaqIB B I B I  (2.72 ± 0.98 mg/I), -BIB2 (2.28 ± 0.62 
mg/I) and -B282 (2.09 ± 0.74 mg/I) genotypes (P < 0.001 for both). In 1405V V allele 
carriers, CETP mass was modestly lower than in II homozygotes (2.52 ± 0.90 mg/I vs 
2.27 ± 0.73 mg/I, P = 0.02). In parallel, plasma CET was higher in -629CC 
homozygotes [12.00 (8.71 - 17.35) nmol/ml.h] than in -629AA homozygotes [9.07 
(6. 13-12.56) nmol/ml.h] with intermediate values in -629CA subjects [9.72 (6.58-
13.72) nmol/ml.h] P < 0.0l ). 
Discussion 
This prospective population-based study in 8141 mostly Caucasians demonstrates that 
the -629A as well as the TaqIB B2 and the I405V V alleles of the CETP gene is not 
associated with a decreased risk for coronary disease, despite the HDL cholesterol 
raising effect of these common CETP polymorphisms. On the contrary, the 
unadjusted hazard for coronary events tended to be higher in -629A carriers than in -
629CC homozygotes and was significantly higher in B2 carriers than in B l  Bl  
homozygotes. As  expected, 1;2 incident coronary disease was inversely related with 
baseline HDL cholesterol. Nevertheless, the association of the -629A allele with 
higher coronary risk became significant and the hazard associated with the B2 allele 
was greater after HDL cholesterol adjustment. Moreover, HDL-cholesterol-adjusted 
coronary hazards were also significantly higher in -629AA than in -629CC and in 
B282 than in B l  B I  homozygotes. We consider our findings robust, because this 
relation remained after further adjustment for apo A-I and triglycerides, as well as for 
age, gender, CRP, smoking, alcohol use, use of lipid lowering drugs, presence of 
diabetes mellitus, and history of myocardial infarction, and because comparable 
results were obtained with respect to the CETP I405V genotype, which is rather 
weakly linked with the promoter polymorphism. Thus, our study supports the notion 
that there are other mechanisms than an effect on the HDL cholesterol level through 
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which coronary risk is associated with these CETP polymorphisms in the general 
population. 
A paradoxically higher coronary risk associated with the -629A and the B2 
allele, which results in lower CETP concentration and higher HDL cholesterol 
(present study), 16- 1 8;20·21;30·31;33;34 is in agreement with subgroup analyses in 
hypertriglyceridaemic men of Japanese ancestry and in Danish women who did not 
receive hormonal replacement therapy.44;45 In these reports, the CETP I4O5V 
genotype leading to a higher HDL cholesterol was associated with an increased 
cardiovascular risk.44;45 In apparent contradiction with our study, a meta-analysis that 
included 3 case-control studies and 4 prospective reports has documented a lower 
cardiovascular risk in B2B2 compared to B 1B I homozygotes.29 The magnitude of the 
effects of the CETP gene variations on circulating CETP and on HDL cholesterol in 
the currently studied cohort42 is similar compared to that reported previously.16 This 
makes it unlikely that the discrepancy can be explained by differences in CETP gene 
effects on CETP and on HDL cholesterol across various populations. Furthermore, the 
-629A allele frequency was 48% in our study, being very similar to a frequency of 
49% in other European populations. 1 7;22;26;32 As opposed to other prospective 
studies,24-2s;3o;33;34 the present findings are based on a single cohort retrieved from the 
general population. Consequently, coronary risk was much lower than that of the 
studies included in the meta-analysis.29 Of note, high circulating CETP levels may 
increase cardiovascular risk in hypertriglyceridaemic subjects.46 In agreement, intima 
media thickness is positively correlated with the rate of plasma cholesteryl ester 
transfer, which is determined by both plasma triglycerides and CETP.47 The median 
triglyceride concentration was clearly lower in our cohort (1.16 mmol/1) compared to 
the previous survey (1.7 mmol/1)46 and to several other studies included in the meta­
analysis.29 These differences in triglyceride levels may contribute to the apparent 
discrepancy between effects of variation in the CETP gene and of the circulating 
CETP level per se on cardiovascular risk. Finally, of potential clinical relevance, 
amelioration of the lipid profile and cardiovascular risk by statin treatment may be 
diminished in TaqIB B2 and in -629A carriers. 1 8;30 In view of the present findings, a 
pharrnacogenomic approach with assessment of CETP gene variation could, therefore, 
be helpful to identify subjects requiring more stringent lipid lowering treatment. 
Because we performed a genetic association study, mechanisms responsible for 
the increased HDL cholesterol-adjusted incidence of coronary heart disease 
associated with CETP genotypes that result in lower CETP and higher HDL 
cholesterol remain putative. A decreased CETP could contribute to a diminished 
transfer of cholesteryl esters from HDL towards VLDL and LDL,3;7-9 which are 
subsequently metabolised by the liver. Hence, genetically determined lower CETP 
levels may impede reverse cholesterol transport.6;9;11 Indeed, our study demonstrates 
for the first time that plasma cholesteryl ester transfer from HDL towards apo B­
containing lipoproteins is lower, in parallel with lower CETP mass levels, in -629A 
allele and B2 allele carriers. Furthermore, it is tempting to hypothesise that CETP 
gene variability may also affect atherosclerosis development via other processes 
involved in reverse cholesterol transport. First, CETP contributes to the generation of 
small lipid-poor pre �-HDL particles48 which stimulate cellular cholesterol efflux via 
ATP-binding cassette transporter A-1 expressed on macrophages and fibroblasts.49 
Thus, lower circulating CETP levels may diminish the ability of plasma to promote 
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cellular cholesterol removal (our unpublished data). Second, it is likely that CETP 
affects cholesterol trafficking at the cellular level, thereby stimulating reverse 
cholesterol transport. Macrophages present in human atherosclerotic lesions produce 
CETP, where it is able to stimulate cellular cholesterol efflux.so Third, CETP 
expressed in hepatocytes may promote selective hepatic uptake of HDL-derived 
cholesteryl esters.s 1 Hence, it is possible that if cellular CETP production is subject to 
regulation by CETP gene variation, CETP polymorphisms that lower CETP may 
impede peripheral cell cholesterol efflux and/or hepatic cholesterol removal. 
A potential limitation of our study is that the participants were recruited from a 
restricted geographical area, i.e. the city of Groningen in the northern part of the 
Netherlands. Moreover, even though the study cohort was enriched with subjects with 
microalbuminuria, cardiovascular risk was relatively low. However, in our opinion 
the present findings can be extrapolated to the general population. First, statistic 
evaluation showed that the enrichment procedure had no effect on the models. 
Second, there was no association of CETP gene variations with the degree of urinary 
albumin excretion nor with the prevalence of micro-albuminuria. Third, the -629A 
allele frequency was similar compared to other European populations, making it very 
unlikely that microalbuminuria enrichment affected -629 CETP C-+A allele 
distribution. 
In conclusion, the CETP -629C-+A and the TaqIB genotypes, which beneficially 
contribute to higher HDL cholesterol levels, are paradoxically associated higher 
incidence of coronary disease in the general population when their effects on HDL 
cholesterol are taken into account. Thus, CETP gene variation may also affect 
coronary risk by other mechanisms than the HDL cholesterol level per se. 
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Introduction 
Since the effect of the CETP -629C>A promoter and the TaqIB polymorphisms on 
HDL cholesterol is modified by gender as well as by metabolic factors, 1•3 analysis of 




Stata SE 8, SPSS 1 2  and Excel were used for data analysis. Since previous studies 
have revealed that HDL cholesterol is lower in-629CC than in -629CA and -629AA 
subjects,3 the effect of carrying a -629A allele on event-free cardiac survival was 
investigated using the CETP -629CC homozygotes as reference group. Likewise, the 
effect of the TaqIB polymorphism on coronary risk was evaluated using the B I B  1 
homozygotes as reference group. The effects of the CETP -629C-+A promoter and 
CETP TaqIB polymorphism on coronary events were studied with Cox regression 
analysis and hazard models were fit to test differences in survival. Event-free survival 
data are plotted graphically. 
Table appendix 6.1. Hazard ratios of coronary disease in CETP -629A allele 
carriers versus -629CC subjects in various subgroups of study population. 
Unadjusted HDL cholesterol-adjusted 
HR 95% CI p HR 95% CI p 
Men (50.6%) 1 .28 0.92 - 1 .79 0. 1 5  1 .43 1 .02 - 2.08 0.04 Women (49.4%) 1 . 1 7  0.68 - 2.01 0.56 1 .38  0.80 - 2.38 0.25 
HDL cholesterol :5 1 .27 mmol/1 1 .63 1 . 1 6 - 2.29 <0.01 
HDL cholesterol > 1 .27 mmol/1 0.93 0.54 - 1 .6 1  0.80 
Serum triglycerides :5 1 . 1 6  mmol/1 0.98 0.59 - 1 .63 0.95 1 .06 0.64 - 1 .76 0.83 
Serum triglycerides > 1 . 1 6  mmol/1 1 .53 1 .08 - 2. 1 7 0.02 1 .67 1 . 1 8 - 2.38 <0.0 1 
Serum apo A-I > 1 .36 g/1 1 .56 1 .08 - 2.27 0.02 1 .73 1 . 1 9 - 2.52 <0.0 1 
Serum apo A-I > 1 .36 g/1 I . I I  0.67 - 1 .85 0.69 1 .27 0.75 - 2. 14  0.37 
HOMA;, :5 1 .68 mU.mmol / (12*22.5) 0.93 0.59 - 1 .47 0.75 1 .06 0.67 - 1 .68 0.8 1 
HOMA,. > 1 .68 mU.mmol I (12*22.5) 1 .58 1 .09 - 2.30 0.02 1 .72 1 . 1 9 - 2.50 <0.01 
Waist :5 88 cm 0.78 0.43 - 1 .45 0.45 0.92 0.50 - 1 .70 0.79 
Waist > 88 cm 1 .38 1 .00 - 1 .91  0.05 1 .52 1 . 1 0 - 2. 1 2  0.01 
UAE :5 9.37 µg/min 1 .00 0.61 - 1 .65 0.98 1 .23 0.74 - 2.05 0.43 
UAE > 9.37 f:!:l�min 1 .39 0.98 - 1 .97 0.06 1 .53 1 .07 - 2. 1 7  0.02 
Subgroups are defined according to the median value of each variable except for gender. Data are 
analyzed by univariate and HDL cholesterol adjusted Cox proportional hazards models. HR, hazard 
ratio; 95% CI, 95% confidence intervals; 95% CI, 95% confidence intervals; HDL, high density 
lipoprotein; apo, apolipoprotein; HOMA,., HOMA index for insulin resistance; UAE, urinary albumin excretion. 
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Results 
Hazard ratios in various subgroups 
Subgroup analyses were performed in men and in women separately, as well as 
according to the median values for HDL cholesterol, triglycerides, apo A-I, HOMAi" 
waist and UAE. As shown in table appendix 6.1 and in figure appendix 6. 1 the 
increased coronary hazard related to the A-allele appeared to be confined to 
subgroups with lower HDL cholesterol, lower apo A-I and higher triglyceride levels, 
higher HOMAi,, higher waist circumference and higher UAE, but was unaffected by 
gender (table appendix 6.1 ). After adjustment for HDL cholesterol the CETP 
promoter-associated increased cardiac hazard remained as least as strong in these 
subgroups (table appendix 6.1 ). 
Discussion 
The effect of CETP gene variation on coronary risk was particularly present in 
subjects with relatively low HDL cholesterol, high triglycerides, a large waist, and 
more profound insulin resistance, all features of the metabolic syndrome. Thus, 
documentation of CETP polymorphisms may be helpful to improve cardiovascular 
risk stratification in subjects with metabolic features associated with higher 
cardiovascular risk. Furthermore, improvement of the lipid profile and cardiovascular 
risk by statin treatment may be diminished in -629A carriers.4;5 A pharmacogenomic 
approach with careful assessment of CETP gene variation could, therefore, be helpful 
to identify subjects requiring more stringent lipid lowering treatment. 
In conclusion, the CETP -629A-C and the TaqIB genotypes which contribute 
to higher HDL cholesterol levels are paradoxically associated with increased risk for 
coronary disease in the general population. The increased coronary risk of these 
common polymorphisms (CETP -629A-C and the TaqIB genotypes) appears to be 
present particularly in subjects with low HDL cholesterol, high triglycerides, central 
obesity and insulin resistance, components of the metabolic syndrome. 
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Figure appendix 6.1. The relationship of CETP -629C-+A promoter 
polymorphism with coronary disease in Cox proportional hazards regression 
analyses according to HDL cholesterol (a.), triglycerides (b.), HOMA;, (c.) and 
waist circumference (d.) 
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Statistics of the relationships are described in table appendix 6. 1  
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Abstract 
Background: A recent population-based study showed that cholesteryl ester transfer 
protein (CETP) gene variations, which relate to lower plasma CETP, may predict 
increased cardiovascular risk, in spite of higher HDL cholesterol. Among other 
functions, CETP activity contributes to cellular cholesterol efflux, an early step in the 
anti-atherogenic reverse cholesterol transport (RCT) process. We hypothesised that 
cellular cholesterol efflux stimulating capacity of plasma could be associated with 
CETP gene variation. 
Methods: In this study, we tested the extent to which the ability of plasma to promote 
cholesterol efflux from cultured human fibroblasts is associated with CETP gene 
variation. In 223 men, the -629C�A CETP promoter polymorphism, plasma lipids, 
CETP mass, cholesteryl ester transfer (CET), lecithin:cholesterol acyltransferase 
(LCA T) activity and the ability of plasma to promote cholesterol efflux from human 
skin fibroblasts, obtained from a single normolipidaemic donor, were determined. 
Results: In -629CC homozygotes (n = 52), cholesterol efflux, plasma CETP mass, 
CET and LCAT activity were higher, whereas HDL cholesterol was lower compared 
to -629AA homozygotes (n = 62) and -629CA+AA carriers (n = 171) (P <0.05 to P 
<0.001). Univariate correlation analysis showed that cellular cholesterol efflux was 
related to CETP genotype (P = 0.04), plasma CET (P <0.05), LCAT activity (P 
<0.001) and apo A-I (P <0.05). Multiple linear regression analysis confirmed the 
independent association of cellular cholesterol efflux to plasma with CETP genotype. 
Conclusion: In conclusion, an association of cellular cholesterol efflux with the -
629C�A CETP polymorphism, possibly also involving LCAT activity, could provide 
a mechanism explaining why CETP gene variation, which relates to lower plasma 
CETP, does not confer diminished cardiovascular risk. 
Keywords: Cellular cholesterol efflux, cholesteryl ester transfer protein, cholesteryl 
ester transfer, cholestery/ ester transfer protein promoter polymorphism, 
lecithin:cholesterol acyltransferase, HDL cholesterol, reverse cholesterol transport, 
triglycerides 
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Introduction 
Human plasma contains cholesteryl ester transfer protein (CETP), which plays a 
pivotal role in several steps in the anti-atherogenic reverse cholesterol transport 
(RCT) pathway, whereby cholesterol is transported from peripheral cells back to the 
liver for metabolism and excretion in the bile.1-3 Despite intensive study, the 
potentially pro-atherogenic and anti-atherogenic consequences of CETP action are 
still poorly understood.3-5 Recent clinical trials with the CETP inhibitor, torcetrapib, 
in subjects with high cardiovascular risk have shown that this treatment in 
combination with statin administration does not necessarily improve cardiovascular 
outcome compared to statin therapy alone, despite a pronounced increase in HDL 
cholesterol. 6 The most widely recognised function of CETP is its ability to transfer 
cholesteryl esters from HDL to apolipoprotein (apo) B-containing lipoproteins, 
thereby contributing to an atherogenic lipoprotein profile. 1 ;7;8 This cholesteryl ester 
transfer process may, however, beneficially stimulate the reverse cholesterol transport 
pathway, since it results in a quantitatively important extra route for delivery of high 
density lipoprotein (HDL)-derived cholesteryl esters to the liver via apo B-containing 
lipoproteins. 1 ;7;9; io Importantly, CETP may also be involved in the transport of free 
cholesterol from peripheral cells to extracellular acceptors, representing an early step 
in the reverse cholesterol transport process.5 CETP has a positive effect on the 
generation of lipid-poor pre-� HDL particles. 1 1 ; 12  These particles are initial acceptors 
of cell-derived free cholesterol via the ATP-binding cassette transporter A I (ABCA I )  
pathway, 13- 15  which is subsequently esterified by lecithin:cholesterol acyltransferase 
(LCAT ). 1 ;2;9; l l ; l2 In keeping with a putative stimulating effect of CETP on cellular 
cholesterol efflux, it has been demonstrated that cholesterol transport out of cultured 
human skin fibroblasts to plasma from mice expressing both human CETP and apo A­
I is increased, consequent to high pre-� HDL levels and LCAT activity. 1 6  
Variations in the CETP gene, such as the -629C�A promoter polymorphism, are 
common in humans. 1 1-20 It has been consistently shown that the -629C�A promoter 
variant, as well as the TaqIB polymorphism, which is in strong linkage disequilibrium 
with this promoter polymorphism, affect HDL cholesterol and plasma CETP mass 
levels in an opposite manner. 1 1- 19;2 1  It is likely that the -629C�A CETP gene variant 
directly affects regulation of plasma CETP mass levels. 22;23 Remarkably, CETP gene 
variations that result in a higher HDL cholesterol may not result in cardiovascular 
protection.24;25 In fact in the largest prospective population-based study to date, we 
recently documented that the -629A allele as well as the TaqIB B2 allele, which 
determine a lower plasma CETP mass and a higher HDL cholesterol, are associated 
with increased cardiovascular risk, particularly when the effect of these CETP gene 
variants on HDL cholesterol is taken into account.26 It is, therefore, of relevance to 
explore potential mechanisms responsible for this paradoxical relationship. Among 
other possibilities, an influence on CETP-mediated processes affecting the ability of 
plasma to stimulate cellular cholesterol removal could be involved in the apparent 
cardioprotective role of CETP gene variation that relates to higher expression of this 
lipid transfer protein. 
In the present study, we tested the extent to which the ability of plasma to 
promote cholesterol efflux out of cultured human skin fibroblasts is related to the -
629C�A CETP promoter polymorphism. 
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Methods 
Subjects and definitions 
The protocol was approved by the medical ethics committee of the University 
Medical Center Groningen, University of Groningen, and the subjects who were 
recruited from the PREVEND study, that is carried out in the city of Groningen, 
provided informed consent. It has been demonstrated that both HDL cholesterol and 
the plasma CETP concentration are higher in women than in men,27 indicating that the 
relationship between HDL cholesterol and CETP varies between genders. In the 
present study, we included men only in order to avoid bias due to gender effects on 
HDL metabolism. Subjects with diabetes mellitus, diagnosed by fasting plasma 
glucose :2: 7.0 mmol/1 and/or use of oral blood lowering drugs or insulin were 
excluded. Because of the CETP lowering effect of statins,9;21 men using lipid 
lowering drugs were not allowed to participate. Subjects with clinically manifest 
cardiac disease (history of myocardial infarction, coronary intervention or major 
ischaemia on an electrocardiogram) were also excluded. Body mass index (BMI) was 
calculated as the ratio between weight and height squared (kg/m2) and waist 
circumference was measured as the largest circumference between the rib cage and 
iliac crest. Hypertension was defined as systolic blood pressure :2: 1 40 mmHg and/or 
diastolic blood pressure :2: 90 mmHg, measured by Dinamap or the use of 
antihypertensive medication. Alcohol consumption was categorised in < 1 and :2: 1 
consumption per day. Venous blood was obtained between 8 and 10 a.m. after at least 
8 h fast. 
Laboratory methods 
Plasma glucose was measured shortly after blood sampling. Plasma for the other 
laboratory analysis was obtained by centrifugation at 4 °c, and the samples were 
stored at - 80 °c until analysis. Total cholesterol was assessed using Kodak Ektachem 
dry chemistry (Eastman Kodak, Rochester, New York, U.S.A.). Triglycerides were 
measured enzymatically. HDL cholesterol was measured with a homogeneous method 
(direct HDL, no. 7D67, AEROSET™ System, Abbott Laboratories, Abbott Park, IL 
60064, USA). Non-HDL cholesterol was calculated as the difference between total 
and HDL cholesterol. Apo A-I and apo B were determined by nephelometry applying 
commercially available reagents for Dade Behring nephelometer systems (BN II, 
Dade Behring Marburg, Germany; apo A-I test kit, code no. OUED; apo B test kit, 
code no. OSAN). 
Plasma CETP concentration was analysed using a double-antibody sandwich 
ELISA. 28 A combination of monoclonal antibodies TP 1 and TP2 was employed as 
coating antibodies and monoclonal antibody TP20, labeled with digoxigenine, as the 
secondary antibody. The CETP control samples were validated using a 
radioimmunoassay (carried out by Dr. R.M. McPherson, Montreal Canada). Plasma 
cholesteryl ester transfer (CET) was measured using endogenous substrates.29 LCAT 
activity was determined using excess exogenous substrate containing [JH]-cholesterol 
as described.Jo Plasma LCAT activity varies linearly with the amount of plasma used 
in the incubations, and is strongly correlated with its plasma mass concentration.J I 
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The -629C�A CETP promoter single nucleotide polymorphism was genotyped using 
two separate allele-specific primers, following a previously described procedure.20 
Cholesterol efflux to plasma was determined using human fibroblasts as 
cholesterol donor.32;33 Fibroblasts were obtained from a normolipidaemic control and 
were cultured (until passage 5-15) in 24 wells culture plates to full confluency. The 
cells were cultured in DMEM supplemented with I 0% vol/vol FCS. After washing 
them with DMEM, they were loaded with [3H]-cholesterol ((0.5 µCi/ml) during 24 h 
in the presence of added unlabelled cholesterol (30 µg/ml) in order to induce ABCA I 
in the fibroblasts. 32 [3H]-cholesterol and unlabelled cholesterol was solubilised in 
ethanol and diluted into DMEM/0.2% fatty acid free BSA. Subsequently, the cells 
were washed 3 times with PBS/BSA 0.2% (weight/volume). The efflux assay was 
started by adding plasma diluted in DMEM ( I% vol/vol) to the cells. 1.25 U/ml 
heparin was added to the efflux medium to prevent clotting. After 4 h incubation at 
37°C the medium was collected and centrifuged. Subsequently, [3H]-cholesterol was 
quantified by liquid scintillation counting. Total cellular [3H]-cholesterol was 
determined after extraction of the cells with 2-propanol. The percentage efflux was 
calculated by dividing the radioactive counts in the efflux medium by the sum of the 
counts in the medium and the cell extract. All values were corrected for radioactivity 
appearing in the culture medium in the absence of plasma. Additional control 
experiments showed that heparin addition to plasma did not influence cholesterol 
efflux rate (data not shown). To be able to normalise results between series of 
experiments and to correct for day-to-day variation, efflux to a human reference 
plasma pool was determined in quadruplicate. Since this assay system estimates 
outward cholesterol efflux from the fibroblasts but no net mass transfer, the influence 
of back flux of cholesterol from serum into the cells was evaluated using double 
isotope labelling experiments. To this end cholesterol loaded cells was also incubated 
with [ 14C]-cholesterol (0.2 µCi/ml) enriched I% vol/vol diluted plasma in a procedure 
that was otherwise similar to that described above. The percentage back flux was 
calculated by dividing the [ 14C]-cholesterol radioactive counts in the cells after 
incubation by the counts in the medium before incubation. The percentage of back 
flux of [ 14C]-cholesterol from plasma to cells was only 5.2 ± 1.0% (triplicate 
experiments in 3 different plasma samples). Thus, under the assay conditions 
employed transport of cholesterol is almost exclusively from cells to the medium. 
Statistical analysis 
SPSS 12 was used for data analysis. Data are expressed as mean ± SD, mean (95% 
confidence intervals) or in median (interquartile range). -629CC homozygotes were 
compared with -629AA homozygotes as well as with -629A allele carriers by 
Student's t-tests, Mann-Whitney tests and by x2 analyses where appropriate . Hardy­
Weinberg equilibrium was also calculated. Univariate correlations were calculated 
using linear regression analysis. Multiple linear regression analysis with a subsequent 
backward procedure was performed to determine the independent relationship 
between variables. Because of skewed distribution, logarithmically transformed 
triglyceride values were used in this analysis.A two-sided P-value .5 0.05 was 
considered to be significant. 
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Table 7.1. Clinical characteristics, plasma lipids and apolipoproteins 
(apos), cholesteryl ester transfer protein (CETP) mass and cellular 
cholesterol efjlux to plasma according to -629C->A CETP promoter 
polymorphism in 223 men 
cc CA AA CA + AA 
n = 52 n - 1 09 n - 62 n �  1 7 1  
{23.3 %) {48.9 %} {27.8 %} {76.7 %} 
Age (years) 5 1  ± 1 1  53 ± 1 3  5 3  ± 1 2  5 3  ± 1 3  
BM! (kg/m2) 26.7 ± 4.0 26.9 ± 3.6 26.0 ± 3.4 26.5 ± 3.5 
Waist {cm} 94. 1 ± 10.5 95.3 ± 10.9 94.2 ± 9.7 94.9 ± 10.4 
Total cholesterol 6.00 ± 1 .00 5.90 ± 1 . 1 6  5.86 ± 1 . 19  5.89 ± 1 . 1 7  
(mmol/1) 
Non-HDL cholesterol 4.97 ± 1 .09 4.78 ± 1 .23 4.64 ± 1 .26 4.73 ± 1 .24 
(mmol/1) 
1 .04 ± 0.301-1 HDL cholesterol 1 . 1 3 ± 0.36 1 .2 1  ± 0.36 1 . 1 6  ± 0.36 
(mmol/1) 
1 .841 Triglycerides (mmol/1) 1 .28 1 .4 1  1 .3 1  
( 1 .06 - 2.49) (0.94 - 1 .66) (0.88 - 2.24) (0.93 - 1 .78) 
Apo A-1 (g/1) 1 .26 ± 0.251 1 .26 ± 0.26 1 .36 ± 0.23 1 .30 ± 0.25 
A� B {&'.Q 1 . 19  ± 0.39 1 . 1 3 ± 0.3 1 1 . 14  ± 0.33 1 . 1 3  ± 0.32 
CETP mass (mg/I) 2.95 ± 0.951 I 2.27 ± 0.67 2 . 1 5  ± 0.71 2.22 ± 0.68 
CET (nmol/ml/h) 1 3.9 ± 8.01J 10.6 ± 5.3 1 0.5 ± 6.6 l0.5 ±5.7 
LCA T activity (AU) 1 1 9.6 ± J5 ,4tJ 1 1 0.4 ± 1 5 . 1  1 1 2.6 ± 16.4 1 12.2 ± 1 5.6 
Cellular cholesterol 8.50 ± 0.921·1 8.30 ± 0.91 8 . 16  ± 0.85 8.25 ± 0.89 
effiux {%/4h) 
Data in mean ± SD or in median (interquartile range). t.U P < 0.05, < 0.0 1 ,  < 0.001 for 
difference between CC and AA homozygotes; IJ P < 0.05, < 0.0 I for difference between CC 
homozygotes and CA + AA genotypes. 
Results 
The CETP promoter genotype distribution was in Hardy-Weinberg equilibrium (P > 
0.90). As shown in table 7. 1 ,  there were no differences in age, BMI and waist 
circumference between the 3 genotype groups and between -629CC homozygotes and 
-629A allele carriers. In the whole group (n = 223), 54% smoked, 77 %used � I 
alcohol containing drink per day and 44% had hypertension, but there were no 
differences in percentages of smokers, alcohol consumers and subjects with 
hypertension between the genotype groups (data not shown). HDL cholesterol and 
apo A-I levels were lowest in -629CC homozygotes. No differences in total 
cholesterol, non-HDL cholesterol and apo B were present among the genotype 
groups, but triglycerides were higher in -629CC homozygotes compared to -629A 
allele carriers. Plasma CETP mass, CET and also LCA T activity were highest in -
629CC homozygotes. Of note, cellular cholesterol efflux to plasma was higher in -
629CC homozygotes compared to -629AA homozygotes as well as to -629A allele 
carriers. Figure 7. 1 shows fibroblast efflux to plasma according to the CETP promoter 
genotype. 
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As shown in table 7.2, 
HDL cholesterol, plasma apo A­
I, CETP mass, CET and LCA T 
activity were significantly related 
to the -629C�A CETP promoter 
polymorphism (-629CC, CA and 
AA genotypes). Multiple linear 
regression analysis confirmed 
that, after adjustment for age, 
plasma CETP mass was 
associated with the promoter 
polymorphism (P < 0.001 ), 
independently of apo A-I and 
triglycerides (all P > 0.05). 
Plasma CET was also 
independently associated with 
the promoter polymorphism (P < 
0.02), as well as with plasma 
triglycerides (P < 0.001 ). In an 
Table 7.2. Univariate relationships of HDL­
related variables, cholesteryl ester transfer 
protein (CETP) mass, cholesteryl ester 
transfer (CET), lecithin:cholesterol 
acyltransferase (LCAT) activity and 
triglycerides with the -629C�A CETP 
promoter polymorphism (-629CC, CA and AA 
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alternative model, which included both the promoter polymorphism and plasma CETP 
mass, CET was related to CETP mass (P = 0.01 )  rather than to the CETP genotype (P 
= 0. 14). Furthermore, there was an association of plasma LCAT activity with the 
promoter polymorphism (P < 0.05) after adjustment for triglycerides (P < 0.001 ), 
HDL cholesterol (P < 0.0 1 )  and apo A-I (P = 0.07). 
As shown in table 7.3, cellular cholesterol efflux to plasma was significantly 
correlated with the CETP promoter polymorphism as well as with plasma apo A-I, 
CET and LCAT activity, but not with CETP mass and with HDL cholesterol. In a 
Table 7.3. Univariate relationships of 
cellular cholesterol ejjlux to plasma with 
HDL-related variables, cholesteryl ester 
transfer protein (CETP) mass, cholesteryl 
ester transfer (CET), lecithin:cholesterol 
acyltransferase (LCAT) activity and the -
629C �A CETP promoter polymorphism (-
629CC, CA and AA genotypes) in 223 men 










-0. 14  0.04 
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0. 14 <0.05 
0.02 0.78 
0. 14  < 0.05 
0.34 <0.00 1 
multiple linear regression model, 
which included the promoter 
polymorphism, plasma apo A-I and 
LCA T activity, it was found that, 
after adjusting for age, cellular 
cholesterol efflux to plasma was 
independently related to the CETP 
genotype (P < 0.05), plasma apo A­
l (P < 0.05) and LCAT activity (P = 
0.001).  In a model with plasma apo 
A-I and CET as potentially 
explaining variables, cellular 
cholesterol efflux was independently 
related to plasma apo A-I (P = 0.01 )  
and CET (P < 0.05). When the 
promoter polymorphism and plasma 
LCAT activity were additionally 
included in the analysis, cellular 
cholesterol efflux to plasma 
remained associated with the CETP 
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genotype (P < 0.05), but not with plasma CET (P > 0.20). 
Discussion 
The present study demonstrates for the first time that the ability of human plasma to 
promote cellular cholesterol efflux, representing an early step in the reverse 
cholesterol transport process, is associated with the -629C�A polymorphism of the 
CETP gene. Cholesterol efflux out of human fibroblasts to plasma from -629CC 
homozygotes, i.e. the genotype that relates to the highest plasma CETP concentration 
and the lowest HDL cholesterol, was found to be increased compared to efflux to 
plasma from subjects who carried at least one -629A allele. There was also a 
significant univariate correlation of cellular cholesterol efflux to plasma with this 
CETP gene variation, which was confirmed in multiple linear regression analysis. The 
generally held contention is that the cellular cholesterol efflux promoting potential of 
plasma reflects an anti-atherogenic process.2; 14 It is, therefore, plausible to propose 
that the presently observed association of cellular cholesterol efflux with this CETP 
gene variation may provide a clue to explain why a CETP gene variant, which 
associates with lower plasma CETP and higher HDL cholesterol levels does not 
necessarily confer a diminished cardiovascular risk.24-26 
Our study confirms the expected effect of the -629C�A CETP promoter 
polymorphism on plasma CETP mass/ 8; 19;22 and demonstrates that this relationship is 
independent of HDL cholesterol, triglycerides and plasma apo A-1. Moreover, we 
suggest that the cholesteryl ester transfer from HDL to apo B-containing lipoproteins 
(CET), i.e. plasma CETP activity measured in the presence of endogenous lipoprotein 
substrates, is indirectly related to the CETP promoter polymorphism via an effect on 
the circulating CETP level. This result is in keeping with previous data showing that 
plasma CET is not only determined by the concentration of apo B-containing 
lipoproteins that accept cholesteryl esters from HDL34 but also by the amount of 
CETP.35;36 Remarkably, we also found that plasma LCAT activity was associated with 
the -629C�A CETP promoter polymorphism, even after adjustment for plasma apo 
A-1, HDL cholesterol and triglycerides. To our knowledge, such an association has 
not been reported earlier. Indirect evidence in favour of a link between LCA T and 
CETP regulation is derived from data in transgenic mice showing that both plasma 
LCAT activity and hepatic LCAT mRNA expression are increased in human apo A-
1/CETP transgenic mice. 1 6  
Efflux of cell-derived cholesterol to extracellular acceptors is  determined by 
several yet incompletely known pathways, including aqueous diffusion, transport via 
ABCA I and the recently discovered ABCG I ,  as well as via the scavenger receptor 
class B type I (SR-B1). 1 5;37;38 In the current report, the ability of plasma to promote 
cholesterol efflux was determined using cultured human skin fibroblasts, a cell system 
which abundantly expresses ABCAI after cholesterol preloading32;39 and possibly 
also ABCGI,40 but essentially no SR-81. 1 5;4 1  The presently documented association of 
cellular cholesterol efflux to plasma with the -629C�A CETP promoter 
polymorphism suggests that the ability of plasma to accept cell-derived cholesterol is 
genetically modified via an effect on CETP affected pathways taking place in the 
extracellular compartment. In agreement, we observed a significant relationship of 
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cellular cholesterol efflux with plasma CET in univariate correlation analysis. More 
specifically, in vitro experiments have demonstrated that besides phospholipid 
transfer protein and hepatic lipase,42;43 CETP is involved in the generation of pre-P 
HDL particles, 11;12 that act as initial acceptors of cell-derived cholesterol via 
ABCAI ,2• 1 3 ;15 which provides an important pathway for cholesterol efflux out of 
fibroblasts.33;44 In keeping with such an effect of CETP on pre-P HDL and cellular 
cholesterol efflux, we have documented relationships of plasma CET with pre-P HDL 
formation and fibroblast cholesterol efflux to plasma in another study comprising 
healthy individuals and subjects with type 2 diabetes mellitus.45 Importantly, ABCAl 
and ABCG 1 may co-ordinately promote cellular cholesterol efflux by first facilitating 
efflux to pre-P HDL, and, thereafter, to a-HDL.38 Accordingly, using ABCAl­
upregulated 1774 macrophages, cholesterol efflux to apo B-depleted serum i s  to  some 
extent related to mature a-HDL besides effects of pre-P HDL.46 Furthermore, LCAT 
may induce net cholesterol efflux out of cellular membranes by a non-specific 
exchange mechanism,47 as well as via its the presence on a-HDL particles.48 Apart 
from CETP gene variation, cholesterol efflux from fibroblasts was independently and 
positively associated with plasma LCAT activity, as well as to plasma apoA-1, in our 
present study. These results would suggest that under the currently employed assay 
conditions, mature a HDL as well as the activity of LCAT may be involved in the 
cholesterol efflux process from human skin fibroblasts to plasma. It should, however, 
be realised that with fibroblasts as cell system the quantitative contribution of the 
various pathways, other than ABCA 1 ,  involved in the cholesterol efflux process is 
still poorly understood. 
Our study was carried out in men, who were on average moderately 
hypercholesterolaemic. Therefore, we cannot extrapolate the present results to women 
and to strictly normocholesterolaemic individuals. Moreover, it is obvious that our 
study does not allow a conclusion about the potential influence of CETP gene 
variations on the actual in situ capacity of peripheral cells to release excess 
cholesterol, an effect that may be relevant because CETP is expressed in human 
atherosclerotic lesions. 49 
In conclusion, our study suggests that a common CETP gene variation that 
relates to higher plasma CETP concentration is associated with a greater ability of 
plasma to stimulate cholesterol efflux from fibroblasts, despite lower HDL 
cholesterol. It is tempting to speculate that such a CETP gene variation-associated 
effect on an early step in the reverse cholesterol transport pathway, possibly also 
involving LCAT activity, could influence the development of cardiovascular disease. 
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Abstract 
Objective: HDL cholesterol is associated with the -629C-+A cholestery/ ester 
transfer protein (CETP) promoter polymorphism. This relationship may in part be 
explained via effects on plasma cholesteryl ester transfer (CET), which reflects the 
activity of CETP in the context of endogenous lipoproteins, but also via CET 
independent pathways involved in HDL metabolism. In this study, we determined the 
contributions of the CETP -629C-+A genotype, plasma CETP mass and cholesteryl 
ester transfer to HDL cholesterol. 
Materials and methods: The -629C-+A CETP gene promoter polymorphism, 
plasma CETP mass, CET, HDL cholesterol, lipids and apolipoprotein (apo) A-I were 
measured in 220 non-diabetic men without cardiovascular disease. 
Results: Plasma CETP mass (P < 0.001 )  and CET (P < 0.001 )  were higher, whereas 
HDL cholesterol (P < 0.05) and plasma apo A-I levels (P < 0.05) were lower in CC 
compared to AA carriers. Univariate regression analysis showed that plasma CET was 
related to the CETP genotype (P = 0.004), plasma CETP mass (P < 0.001)  and 
triglycerides (P < 0.001). In a multiple linear regression model, HDL cholesterol was 
related to CETP genotype (P = 0.04) and plasma triglycerides (p < 0.001 )  without 
independent contributions of plasma CETP mass and CET (p > 0.20 for both). 
Conclusions: This study suggests that, despite a relationship between a common 
CETP gene variation and plasma cholesteryl ester transfer, the association between 
CETP gene and HDL cholesterol appears to be at least in part unexplained by the 
plasma cholesteryl ester transfer process. 
Key words: cholesteryl ester transfer protein polymorphism, cholesteryl ester 
transfer, cholesteryl ester transfer protein, HDL cholesterol, triglycerides 
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Introduction 
The cardioprotective effect of high density lipoproteins (HDL) is generally attributed 
to its function in the anti-atherogenic reverse cholesterol transport pathway, whereby 
excess cholesterol is removed from the blood vessel wall to the liver for metabolism 
and subsequent biliary excretion. 1-3 Human plasma contains cholesteryl ester transfer 
protein (CETP), which has the ability to transfer cholesteryl esters from HDL towards 
apolipoprotein (apo) B- containing lipoproteins.4;5 In concert with other proteins such 
as lecithin:cholesterol acyltransferase, phospholipid transfer protein (PLTP) and 
lipases, CETP is crucially involved in the metabolism of HDL particles,3;4 as 
evidenced by very high levels of HDL cholesterol in human genetic CETP 
deficiency,5 and its pronounced rise following pharmacological CETP inhibition.6 Of 
relevance, the process of plasma cholesteryl ester transfer is not only governed by the 
plasma CETP level, but also to a considerable extent by the concentration and 
composition of triglyceride-rich lipoproteins that accept cholesteryl esters from HDL 
particles in exchange for triglycerides. 7;s 
An increasing body of evidence supports the notion that common variations in 
the CETP gene are associated with HDL cholesterol levels in such a way that 
polymorphisms which are associated with a lower plasma CETP level give rise to 
higher HDL cholesterol.9;10 The Taq I B polymorphism in intron I of the CETP gene 
has received most attention,9;11 but this variant most likely does not represent a 
functional mutation. Indeed, the Taq 1 B variant may be associated with plasma CETP 
levels and HDL cholesterol in an independent manner.12 This Taq 1 B  polymorphism is 
in strong linkage disequilibrium with the -629C-+A promoter variant which affects 
CETP gene transcriptional activity in vitro. 13; 14 It has been suggested that the -
629C-+A variant as well as other variations in the CETP gene promoter, rather than 
the intronic Taq 1 B variant, directly contribute to regulation of plasma CETP mass 
levels.15;16 The rate of plasma cholesteryl ester mass transfer between HDL and apo 
B-containing lipoproteins reflects the action of CETP on HDL in the context of the 
constellation and composition of endogenous cholesteryl ester acceptor lipoproteins.7 
The effect of CETP gene variation on plasma cholesteryl ester transfer has been 
evaluated in only one report comprising type 2 diabetic patients. 17 In that study, 
plasma cholesteryl ester mass transfer did not vary according to the Taq 1 B genotype, 
despite the expected effect of this CETP gene variation on HDL cholesterol. 17 
Additional studies are, therefore, required to further investigate and explain the 
relationship between genotype variations in the CETP gene and HDL cholesterol. 
We questioned whether plasma cholesteryl ester transfer is associated with the 
CETP -629C-+A promoter polymorphism in men without diabetes mellitus, and 
determined the contributions of the CETP -629C-+A genotype, plasma CETP mass 
and cholesteryl ester transfer to HDL cholesterol. 
Methods 
Subjects and definitions 
The study was approved by the medical ethics committee of the University Medical 
Centre Groningen, University of Groningen, and was part of a project which aimed to 
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determine the role of variation in the CETP gene on HDL metabolism and reverse 
cholesterol transport. Since plasma CETP mass may be higher in women despite 
higher HDL cholesterol, 18 it is likely that there are gender differences in the relation 
between plasma CETP concentration and HDL cholesterol. For this reason we 
decided to include only men in the present study. Subjects using lipid lowering drugs 
were not allowed to participate, because of the CETP lowering effect of statins.3; 1 4  
Subjects with diabetes mellitus, as determined by fasting plasma glucose � 7.0 mmoVI 
and/or use of oral blood lowering drugs or insulin, or with clinically manifest 
coronary heart disease (history of myocardial infarction, coronary intervention or 
major ischemia on an electrocardiogram) were also excluded. 
Body mass index (BMI) was calculated as weight divided by height squared. 
Hypertension was defined as systolic blood pressure � 140 mmHg and/or diastolic 
blood pressure � 90 mmHg, measured by Dinamap or the use of antihypertensive 
medication. Alcohol consumption was categorised in < 1 and � I consumption per 
day. Venous blood was obtained between 8 and 10  a.m. after 1 5  min rest, while the 
subjects were fasting for at least 8 h. 
Laboratory Methods 
Plasma was obtained by centrifugation at 4 °c and the samples were stored at - 80 °c 
until analysis. Total cholesterol was assessed using Kodak Ektachem dry chemistry 
(Eastman Kodak, Rochester, New York, U.S.A.). Triglycerides were measured 
enzymatically. HDL cholesterol was measured with a homogeneous method (direct 
HDL, no. 7D67, AEROSET™ System, Abbott Laboratories, Abbott Park, IL 60064, 
USA). In this assay system, HDL and apo 8-containing lipoproteins are complexed 
with one reagent, followed by solubilising HDL particles by another reagent. Non­
HDL cholesterol was calculated as the difference between serum total and HDL 
cholesterol. Apolipoprotein (apo) A-I was determined by nephelometry applying 
commercially available reagents for Dade Behring nephelometer systems (BN II, 
Dade Behring Marburg, Germany; apo A-I test kit, code no. OUED). 
Plasma CETP mass was analysed using a double-antibody sandwich ELISA.19 A 
combination of monoclonal antibodies TP I and TP2 was employed as coating 
antibodies and monoclonal antibody TP20, labeled with digoxigenine, as the 
secondary antibody. The CETP control samples were validated using a 
radioimmunoassay (carried out by Dr. R.M. McPherson, Montreal Canada). Plasma 
cholesteryl ester transfer (CET) was assayed as described previously.20;2 1  In brief, 
[3H] cholesterol was equilibrated for 24 h with plasma-free cholesterol at 4 °C 
followed by incubation of the sample at 37 °C for 3 h. Subsequently, VLDL+LDL 
were precipitated by addition of phosphotungstate/MgC'2. Lipids were extracted from 
the precipitate and the cholesteryl esters were isolated on silica columns and 
radioactivity was counted. The -629C-+A CETP promoter single nucleotide 
polymorphism was genotyped by two separate PCRs with allele-specific primers, 
exactly as described. 1 0  
Statistical analysis 
SPSS 12  used for data analysis. Data are expressed as mean ± SD or in median 
(interquartile range), where appropriate. Variables were compared by one-way 
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ANOVA or K.ruskal-Wallis tests. Unpaired t-tests or Mann-Whitney U tests were 
used to subsequently test differences between groups. X2 analysis was used to evaluate 
differences in proportions of variables between genotype groups. Univariate relations 
were evaluated with Spearman's rank correlation analysis. Multiple linear (stepwise) 
regression analysis was used to disclose the independent contributions of parameters. 
In this analysis log transformed plasma triglyceride and CET values were used in 
order to normalise for their skewed distributions. Furthermore, plasma CET and HDL 
cholesterol were compared according to the different -629C-+A CETP genotypes 
after controlling for plasma triglycerides. A two-sided P value :S 0.05 was considered 
to be significant. 
Table 8.1. Clinical characteristics, plasma cholesteryl ester transfer protein 
(CETP) concentration, cholesteryl ester transfer (CET), HDL cholesterol, lipids 
and apolipoprotein (apo) A-I according to the CETP -629C--+A promoter 
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(n = 220) 
52.5 ±12.3 
26.6 ± 3.6 
138 ± 20 
79 ± 10  
44.5 
69.4 
2.39 ± 0.81 
2.7 
( 1 .9-3.9) 
1 . 1 3  ± 0.35 
1 .29 ± 0.25 
5.92 ± 1 . 13  
AA 
(n = 60, 
27.3 %) 
52.7 ± 12.3 
26. 1 ± 3.4 
139 ± 19 
79 ± 9  
40.0 
67.8 
2 . 13 ± 0.66' 
2.6 
( 1 .7-3.5)' 
1 .2 1  ± 0.36" 
1 .36± 0.23' 
5.87 ± 1 .20 
CA 
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49.5 %) 
53.0 ± 1 2.8 
26.8 ± 3.5 
138 ± 20 
79 ± 10 
43. 1  
67.0 
2.26 ± 0.67' 
2.7 
( 1 .8-3.8)' 
1 . 13  ± 0.36 
1 .26 ± 0.26 
5.90 ± 1 . 1 6  
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(n = 5 1 ,  
23.2 %) 
5 1 .0 ±  I I . I  
26.8 ± 4.0 
139 ± 22 
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2.96 ± 0.96 
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(2.4-4.8) 
1 .04 ± 0.30 
1 .26 ± 0.26 
6.00 ± I .O J  















(mmol/L) (0.96-1 .96) (0.91-2.25) (0.92- 1 .67)8 (1.06-2.49) 
Data in mean ± SD or in median (interquartile range). •p < 0.05; 6P < 0.0 1 ;  'P < 0.001 from CC 
homozygotes. 
Results 
Two hundred twenty men participated in the study. Their clinical characteristics are 
shown in table 8. 1. No significant differences in age, BMI, blood pressure, prevalent 
smoking and alcohol consumption were observed between the -629C--+A CETP 
genotype groups. In the whole group, 23.3% used antihypertensive medication, but 
this did not vary among the genotype groups (P = 0.98, data not shown). 
The-629C-+A genotype distribution was in Hardy-Weinberg equilibrium (X2 df2 
= 0.012, P = 0.99). As shown in table 8. 1, plasma CETP concentration was 
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significantly higher in -629CC compared to -AA and -CA carriers, with the average 
difference between subjects with contrasting genotypes amounting to 39%. As shown 
in table 8 . 1  and in figure 8. 1 ,  plasma CET was also significantly higher in -629AA 
homozygotes than in -CC homozygotes and -CA heterozygotes with a difference in 
the median plasma CET level between -CC and -AA of 32%. Conversely, HDL 
cholesterol and plasma apo A-I levels were on average 14 % and 7% lower in -CC 
than in -AA carriers. Plasma total cholesterol was not different among the three 
genotype groups. Plasma triglycerides were lower in -CA than in -CC carriers, but did 
not differ between -CC and -AA carriers. 
Figure 8.1. Association of plasma cholesteryl ester transfer (CET) with 
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CETP -629C>A promoter polymorphism 
As shown in table 8 .2, plasma CET was positively related to the -629C allele, as 
well as to plasma triglycerides and to CETP mass in univariate regression analysis. 
Furthermore, plasma CET remained lower -AA homozygotes than in -CC 
homozygotes (P = 0.0 I )  after adjusting for triglycerides. 
Table 8.2. Univariate correlations of plasma cholesteryl ester transfer 
(CET) with cholesteryl ester transfer protein (CETP) genotype, plasma 
CETP mass and triglycerides, and of HDL cholesterol with CETP genotype, 
plasma CET, CETP mass and triglycerides 





Spearman's p P 




Spearman's p P 
-0. 1 9  0.005 
-0. 1 4  0.037 
-0.29 <0.001 
-0.57 <0.001 
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Univariate regression analysis showed that HDL cholesterol was negatively 
correlated with the -629C allele, and with plasma CETP mass, CET and triglycerides 
(table 8.2). In a multiple (stepwise)regression model which included CETP genotype, 
plasma CETP mass, CET and triglycerides, HDL cholesterol was inversely related to 
the -629C allele (P = 0.04) and to plasma triglycerides (P < 0.001). In this model, the 
relationships of HDL cholesterol with plasma CETP mass and CET were not 
significant (P > 0.20 for both). This association of HDL cholesterol with the CETP 
genotype, remained significant (P < 0.05) after adjustment for age (P = 0.27), 
smoking (P = 0.19), alcohol consumption (P = 0.006) and use of antihypertensive 
medication (P = 0.69). Figure 8.2 shows the relationship of HDL cholesterol with 
CETP gene variation controlled for plasma triglycerides. After triglyceride 
adjustment, HDL cholesterol was on average 10% lower in -CC than in -AA 
homozygotes. 
Figure 8.2. Association of HDL cholesterol with -629C--+A 
CETP gene polymorphism after controlling for plasma 
triglycerides. Bars indicate marginal mean values; error bars 
indicate 95 % corifidence intervals. 
1 .6 










AA AC cc 
CETP -629C>A promoter polymorphism 
Discussion 
This study shows that in non-diabetic men without clinically manifest cardiovascular 
disease the -629C--+A variation in the CETP gene promoter is not only associated 
with plasma CETP concentration, but also with CET, which is considered to provide a 
metabolic intermediate between plasma triglycerides and HDL cholesterol. Our study 
furthermore reveals that the relationship of the -629C--+A genotype with plasma CET 
is also present when taking the triglyceride level into account. Despite associations of 
this CETP gene variation with both plasma CETP mass and CET, multiple linear 
regression analysis showed that HDL cholesterol was independently related to the -
629C--+A polymorphism, even when taking plasma triglycerides, CETP and CET into 
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consideration. Therefore, the present data raise the possibility that the effect of this 
CETP gene variation on HDL cholesterol is in part attributable to mechanisms that are 
not explained by the CETP-mediated cholesteryl ester transfer process in plasma. 
Plasma CET, measured with the assay system which was used in the present 
study, is strongly correlated with net cholesteryl ester mass transfer from HDL to apo 
B-containing lipoproteins,22 and reflects the activity of CETP in the context of 
endogenous lipoproteins.20 Of relevance, this method should be discerned from 
plasma CETP activity as measured using an excess exogenous lipoprotein substrate 
assay.3 Using the latter type of assay, plasma CETP activity is strongly correlated 
with is concentration in plasma.23 In the current report, plasma CET was determined 
by both plasma triglycerides, reflecting the concentration of triglyceride-rich 
lipoproteins that accept cholesteryl esters from HDL, and by the plasma CETP 
concentration. Several previous studies have accordingly demonstrated that plasma 
CET can be governed the plasma CETP (activity) level per se. 7;8 Of relevance, -
629CC carriers had a higher plasma CET than -AA carriers, and this difference 
remained statistically significant after controlling for triglycerides. This observation 
seems to be at variance with a previous report showing that, in subjects with type 2 
diabetes mellitus, plasma net cholesteryl ester mass transfer does not differ 
significantly according to the TaqIB CETP gene variation. 1 7  Complex abnormalities 
in plasma CET have been noted in type 2 diabetes,3;23-25 which may explain the 
apparent discrepancy. Moreover, both men and women participated in the previous 
study, 1 7  which could obscure a relation between CETP gene variation and plasma 
cholesteryl ester transfer, in view of a gender difference in the relationship between 
plasma CETP levels and HDL cholesterol. 1 8  
An inverse correlation of HDL cholesterol with CET was observed in univariate 
analysis, but the inverse relationship of HDL cholesterol with plasma triglycerides 
was more prominent. Thus, apart from the cholesteryl ester transfer pathway other 
triglyceride-related processes are likely to affect HDL cholesterol. In a multiple linear 
regression model, HDL cholesterol was determined by the CETP promoter variant 
and by the plasma triglyceride level, but not independently by plasma CETP mass and 
CET. These findings, therefore, underscore the possibility that, apart from the plasma 
cholesteryl ester transfer process, other mechanisms could contribute to the 
association of -629C--+A CETP polymorphism with HDL cholesterol. It cannot be 
excluded, however, that this lack of effect of plasma CETP mass and CET on HDL 
cholesterol is in part related to insufficient statistical power. 
Besides affecting the distribution of cholesteryl esters between HDL and apo B­
containing lipoproteins, CETP may also be intracellularly functional. CETP is present 
in macrophages, and intracellular CETP may contribute to cellular cholesterol 
efflux. 26 If an increased intracellular CETP level, consequent to the -629C allele, 
results in an enhanced transport of cell-derived cholesterol to extracellular acceptors, 
then this would most likely contribute to an increase rather than to a decrease in 
cholesterol loading of HDL particles and, hence, would result in a higher HDL 
cholesterol in plasma. It seems, therefore, unlikely that an effect of CETP gene 
variation on CETP expression in peripheral cells provides a mechanism to explain the 
inverse relationship of HDL cholesterol with the -629C allele. In addition, the ability 
of plasma from -629CC homozygotes to remove cholesterol out of cultured skin 
fibroblasts, derived from one single donor, is increased rather than decreased 
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compared to that of plasma from -629AA carriers.27 Thus, it is also unlikely that the -
629C allele adversely affects the cellular cholesterol removal capacity of plasma. 
Importantly, a recent study has established that hepatocyte-associated CETP is able to 
stimulate uptake of HDL-derived cholesteryl esters by the liver in a manner that is 
unrelated to SR-BI, to other hepatic lipoprotein receptors and to circulating CETP.28 
Thus, if an increased CETP concentration in hepatocytes, consequent to the -629C 
allele, results in enhanced removal of HDL-derived cholesteryl esters by the liver, this 
would be expected to result in a lower HDL cholesterol, by a process which is not 
mediated by an effect on the cholesteryl ester transfer process in plasma. Our study 
provides a rationale to test this hypothesis, but it is obvious that other yet unknown 
factors could also be involved in a CETP gene effect on HDL cholesterol which is 
unexplained by the plasma cholesteryl ester transfer process. 
There is considerable controversy concerning the associations of CETP with 
cardiovascular disease. 1 1 ;29•3 1  In a prospective population-based cohort we have 
recently documented that the -629A allele and the TaqlB B2 allele, i.e. CETP 
genotypes which relate to a higher HDL cholesterol, are paradoxically associated with 
an increased cardiovascular risk, despite incident coronary disease being inversely 
related to HDL cholesterol.3 1  Of further clinical relevance, the several 
pharmacological CETP inhibitors have been developed, and their efficacy with 
respect to HDL cholesterol raising and cardiovascular disease is currently being tested 
in clinical trials. 32 Of note, the research development program of the CETP inhibitor, 
torcetrapib, has been recently terminated prematurely, since an excess mortality was 
observed in subjects receiving this drug in combination with a statin compared to 
statin administration alone.33 In view of the hypothesis that CETP polymorphisms 
may affect the HDL cholesterol concentration via a CETP-mediated effect on 
cholesteryl ester uptake by the liver, it is tempting to speculate that at least under 
some circumstances the reverse cholesterol transport pathway could be less effective 
in subjects carrying CETP gene variations that are associated with higher HDL 
cholesterol. Moreover, an effect of CETP gene variation on HDL cholesterol that is 
not attributable to the plasma cholesteryl ester transfer process, as suggested by the 
present data, is relevant, because it may provide a rationale for a pharmacogenomic 
approach to determine whether variations in the CETP gene affect the HDL 
cholesterol response to CETP inhibitor treatment. 
Several methodological aspects of our study need to be considered. Firstly, 
plasma total cholesterol, blood pressure and BMI were on average relatively high in 
our cohort, making it uncertain whether our findings also hold true for subjects with a 
more favourable cardiovascular risk profile. Secondly, the current results cannot be 
extrapolated to women. Thirdly, we did not document HDL subfraction composition 
and HDL particle size. Other studies have shown an effect of the Taql B  
polymorphism on HDL2 cholesterol,34 and of the 1405V CETP gene polymorphism on 
HDL particle size,35 in such a way that HDL2 cholesterol and HDL particle size are 
increased in carriers of CETP gene variations that relate to lower plasma CETP levels. 
In conclusion, this study suggests that, despite an observed relationship of 
plasma cholesteryl ester transfer with a common CETP gene variant, this could not 
fully explain its observed relationship with HDL cholesterol. The present data provide 
a rationale to test the effect of CETP gene variation on hepatic HDL cholesteryl ester 
removal, and the HDL cholesterol response to CETP inhibitor treatment. 
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Research questions of this thesis 
I. Circulating CETP, HDL and cardiac disease 
Our first aim was to assess how circulating CETP and HDL lipids and 
apo/ipoproteins relate to prevalent cardiac disease? In chapter 2 we reviewed the 
current knowledge of actions of CETP in HDL metabolism, and described to which 
extent these effects are modified by abnormal triglyceride metabolism, secondary to 
insulin resistance and type 2 diabetes mellitus. Reverse cholesterol transport is a 
process by which cholesterol is cleared from vessel walls by means of HDL for 
metabolism in the liver and subsequent removal out of the body. Hence, the HDL 
fraction, commonly measured as HDL cholesterol, reflects protection against 
atherosclerosis, as abundantly proven in epidemiological studies. 
CETP mass is associated with risk factors for cardiac disease, such as lower 
HDL cholesterol. 1 Therefore, the plasma CETP level has been frequently proposed to 
be positively associated with cardiovascular disease (figure 9. l .a.). Because low 
HDL cholesterol is considered to be a cardiovascular risk factor, CETP inhibitors are 
being developed, aimed to protect against atherosclerosis (figure 9. l .b.). However, 
when taking the effect of the CETP-mediated process of cholesteryl ester transfer into 
account, the opposite could also proposed: CETP plays important role in the 
beneficial reverse cholesterol transport pathway, which suggests an atheroprotective 
role. 
Fig11re 9.1. 'Classic ' proposal for the consequences of lowering CETP 





b. 'Classically' proposed effect on lowering CETP 
CETP ! HDL f---t Cardiovascular cholesterol j disease ! 
Literature provides evidence that healthy subjects and patients with abnormal 
triglyceride metabolism differ in reverse cholesterol transport, cholesteryl ester 
transport and CETP.2-5 This is also plausible from metabolic point of view, since the 
cholesteryl ester transfer is not only driven by CETP, but also by triglycerides, 
particularly those in triglyceride-rich lipoproteins (chapter 2). So, a high triglyceride 
level stimulates cholesteryl ester transfer out of HDL and may affect the action of 
CETP in the reverse cholesterol transport as well. Therefore we have specifically 
explored differences between subjects with higher and lower triglycerides and, if 
possible, (statistical) interactions in the reverse cholesterol transport with 
triglycerides. 
General discussion 143 
The inverse relation of HDL cholesterol, and to a lesser extent of apolipoprotein 
(apo) A-I, with cardiac disease is generally accepted, but the association with the 
closely related apolipoprotein A-II is less clear.6-9 As described in more detail in 
chapter 2, apo A-I and apo A-II are quantitatively the most important apolipoproteins 
associated with HDL cholesterol. Therefore, before the investigation described in 
chapter 3 it was not yet clear epidemiologically whether the cardioprotection by HDL 
is mostly explained by HDL cholesterol, apo A-I or possibly apo A-II, and whether 
this relationship may be different between men and women. In order to clarify this, 
the interdependent associations of HDL cholesterol, apo A-I and apo A-II in their 
effect to predict prevalent myocardial infarction was assessed. After adjustment for 
HDL-related factors and lipids, myocardial infarction was most closely associated 
with apo A-II in men and with HDL cholesterol in women. Moreover, associations of 
HDL cholesterol, apo A-I and apo A-II with each other differed between men and 
women. This may be due to specific gender-dependent effects on HDL composition. 
Our results raise the possibility that measurement of apo-AII may assist to better 
predict cardiovascular events in men. 
Although several papers have been published on the associations between CETP 
and existing cardiovascular disease, very little was known about the prospective role 
of CETP in the development of cardiovascular disease. In addition, the majority of the 
research towards the role of CETP in the process of atherosclerosis was performed in 
selected groups of patients with an increased cardiovascular risk, e.g. subjects with 
hypertriglyceridaemia, diabetes or a cardiovascular history. Therefore, our next aim 
was to assess the prognostic significance of plasma CETP levels for cardiac disease 
in the general population. In addition, we evaluated whether this prognostic 
significance was modified by the prevailing triglyceride levels. 
Earlier studies showed that CETP was associated with the development of new 
cardiac disease in subjects with high triglycerides. 1 However, the effect of CETP on 
prospective cardiac disease in persons without previous cardiovascular disease and 
with more moderate triglyceride levels was unknown. Chapter 4 focussed on this 
effect in men without previous cardiovascular disease who were selected from a 
general population. In this study, we included men only, because of gender 
differences in HDL cholesterol and plasma CETP mass. Also, we expected that in our 
population only a small number of women would develop cardiac events during 
follow-up. This investigation was the first to show that circulating CETP may also 
protect against cardiac disease. When plasma triglycerides were below the median, 
men with CETP levels above the median had an age-adjusted hazard ratio of 0. 46 
(95% CI 0.24 - 0.90, P = 0.03) for incident cardiac disease compared to men with 
lower CETP. So the "classic" hypothesis, as depicted in figure 9. l ,  is shown not to 
suffice under all circumstances, and the effects of CETP are more divers than can be 
explained by a simple cause-effect model. These new results also suggest that raising 
HDL cholesterol by artificially counteracting CETP levels may not necessarily 
provide an effective protection against cardiovascular disease. 
We next evaluated whether the effect of CETP on cardiac disease was influenced 
by different circulating triglyceride levels (chapter 4). Our study demonstrates that 
high plasma CETP is associated with low cardiac risk in men with the lowest 
triglycerides. On first glance, our results seem to contradict the results of other 
studies, such as the EPIC-Norfolk Study. 1 However, triglyceride levels reported in the 
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participants of this study were considerably higher compared to the levels of our study 
(median 1 .7 mmol/1 vs 1 .38 mmol/1). The EPIC-Norfolk Study showed that when 
triglyceride levels were higher than the median level of 1 .  7 mmol/1, CETP was 
associated with the development of more new cardiac disease, 1 but this pro­
atherogenic influence was not observed in subjects with triglycerides below 1 .  7 
mmol/1. 1 This may be in agreement of our finding that, in men with triglycerides 
higher than median of 1 ,3 8 mmol/1 of our group, no effect of CETP mass on cardiac 
hazard was observed (HR: 1 .00 (95 % CI 0.63- 1 .58, P = 0.98)). Therefore, the study 
we describe in chapter 4 is the first to show that CETP even may protect against the 
development of cardiac disease under some circumstances, i.e. low triglycerides 
levels. 
We conclude that high plasma CETP relates to low cardiovascular risk with the 
lowest triglycerides, no modification of cardiovascular risk at intermediate 
triglyceride levels and increased cardiovascular risk with the highest triglycerides. 
This is schematically depicted figure 9.2. These findings are consistent with the 
finding that high CETP mass promotes cardiovascular disease in type 2 diabetic 
patients women, 10 but are inconsistent with a study of our group where CETP mass 
did not appear to be associated with intima media thickness in diabetic or healthy 
subjects patients. 1 1  In the same study, even a positive effect of high plasma 
cholesteryl ester transfer on intima media thickness was observed in type 2 diabetic 
patients as well as in control subjects. 1 1  We propose that the "classic" hypothesis on 
the effect of CETP on cardiac disease ( figure 9 . 1 )  may be replaced by a model where 
the influence ofCETP on cardiac disease is modified by triglycerides (figure 9.2). 
Figure 9.2. Relation between CETP and cardiac risk in varying triglyceride 
levels 
CETP mass 1--------- cardiac disease 
+ 
Triglycerides t 
The data provided in chapter 4 may have clinical consequences, because it 
allows to anticipate that benefit of pharmacological CETP lowering would only be 
obtained in patients with high triglyceride levels, but would be doubtful when 
triglyceride levels are lower, and could even be detrimental in patients with lowest 
triglycerides (and as a consequence highest HDL cholesterol levels). 
II. CETP genotype, HDL and cardiac disease 
As described in chapter 6, circulating CETP mass of the subgroup of men correlated 
with the assessed CETP genotypes. CETP mass was highest in men with CETP -
629CC promoter genotype, intermediate in -629CA subjects and lowest in men 
genotyped as -629AA. 
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It has been previously shown that the assoc1at1on of common CETP 
polymorphisms with HDL cholesterol is modified by environmental factors such as 
obesity and insulin resistance which are determinants of high plasma triglycerides.12;13 
Therefore, our third aim was to study the extent to which the association of HDL 
cholesterol with CETP gene variations is modified by plasma triglycerides ( chapter 
5). The difference between CETP -629AA and -629CC promoter homozygotes was 
0.15 mmol/1 in subjects with triglycerides in the lowest tertile and only 0.08 mmol/1 
for triglycerides in the highest tertile (figure 9.3). In men this CETP genotype effect 
on HDL cholesterol was smaller than in women, while the effect of triglycerides was 
higher. Similar results were observed for the CETP TaqIB polymorphism, which is 
tightly associated with the 629C-+A promoter polymorphism. 14 Our models on the 
CETP -629C-+A and of TaqIB polymorphisms are summarized in chapter 5, and 
confirm an interaction of triglycerides and gender on HDL cholesterol. The 
interaction with gender is in accordance with other data, which show that in women, 
but not in men, the HDL cholesterol levels were associated with TaqIB 
polymorphism. 15;16 Our findings also raise the possibility that the increase in HDL 
cholesterol after triglyceride lowering treatment is determined by CETP gene 
variation. 
Fig11re 9.3. Association of CETP promoter polymorphism with HDL cholesterol 
Triglycerides 1 
CETP -629A allele 1-------11,----+--.i HDL cholesterol 
Our fourth research question explored the associations of frequently occurring 
CETP polymorphisms with future cardiac disease, HDL cholesterol and cholesterol 
ejjlux, and assessed whether the putative associations with cardiac disease and HDL 
cholesterol are ef ected by respectively HDL cholesterol and/or the effect of CETP on 
lipid transfer. 
First, associations of three common CETP polymorphisms with future cardiac 
risk revealed that carriers of the CETP -629A allele as well as of the closely 
associated TaqIB B2 allele had lower CETP mass and higher HDL cholesterol than -
629CC, respectively TaqB 1 B 1 homozygotes. Yet, they had a higher incidence of 
cardiac disease, which increased even further after adjustment for HDL cholesterol. 
Results for the CETP 1405V polymorphism were weaker, but pointed in the same 
direction. So, a common CETP promoter genotype, which beneficially contributes to 
higher HDL cholesterol, is paradoxically associated with an increased incidence of 
coronary heart disease in the general population. Therefore, the data presented in 
chapter 6 show that CETP gene variation may affect coronary risk by mechanisms 
other than the effect on the level of HDL cholesterol per se. In the literature the TaqIB 
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B2 allele has also been described as being associated with decreased cardiovascular 
disease. 1 7  The differences in results which have been reported in the different papers 
probably are related to characteristics of the groups that were studied. studies 
performed in groups with prevalent cardiac disease and/or hypertriglyceridaemia yield 
different results than those performed in the general population. 
The associations shown in chapter 6 could be explained by the specific effects on 
HDL cholesterol levels associated with these polymorphisms. The lower circulating 
CETP, which is associated with the TaqIB B2 allele, contributes to higher levels of 
HDL cholesterol, which in turn is a potent cardioprotective factor. However, our 
results indicate that CETP acts in more ways on cardiac disease than only via its 
effect on HDL cholesterol levels. For when the models of three common CETP 
polymorphisms were adjusted for the HDL-related cardioprotection, the risk for 
cardiac disease was increased rather than decreased in subjects with genotypes that 
are associated with lower CETP, -629A en TaqIB. This finding suggests that CETP 
polymorphisms may have an additional effect on atherosclerosis development that is 
not explained by its association with HDL cholesterol. 
The specific assessment whether a common CETP promoter polymorphism is 
associated with the ability of plasma to stimulate cholesterol efflux, is summarized in 
chapter 7. Despite lower HDL cholesterol, in CETP -629CC genotyped men, the 
genotype associated with highest CETP mass, cholesterol efflux was higher than in 
men with other -629C->A CETP genotypes. The ability to stimulate cholesterol 
efflux was not only associated with the CETP -629C->A promoter, but also with 
cholesteryl ester transfer, LCAT activity and apo A-1. These findings could provide a 
mechanism to explain why a CETP polymorphism which relate to lower plasma 
CETP and higher HDL cholesterol may confer increased cardiac risk. 
Finally, we established that the association of HDL cholesterol with the -
629C->A promoter polymorphism can not be solely explained by CETP in blood and 
the transfer it acts in (chapter 8). It suggests that other mechanisms exist by which 
CETP acts in addition to its function in CET, for example its actions in the vessel wall 
or its possible promotion of uptake of HDL-derived cholesterol by the liver. 
Alternatively, CETP levels may also be influenced by factors which also affect HDL 
cholesterol, such as factors of the metabolic syndrome, alcohol consumption, physical 
exercise, etcetera. 
Dual effect of CETP on cardiac disease 
In our studies, we have meticulously depicted the dual effect of CETP (see also figure 
9.4). In men with low triglycerides a higher CETP mass did not affect HDL 
cholesterol, but did decrease cardiac risk. Conversely, in men with higher 
triglycerides, higher CETP mass was marginally related to lower HDL cholesterol, 
without significant effect on incident cardiac disease. Our findings on the 
relationships of CETP mass, cardiac disease and HDL cholesterol are depicted in 
figure 9.4. If it is assumed that the amount of active CETP in plasma becomes critical 
for efficient reverse cholesterol transport under conditions of low triglycerides, then 
these findings are consistent with the possibility that the effects of CETP on HDL 
metabolism are not necessarily reflected by an effect on HDL cholesterol 
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Figure 9.4. Observed relationships of circulating CETP, HDL and cardiac 
disease (part I of thesis) 
CETP 1-----------------+1- Cardiac disease 
TG, triglycerides, 
HDL-C, HDL cholesterol 
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concentration as such. Such a phenomenon may be regarded as a dissociation between 
the impact of circulating CETP on atherosclerosis development on the one hand 
versus effects on HDL cholesterol on the other. 
Subjects with CETP -629CC genotype, the genotype associated with higher 
CETP mass, suffered less from heart disease than CETP -629A carriers, the allele 
associated with lower CETP (depicted in figure 9.5; described in chapter 6). As 
shown in the appendix of chapter 6, this effect could be attributed to the subjects in 
the higher half of triglyceride levels in the PREVEND population (see figure 9.5). 
This finding is consistent with a previous study towards the CETP I405V 
polymorphism, which reports that in men with triglycerides of at least 1 ,86 mmol/1 
coronary heart disease prevalence tended to decrease from VV to VI to II genotype, 
the latter being the genotype associated with highest CETP mass.18 In men with lower 
triglycerides, no such relation of the CETP I405V polymorphism was observed. 
Chapter 5, in contrast, describes a decrease of CETP genotype-effect on HDL 
cholesterol in raising triglyceride levels (figure 9.5). This is however inconsistent with 
the much smaller previous report, where the CETP I405V polymorphism has been 
observed to be associated with HDL cholesterol in men with triglycerides of at least 
1 ,86 mmol/1, but not in men with lower triglycerides. 18 So, when cardioprotective 
effects via HDL cholesterol are decreased in hypertriglyceridaemic states, the 
cardioprotection mediated by the reverse cholesterol transport becomes more 
predominant. 
Taken together, our findings again point to a dual effect of CETP on HDL 
cholesterol on one hand and cardiovascular risk on the other, now for CETP genotype. 
Based on these findings, we propose that these effects may be modified by the level 
of triglycerides (figure 9.5 ; appendix of chapter 6): In some states, i.e. states with 
lower triglycerides, the studied CETP promoter was more strongly associated with 
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Figure 9.5. Observed relationships of CETP genotype, HDL and cardiac disease 
(part II of thesis) 
CETP -629CC Is associated with t CETP 
'-----' TG, tnglycerides; 
HDL-C, HDL cholesterol 
HDL cholesterol but was not associated with incident cardiac disease. Whereas in 
states with higher triglycerides, we propose that the promoter polymorphism was 
associated with cardiac risk, but less with HDL cholesterol. Again, atherosclerotic 
effects of CETP genotype on HDL cholesterol appear to be abolished by another, 
cardioprotective, effect on cardiac risk via CETP genotype. 
Possible mechanistic explanations for this paradoxical effect include 
relationships of CETP polymorphism with the ability of plasma to stimulate cell­
derived cholesterol efflux, and extra-vascular effects of CETP, for example in 
stimulating hepatic removal of HDL-derived cholesteryl esters, 19 or the effect of 
CETP in atherosclerotic laesions on cholesterol eftlux.20 
Collectively, our data concerning the effects of CETP mass and CETP 
polymorphisms on incident cardiac risk suggest that measurement of both plasma 
CETP and determination of common CETP polymorphisms could be helpful in 
cardiovascular risk assessment. This approach can be tested in clinical outcome 
studies and subsequently be incorporated in the design of future intervention trials. 
A high circulating CETP mass, on one hand, is shown to protect against cardiac 
disease when triglycerides are relatively low. Therefore we speculate that in patients 
with lower triglycerides but low CETP it may be advisable to improve the reverse 
cholesterol transport. Such an approach could even include the use of a yet to develop 
CETP-analogue. We propose that CETP inhibitors should be avoided in men with 
lower triglycerides but an elevated cardiac risk, for example because of low HDL 
cholesterol levels or with a family history of cardiac diseases. Based on our data, in 
men with higher triglycerides of our data no (dis)advantage of promoting or inhibiting 
circulating CETP is to be expected. However, raised CETP levels in selected patients 
with even higher triglycerides are described to be associated with increased cardiac 
risk. 1 On the other hand, the observations of CETP genotype could implicate that men 
with high triglycerides and other risk factors should be genotyped. Although more 
research is warranted, we might tentatively speculate that when the patient is a CETP 
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-629A carrier, indicating lower CETP expression and thus hypothetically less CETP 
bound to the atherosclerotic laesions,20 his lipids should more aggressively treated. 
Hypertriglyceridaemia or metabolic syndrome as modulating factor? 
This thesis proposes triglycerides as a modifying factor of the relationship between 
CETP mass and CETP genotype on one hand, and HDL cholesterol and cardiac 
disease on the other. However, hypertriglyceridaemic subjects frequently have other 
cardiac risk factors such as low apo A-I and/or high waist circumference, 
hypertension and/or elevated PAI- I levels. Also, higher triglycerides are associated 
with male gender. Together, with the exception of gender, this cluster of risk factors is 
referred to as 'metabolic syndrome' or 'insulin resistance syndrome'. It is possible that 
triglycerides are not the explaining modifying factor, but one or more factors 
belonging to the metabolic syndrome. 
To determine whether the relationship between CETP genotype and cardiac risk 
is modified by factors of the metabolic syndrome in the PREVEND cohort, a 
secondary analysis has been performed which is described in the appendix of chapter 
6. From these analyses it became apparent that the increased cardiac risk for CETP -
629A-allele carriers with triglycerides higher than the median, could also be 
demonstrated for subgroups with lower HDL cholesterol, lower apo A-1, higher waist 
circumference and higher urinary albumin excretion (UAE). Thus, these secondary 
analyses suggest that the association of incident cardiac disease with the CETP 
promoter polymorphism is exaggerated in subjects with features of the metabolic 
syndrome. 
We tested if other characteristics of the metabolic syndrome also modified the 
relation between CETP mass and cardiac disease. We used the database of chapter 4 
and similar statistics and we divided the subset of men of chapter 4 according to 
median levels of CETP and of HDL cholesterol, waist circumference and UAE, 
similarly to the methods described in chapter 4. Results for men with relatively 
beneficial HDL cholesterol, waist circumference and UAE were similar to men with 
lower triglycerides, although in these analyses the effects of CETP mass on cardiac 
risk appeared not as strong (data not shown). 
Taken together, the relation of the CETP promoter polymorphism and cardiac 
disease as well as the relation of CETP mass with cardiac disease were not only 
modified by triglyceride levels, but also by various other factors of the metabolic 
syndrome. While we propose that triglycerides modify the effects of CETP mass and 
CETP genotype on cardiac disease, we cannot exclude that these effects may be 
influenced by other means of modification. Our data do not confirm that triglycerides 
influence the transcription, translation or any posttranslational modification of CETP, 
as in men with lower and higher triglycerides the association between the CETP -
629C-+A promoter polymorphism and CETP mass is similar (data not shown). 
Neither do HDL cholesterol, apo A-I and, to a lesser extent, waist circumference and 
higher UAE appear to influence relation between CETP genotype and CETP mass 
(data not shown). Nevertheless, other gene-environment interactions could play a role 
in the association between CETP genotype and HDL cholesterol or cardiac disease. 
Putative environmental interacting factors are physical activity2 1 and fat-content of 
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diet22:23 _ Another CETP gene-environment interaction has been demonstrated,24;25 as 
the relationship between the TaqIB polymorphism with cardiovascular disease is 
modified by alcohol intake, a finding which has been recently replicated in 
prospective studies.26 However, in our data we could not show an interaction of CETP 
polymorphism with alcohol consumption on HDL cholesterol or cardiac disease (data 
not shown). 
Alternatively, the association between the CETP promoter polymorphism and 
HDL cholesterol or cardiac disease could also be modulated by gene-gene 
interactions. A potential candidate might possibly be genes related to the metabolic 
syndrome or insulin resistance syndrome. Because of the complexity of this syndrome 
conclusive indications are scarce. Nevertheless, some studies point towards this 
hypothesis. For instance, in women the TaqIB polymorphism, which is tightly 
associated with the promoter polymorphism, has been observed to interact with 
adiposity on HDL cholesterol.27 
CETP in the perspective of the PREVEND study 
The PREVEND study has been designed to investigate the impact of urinary albumin 
excretion on renal and cardiovascular disease in the general population. For that 
purpose, of inhabitants aged 28 to 75 years with a morning spot urine with urinary 
albumin excretion of at least 1 0  mg/I (n = 7 768) were invited, after exclusion of 
insulin-using diabetic patients and pregnant women, together with a randomly 
selected sample with a urinary albumin concentration below 1 0  mg/I (n = 3 395).28 
So, in stead of an unselected reflection of the population, this cohort is 'albuminuria­
enriched', i.e. urinary albumin excretion of this cohort is artificially high. To ensure 
that the results of our studies were not biased by the selection procedure of the 
PREVEND study, we perfonned additional statistical analyses to those presented in 
chapters 3 to 6, by adding the selection parameter 'albuminuria' as an extra variable 
and as a confounder interacting with the parameters of interest. This clearly revealed 
that the models of chapter 3 did not change when the presence of albuminuria was 
taken into account. In addition, in chapter 5 urinary albumin excretion was no 
contributing factor to the models. Therefore, our results can be applied to the general 
population. 
It should be noted that we have perfonned genetic association studies, which 
does not automatically imply that the effects of CETP gene variation on incident 
cardiac disease are causal. However, we have extensively assessed whether in our 
population-based study there could exist a potential selection in favour of a particular 
CETP genotype resulting in altered associations with cardiac disease. Several studies 
have been perfonned on the effect of common CETP polymorphisms on 
cardiovascular disease in (predominantly) Caucasian populations, of which CETP 
TaqlB genotype has been studied most frequently. 1 1:29 Our updated literature review 
shown in table 9. I is, therefore, restricted to the TaqIB CETP polymorphism. While 
in our cohort a protective effect for the 'wildtype' TaqlB B l  allele was observed 
( chapter 6), a detrimental effect for the B2B2 vs the B I B  I homozygotes was reported 
in 3 cohorts 1 7  and no significant relation in 5 other cohorts. 11:29 Of these cohorts, 6 are 
selected groups, consisting solely of survivors of cardiac disease25:29:3o or a case-
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control design of MI survivors30-33 • Also, 4 of those selected cohorts consisted of 
men25;3 l-33 (table 9. 1 ). Only three cohorts were population-based, 15;34 including the 
PRE VEND population. As shown in table 9. I ,  from these data can be derived that the 
CETP TaqIB B2 allele is negatively associated cardiovascular disease in population­
based studies (unadjusted OR 0.77 (95% CI 0.61 ;0.97), P = 0.03), while in selected 
populations the B2 allele is positively associated with cardiovascular disease 
(unadjusted OR 1 . 1 2  (95% CI 1 .02; 1 .23), P = 0.02). It seems more plausible that 
apparent differences in the observed associations of this CETP polymorphisms with 
cardiovascular disease are attributable to genetic selection in the non-population­
based studies and not in population-based studies as the PREVEND cohort. 
Table 9.1. CETP TaqlB polymorphism with genotype frequencies, and odds 
ratios (OR, 95% confidence intervals) for cardiovascular disease in B2B2 vs 
B1B1 homozygotes in population-based studies and in studies in selected 
f!.Of!.Ulations 
Study Controls, Cases, OR 
TaqlB genotypes TaqIB genotypes 8282 vs B IB I  
Population-based B I B I  8 1 82 8282 B I B I  8 1 82 8282 OR (95% Cl) 
studies 
Kauma el al, Oulu 13 1 56 240 90 12  16  10  1 .44 ns (0.60-3.48) 
Northwick Park 490 871 307 10  26 1 0  1 .60 ns (0.66-3.88) 
Heart14 
PREVEND45 27 1 6  3800 1 500 76 1 37 60 1 .42 (1 .0 1 -2.02) 
Studies in selected e.oeulalions 
ECTIM25 433 641 236 4 12  595 1 73 0.77 (0.6 1 -0.98) 
Carlquist el al. 29 502 782 264 83 133 47 1 .08 ns (0. 73- 1 .59) 
Arca el al.30 132 1 83 7 1  1 52 1 86 68 0.83 ns (0.55- 1 .25) 
Reykjavik3 1  1 68 335 128 1 60 261 82 0.67 (0.47;0.96) 
Physicians' Health 32 96 157 53 86 1 39 35 0.74 ns (0.44; 1 .24) 
WOSCOPS33 358 580 233 142 2 17  66 0.7 1 (0.5 1 ;  1 .00) 
Data from studies 14, 24 and 29-33 derived from S.M. Boekholdt et al. 17 
Chapter 4 is based on the results of a nested case control study. We did not 
match cases and controls for clinical variables such as age, body mass index and lipid 
levels, to ensure that the control population was representative of the whole 
PREVEND cohort and to prevent "over-matching" of control subjects with cases. We 
included cases and controls in a I :  1 ratio. In this way, the smallest number of 
participants which was necessary to discern a relationship of plasma CETP mass with 
cardiac disease was chosen. As a consequence, our study may have been 
underpowered to determine interactions of plasma CETP with triglycerides when 
analysed as continuous variables. Results pertain to men only, and the relationship 
between HDL cholesterol and CETP mass might be different in men compared to 
women.35 
Future research 
When the research described of this thesis was in progress, a new class of drugs, i.e. 
CETP inhibitors, was being tested in clinical trials, aimed to protect against 
cardiovascular disease. One of these trials, the ILLUMINATE study, was a large fase 
III study comparing the effects of the torcetrapib added to statin treatment with statin 
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treatment alone. This study has been stopped prematurely in 2006, because of an 
excess of deaths in the active drug arm of the study. A key question is whether the 
adverse effect of torcetrapib is indeed caused by the off-target hypertensive effect of 
this compound, as has been proposed recently.36-39 The increase in blood pressure 
might have been caused by raised aldosterone levels induced by torcetrapib,39 and 
may have been involved in the increased cardiovascular mortality. Of note however, 
more patients on torcetrapib died when the rise in systolic blood pressure was below 
median compared to those subjects whom had a larger increase in blood pressure.39 
Alternatively, the increased mortality has been proposed to be consequent to the 
intrinsic effect of CETP inhibition on the HDL metabolism and on the reverse 
cholesterol transport pathway.40;41 Such a possibility is in keeping with the results 
presented in this thesis ( chapters 4 and 6), where we demonstrated that higher CETP 
mass may lower incident cardiac disease under low-triglyceridaemic circumstances 
(chapter 4) and that two common CETP polymorphism associated with higher CETP 
mass are associated with a decreased cardiac hazard, especially when triglyceride 
levels are higher ( chapter 6). Studies using other CETP inhibitors, such as JTT-70542 
and anacetrapib43, might elucidate whether the disappointing results of the torcetrapib 
studies 37-39;4 I ;44 are caused by the specific action of the drug or are uniquely confined 
to torcetrapib. So far, anacetrapib does not appear to affect systemic blood pressure.43 
The phase I study did not show a diastolic or systolic raising effect of anacetrapib, 
despite that the dose-dependent HDL raising and LDL lowering effects of this CETP 
inhibitor appeared to be greater than of both torcetrapib and JTT-705. Obviously, the 
results of these CETP inhibitors on cardiovascular disease in subjects with varying 
plasma levels of triglycerides will be of interest. Future studies will need to include a 
larger sample than our nested case control study in order to assess the effect of CETP 
mass and triglycerides as continuous variables, in stead of by categories as described 
in chapter 4_ Additionally, this will allow calculating a formal, continuous interaction 
of CETP mass and triglycerides on cardiac disease. 
Since users of lipid lowering drugs have been excluded from the nested case 
control study, it was not possible to establish any effect of these drugs on the 
observed relationships between circulating CETP, cardiac disease and triglycerides. 
Future research is warranted to investigate whether statins or fibrates may alter 
relations between CETP, lipids and cardiac disease. 
While this thesis (partly) focuses on the question whether or not triglycerides 
influence the association of CETP mass with cardiac risk, other determinants of the 
metabolic syndrome need to be included. As described earlier, we hypothesise that 
other factors of the metabolic syndrome exhibit roughly similar results as 
triglycerides. More research upon the role of ( determinants of) the metabolic 
syndrome in modulating the effect of CETP on cardiac disease is required to assess 
whether triglycerides are the explaining factor or, alternatively, only represent the 
underlying causes. 
It needs to be mentioned that our studies on circulating CETP and on cholesterol 
efflux were carried out in men only_ In future research, women should therefore also 
be included. Moreover in our in vitro studies, the cell system that was used to 
document cholesterol efflux was held constant, so that the effect of variation in the 
ability of individual subjects plasma to promote cholesterol efflux could be studied. 
Obviously, in such a study the observed relation of efflux with CETP gene variation is 
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indirect, and is explained by effects of CETP polymorphisms on plasma CETP itself 
and by CETP-mediated changes in lipoprotein particles that are able to accept cell­
derived cholesterol. Therefore, it would be of great interest to design cholesterol­
efflux studies using cells from subjects with particular CETP genotypes as cholesterol 
donor, while leaving the extracellular cholesterol acceptors constant. Application of 
both methods will probably allow to further unravel the role of CETP gene variation 
in this early step in the reverse cholesterol transport pathway. 
The study of local effects of CETP in the arterial wall is expected to provide 
important information on possible pro- vs anti-atherogenic effects of CETP. Animal 
studies using the technique of bone marrow transplantation will be able to define the 
role of macrophage-derived CETP in atherogenesis. 
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Zoals aangestipt m hoofdstuk 1 ,  vonnen hartvaatziekten nog steeds een van de 
belangrijkste oorzaken van ziekte en overlijden in Nederland, ondanks veelvuldig 
onderzoek en de daannee samenhangende grote versnelling in de therapeutische en 
preventieve mogelijkheden. Dankzij de vooruitgang in kennis omtrent de 
pathofysiologie van hartvaatziekten, wordt (secundaire) preventie veelvuldig gericht 
op het verlagen van atherogene lipiden in het bloed. Omdat deze lipideverlagende 
strategieen onvoldoende effect sorteren, is er de laatste jaren steeds meer aandacht 
voor het metabolisme van HDL ('high density lipoprotein), een vetdeeltje in het bloed 
dat cardioprotectief is, en op de factoren die het HDL beinvloeden. 
Hoofdstuk 2 geeft een overzicht van het HDL metabolisme en de daannee 
samenhangende factoren. In het zogenaamde omgekeerde cholesterol transport 
('reverse cholesterol transport') vervoert het HDL-deeltje cholesterol van de vaatwand 
terug naar de lever, waar het cholesterol omgebouwd wordt tot galzuren, en wordt 
uitgescheiden in de dannen. Zodoende levert het omgekeerde cholesterol transport 
een natuurlijke beschenning tegen atherosclerose. In dit hoofdstuk is het metabolisme 
van HDL en het omgekeerde cholesterol transport beschreven in nonnolipidaemische 
omstandigheden en in patienten met insuline resistentie en type 2 diabetes mellitus, 
omdat deze laatste aandoeningen worden gekenmerkt door een verlaagd HDL 
cholesterol en een hoog triglyceridengehalte in bloed, beide belangrijke risicofactoren 
voor hartvaatziekten. Verscheidene enzymen nemen tijdens het omgekeerde 
cholesterol transport dee) aan het metabolisme van HDL, zoals fosfolipide transport 
proteine (PLTP), lecithine:cholesterol acyltransferase (LCA T), lipoproteine lipase 
(LPL), hepatisch lipase (HL) en cholesteryl ester transport proteine (CETP). Het 
enzym PLTP genereert kleine pre P-HDL deeltjes, dit zijn de eerste acceptoren van 
cholesterol uit de vaatwand. Deze cholesterol efflux wordt bij insuline resistentie op 
peil gehouden door verhoogde PLTP activiteit en verhoogd pre P-HDL spiegels in 
bloed. Vervolgens groeien HDL deeltjes door toedoen van LCAT, dat vrij cholesterol 
verestert. LPL levert lipiden voor HDL vonning, en HL verkleint HDL via hydrolyse 
van de inhoud ervan. CETP bevordert het cholesteryl ester transport van HDL naar 
triglyceridenrijke lipoproteinen, waardoor HDL partikels worden verkleind. Personen 
met insuline resistente vertonen vaak een versterkt cholesteryl ester transport, wat 
wordt beschouwd als een determinant van laag HDL cholesterol. Recent zijn 
specifieke CETP remmers ontwikkeld, met als doe) het HDL cholesterol gehalte in 
mensen te verhogen. Studies moeten nog aantonen wat het effect van deze middelen 
op de hartvaatziekten in de praktijk  is. 
In hoofdstuk 3 worden de resultaten beschreven van ons onderzoek naar het 
verband tussen myocardinfarct en verschillende componenten van HDL, te weten het 
HDL cholesterol gehalte van bloed, en de voomaamste apolipoproteinen (apo's) van 
HDL, namelijk apo A-I en apo A-II. In tegenstelling tot het algemeen aangenomen 
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cardiovasculair beschermende effect van HDL en van apo A-I, zijn de gerapporteerde 
associaties tussen apo A-II concentraties en hartvaatziekten tegenstrijdig. De 
associaties van HDL cholesterol, apo A-I en apo A-II spiegels met een voorafgaand 
myocardinfarct zijn hier voor het eerst onafhankelijk van elkaar onderzocht. Hiertoe 
zijn 5 1 5  mannen en vrouwen met een doorgemaakt myocardinfarct vergeleken met 
6 1 1 5  personen zonder doorgemaakte cardiovasculaire aandoeningen. Zowel mannen 
als vrouwen, die een myocardinfarct hadden doorgemaakt, hadden verlaagde HDL 
cholesterol en apo A-I spiegels, maar bet apo A-II gehalte was alleen verlaagd bij de 
mannen. Bij de mannen was het hebben doorgemaakt van een myocardinfarct het 
sterkst negatief geassocieerd met apo A-II concentratie, gevolgd door apo A-I gehalte. 
Daarentegen was bij de vrouwen een myocardinfarct in het verleden in de eerste 
plaats negatief geassocieerd met de HDL cholesterol concentratie. Tevens was bij 
vrouwen bet HDL cholesterol gehalte hoger dan bij mannen bij elke apo A-I en apo 
A-II spiegel, duidend op grotere HDL partikels bij vrouwen dan bij mannen. Onze 
bevinding dat de verbanden tussen myocardinfarct en HDL cholesterol, apo A-I en 
apo A-II concentraties verschilt tussen mannen en vrouwen, kan dus verklaard 
worden door geslachts-afhankelijke effecten op de samenstelling van HDL. Daarom 
stellen wij dat het prospectief vastgestelde risico op cardiovasculaire aandoeningen, 
ten gevolge van een verlaagde HDL cholesterol, apo A-I en apo A-II spiegels, voor 
mannen en vrouwen apart moet worden vastgesteld. 
In hoofdstuk 4 beschreven wij bet effect van CETP concentraties op de 
incidentie van hartvaatziekten in een groep mannen met een relatief laag 
triglyceridengehalte. Bij mensen met hoge triglyceriden spiegels is in eerder 
onderzoek een toename van cardiovasculaire ziekten beschreven bij hoger circulerend 
CETP. In een prospectieve 'case-control' studie zijn uit een populatie van xxx mannen 
in de Prevend studie 111 mannen geselecteerd die wel en 1 16 mannen die geen 
cardiovasculaire ziekte hebben gekregen tijdens de follow-up. Niemand had bij 
aanvang van de studie hartvaatziekten, diabetes mellitus of gebruikte lipideverlagende 
medicijnen. In hartvaatpatienten was het totaal cholesterol- en triglyceridengehalte 
hoger, het HDL cholesterol-gehalte lager, maar de concentratie CETP kwam overeen 
met <lat van de controles. Echter, bij mannen met triglyceriden concentraties onder de 
mediaan bleken CETP spiegels lager te zijn bij hen, die een cardiovasculaire 
aandoening hadden gekregen dan bij mannen die vrij waren gebleven van 
hartvaatziekten. In de groep met lagere triglyceriden hadden mannen met CETP­
concentraties boven de mediaan bijna drie maal minder kans op hartvaatziekten dan 
mannen met lager CETP, na correctie voor leeftijd. Dit verminderde cardiovasculaire 
risico voor de groep met hogere CETP-waardes was niet zichtbaar in de groep met 
hogere triglyceriden. Wij concluderen <lat het effect van CETP op hartvaatziekten 
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atbankelijk is van het triglyceridengehalte, met een beschermende werking van CETP 
bij een laag triglyceridengehalte. 
Hoofdstukken 5 tot en met 7 zijn gericht op het effect van CETP polymorfismen 
op HDL gerelateerde factoren en op hartvaatziekten. Eerst is in hoofdstuk 5 de relatie 
van twee algemeen voorkomende CETP polymorfismen met HDL bestudeerd bij 
circa 7000 mensen zonder diabetes. Het -629C-+A CETP promoter polymorfisme is 
een determinant van HDL cholesterol. In de literatuur zijn aanwijzingen dat obesitas 
en hyperinsulinemie bet effect veranderen van het zeer dichtbij liggende CETP TaqIB 
polymorfisme op HDL cholesterol. Het is bekend dat een hoog triglyceridengehalte 
het CETP-gemedieerd cholesteryl ester transport uit HDL stimuleert. In dit licht toont 
dit onderzoek aan dat triglyceriden het effect van de CETP -629A-+C promoter op 
HDL cholesterol veranderen. Zowel HDL cholesterol als apo A-I spiegels waren 
hoger in -629AA dan in -629CC homozygoten. Wat daarbij opvalt is dat dit effect van 
het CETP genotype bijna twee keer zo groot was in het laagste triglyceriden tertiel als 
in het hoogste tertiel. Behalve dat het HDL cholesterol gehalte werd bei"nvloed door 
het CETP promoter genotype, geslacht en de triglyceriden concentratie, bepaalden 
deze drie factoren op hun beurt weer de verbanden tussen elk van beide andere 
factoren met HDL cholesterol. De associaties waren onatbankelijk van middelomtrek, 
insulineresistentie (aangeduid door HOMAir), alcoholgebruik, Ieeftijd en gebruik van 
lipideverlagers. Ook bij bet TaqIB polymorfisme bleken triglyceriden concentratie en 
genotype elkaar te bei"nvloeden in hun associatie met HDL cholesterol gehalte. Het 
effect van het -629C-+A promoter polymorfisme op de HDL cholesterol spiegel werd 
niet gewijzigd door obesitas of HOMAir. Oat bet HDL cholesterol verhogende effect 
van het CETP -629A allel werd verzwakt door hogere triglyceriden in bloed, wordt 
wellicht verklaard door een zwaarder wegende invloed van triglyceridenrijke 
lipoprotei"nen dan dat van circulerend CETP op cholesteryl ester transport uit HDL, 
bij een stijgend triglyceridengehalte. 
Aanvullend op de invloed van CETP polymorfismen op HDL-gerelateerde 
parameters van bet voorgaande hoofdstuk, is in hoofdstuk 6 de relatie tussen drie 
algemene CETP polymorfismen en de incidentie van hartziekten in ruim 8000 
personen in de algemene bevolking belicht. De invloed van de CETP polymorfismen 
op HDL cholesterol concentratie, evenals het omgekeerde verband van HDL 
cholesterol met hartvaatziekten zijn bekend. Wat de invloed is van drie algemene 
CETP polymorfismen op coronaire ziekten als de beschermende invloed van HDL in 
ogenschouw wordt genomen, is bier voor het eerst onderzocht. Ondanks een hogere 
HDL cholesterol spiegel, hadden dragers van het -629A allel een 26% hoger risico op 
coronaire ziekte dan mensen zonder dit allel. Dit risico was zelfs 46% hoger als werd 
gecorrigeerd voor HDL cholesterol gehalte. Deze verbanden bleven bestaan na 
verdere correctie voor apo A-I, triglyceriden, C-reactief protei"ne, leeftijd en geslacht. 
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Voor het CETP TaqIB polymorfisme werden vergelijkbare resultaten gevonden. Het 
V allel van het CETP 1405V polymorfisme, dat eveneens was geassocieerd met hoger 
HDL cholesterol, was zwak gerelateerd met een verhoogde incidentie van coronaire 
events. Concluderend is er een paradoxale associatie van algemeen voorkomende 
CETP genotypes, die enerzijds bijdragen aan cardioprotectie door hogere HDL 
cholesterol spiegels en anderzijds gepaard gaan met een hogere incidentie van 
coronaire ziekten in een algemene, overwegend Kaukasische bevolking. CETP 
genotype lijkt dus cardiale aandoeningen te beinvloeden (deels) los van het HDL 
cholesterol gehalte. 
Wegens de aangetoonde verbanden van CETP polymorfismen met hartziekte, is 
in hoofdstuk 7 ingegaan op de invloed van de CETP -629C--+A promoter op 
cholesterol efflux. Want cellulaire cholesterol efflux is de eerste stap van het 
omgekeerde cholesterol transport en CETP activiteit draagt bij aan deze cholesterol 
efflux. In de subgroep hebben wij daarom bestudeerd of het vermogen van plasma om 
cellulaire cholesterol efflux te stimuleren in verband stond met de CETP -629C-+A 
promoter. Dragers van het CETP -629A allel hadden een lagere cholesterol efflux, 
plasma CETP, CET en LCAT activiteit en een hoger HDL cholesterol gehalte. De 
efflux van cellulair cholesterol naar plasma stood in positief verband met het CETP 
genotype dat geassocieerd was met hoger CETP massa, eveneens met plasma CET, 
LCAT activiteit en apo A-I, maar niet met HDL cholesterol en CETP massa. Het 
CETP -629C allel was geassocieerd met hogere LCA T activiteit. De geobserveerde 
associatie tussen cholesterol efflux en CETP promoter polymorfisme kan ons een 
verklarend mechanisme geven waarom CETP gen variaties gerelateerd aan lager 
plasma CETP en hoger HDL cholesterol een versterkt cardiovasculair risico kan 
geven. 
Zoals beschreven, staat HDL cholesterol in verband met de CETP -629C-+A 
promoter. Dit verband kan mede toegeschreven zijn aan de werking van CETP in het 
transport van cholesteryl ester tussen lipoprotei"nen, weerspiegeld in het zogenaamde 
CET (cholesteryl ester transport), maar ook aan mechanismen in het HDL 
metabolisme die in onafhankelijk zijn van het CET. In hoofdstuk 8 hebben wij de 
bijdragen bepaald van het CETP -629C--+A polymorfisme, CETP massa in bloed en 
cholesteryl ester transport aan het HDL cholesterol gehalte in de subgroep mannen. 
CETP massa en cholesteryl ester transport waren hoger in mannen met het CC dan 
met het AA genotype, terwijl gehaltes van HDL cholesterol en apo A-I lager waren. 
Cholesteryl ester transport in plasma was univariaat gerelateerd aan het CETP 
genotype, CETP massa en triglyceriden. HDL cholesterol stood in onafhankelijk 
verband met de CETP promoter en met het triglyceride gehalte, zonder 
onafhankelijke bijdrage van bloed CETP massa en cholesteryl ester transport. Daarom 
concluderen wij dat ondanks het verband tussen de algemeen voorkomende CETP 
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promoter en cholesteryl ester transport in plasma, de associatie tussen dit CETP gen 
en HDL cholesterol tenminste niet geheel verklaard wordt door het proces van het 
cholesteryl ester transport. 
Het onderzoek van dit proefschrift werpt nieuw licht op de verbanden tussen 
CETP, HDL metabolisme en cardiovasculair risico (zoals besproken in hoofdstuk 9). 
Hier blijkt dat tussen mannen en vrouwen de relaties van enkele algemeen 
voorkomende varianten van het CETP gen met HDL cholesterol verschillen. Daarbij 
lijken de relaties van verschillende componenten van HDL met hartvaatziekten tussen 
mannen en vrouwen te verschillen. De relatie van de onderzochte, algemene CETP 
polymorfismen met HDL cholesterol, dat beschermt tegen atherosclerose, wordt 
veranderd door het triglyceriden gehalte: hoe hoger de triglyceriden, hoe minder 
effect het CETP genotype op HDL cholesterol heeft. Als wordt gecorrigeerd voor 
HDL cholesterol gehalte, blijken CETP genotypen die leiden tot hoger CETP en lager 
HDL cholesterol in bloed, gerelateerd te zijn met lagere incidentie van cardiale 
ziekten. Dit proefschrift noopt tot aarzeling de nieuwe CETP remmers, die nog op de 
markt moeten worden gebracht, bij iedereen voor te schrijven, met name bij patienten 
met !age tot normale triglyceriden spiegels. Inderdaad is recent (december 2006) een 
grote fase III studie met de CETP remmer torcetrapib gestaakt, wegens een hogere 
cardiovasculaire sterfte bij de groep die dit middel gebruikte. 
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Mijn dank gaat ten eerste uit naar mijn begeleiders. 
Beste Robin, als aanvrager van dit project ben jij bet nauwste betrokken geweest bij 
mijn promotietraject. lk ben je dankbaar voor jouw grote liefde voor bet onderwerp, 
die zeer aanstekelijk  was. Dank ook voor bet delen van je uitvoerige kennis over bet 
onderwerp. Daarbij was je zeer betrokken en laagdrempelig; je had altijd tijd voor mij 
en mijn collega en was zeer mededeelzaam over nieuwe ontwikkelingen en 
venneldenswaardigheden. Jouw humor werkte aangenaam relativerend. 
Beste Bruce, dank voor bet afzijdig blijven als voldoende in de keuken stonden en bet 
op de voorgrond treden als bet gewenst was. Jouw kritische blik in de juiste mate en 
je goede overzicht waren leerzaam. Ik hoop ooit te leren schrijven zoals j ij. Niet 
alleen door mij bij te sturen als ik te lang met iets doorging, maar ook met jouw 
politieke vaardigheden heb jij mij erg geholpen. 
Beste Hans, jouw eerlijkheid en duidelijkheid stel ik erg op prijs. Dank voor bet 
waarborgen van de kwaliteit van bet statistische gedeelte en jouw vennogen dingen te 
simplificeren. Uit waardering voor jou is dit kort, want deze kunst neem ik graag van 
jou over. 
Beste Paul, de heldere stijl die jij hanteert is mij tot inspiratie. l k  ben blij te kunnen 
meekrijgen hoe jij een verhaal opbouwt. Van jou heb ik geleerd schematisch te 
werken; deze vonn van werken is mij voor vele dingen van nut en is van blijvende 
waarde. Daarvoor dank, als ook voor je vermogen te motiveren, je belangstellendheid 
en behulpzaamheid. 
Verder dank ik de leescommissie, dankzij wie dit boekje voor u ligt. Professor 
Wouter Jukema, professor Ronald Stolk en professor Gerjan Navis, dank u we! voor 
de beoordeling van dit manuscript en dank voor de aanwijzingen waannee ik het 
proefschrift kon verbeteren. 
Dank ook aan de medeschrijvers van de artikelen in dit boekje en aan ieder die 
de extra labbepalingen heeft mogelijk  gemaakt. Geesje Dallinga-Thie, Bert Groen, 
Gerrit van der Steege, Mike Zuurman, dank voor de vaak bewerkelijke labbepa\ingen 
die de basis waren voor het gros van de artikelen. Rindert de Vries, Aad van Toi, 
Stefan Bakker, Dick de Zeeuw, Diederik Grobbee, Geesje Dallinga-Thie, Bert Groen, 
Gerrit van der Steege, Mike Zuunnan, dank voor het leerzame overleg en het 
meehelpen met schrijven. 
Kamergenoten en mede-onderzoekers van de afdeling Endocrinologie: jullie 
alien bedankt voor de aangename tijd  samen. 
Rindert, jou beschouwde ik als mijn maatje, omdat wij tegelijkertijd zijn begonnen 
aan een dubbel opgestart project en omdat wij in de wisselende samenstelling van de 
kamer(s) altijd kamergenoten zijn geweest. Wat ik bet prettigst hieraan vond was dat, 
in mijn beleving, jouw karakter complementair aan het mijne was. 
Udo, ik heb mij we! eens verbaast over je enorme organisatievermogen. Ik herinner 
mij met veel plezier de eenaprilgrappen en het handballen met papierproppen op de 
kamer. Dank voor je vriendelijke karakter. 
Adrienne, ik wil je bedanken voor de gezelligheid die je inbracht. Maar vooral omdat 
j ij zowel hartelij k  als eerlijk  bent. Deze combinatie is bijzonder en heb ik erg op prijs 
gesteld. 
Aan alle anderen van de Triadekamer, die een gemengde samenstelling had: dank 
voor de prettige tijd in de afgelegen kamer. 
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Met de onderzoekers op de Endocrinologie kregen wij later meer contact toen een 
dee! van ons op de stafafdeling van de Endocrinologie terecht kwam. lk ervoer hen als 
een gezellige groep, ook hen wil ik bedanken voor de goede tijd. 
PREVEND wordt mogelijk gemaakt door vele mensen, die ik daarom alien dank 
verschuldigd hen. 
De onderzoekers van de PREVEND wil ik bedanken voor de hulp en de feedback. 
En natuurlijk de assistentes van de PREVEND en ieder ander die voor, met en na mij 
heeft meegeholpen Prevendpoli's te draaien. 
De datamanagers, Rob en Marco, hen ik veel dank verschuldigd voor de lastige taak 
de PREVEND-database op orde te maken en houden. 
Ten zeerste dank ik de deelnemers van PREVEND. Zij zijn de eersten dankzij wie ik 
en vele andere onderzoekers hebben kunnen promoveren op het ruime gebied van 
nier- en hartvaatziekten. 
Geen afdeling, geen bedrijf en zeker geen onderzoeksomgeving draait zonder de 
ondersteuning van hen die alles weten, regelen en bijhouden. Ik dank daarom Ellis en 
Caroline van de Endocrinologie en Winnie van de PREVEND. 
Paranimfen, mijn zus Hella en mijn vriendin Eefje, dank jullie we! voor jullie 
praktische hulp en jullie gevraagde en soms ongevraagde advies. 
Ik dank ook de rest van mijn familie en vrienden. Sommigen voor het lezen (al 
een ding op zich), het meehelpen en het advies. Maar alien bedankt voor de plezierige 
tijd er tussenin. Medemensen, medestanders, mededingers: ik mag jullie. 
Grote man, steun en toeverlaat, dank. Speciaal voor jou: zwaarden zijn je vriend. 
Ik dank Eenhand en Eenoog. 

